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Abstract 
 
Colorectal cancer (CRC) is a leading cause of global cancer-related morbidity and 
mortality. A deeper understanding of the biological processes that drive CRC 
development and progression is essential in order to improve patient outcomes along 
the CRC clinical pathway (diagnosis; treatment; prognostication/surveillance).  
Metabonomics (metabolic profiling/metabolomics) is a rapidly advancing field in 
systems biology that generates disease-relevant micro-molecular information 
downstream of the genome and proteome. Metabolic profiling studies utilising nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) have 
demonstrated early promise in cancer research.  
For this body of work I have designed and implemented a multi-axis metabolic 
profiling strategy for evaluation of fresh frozen CRC tissue; the study framework has 
been specifically designed to assess the translational utility of different NMR and MS –
based technologies at key phases of the CRC clinical spectrum and to develop next-
generation bioinformatics solutions to facilitate translational deployment of these 
approaches. My findings have demonstrated that:  
(i) High-resolution magic angle spinning NMR (HR-MAS NMR) 
spectroscopy allows rapid and accurate diagnosis and local staging of 
CRC, making it well suited to translational deployment at the diagnostic 
end of the CRC clinical pathway. In addition this approach can potentially 
be used to develop an alternative to frozen section for intra-operative 
tissue evaluation.  
(ii) Matrix-assisted laser desorption ionisation imaging MS (MALDI-MSI) 
has potential to supplement conventional histopathological methods of 
tissue assessment and reveals novel tumour-associated ‘field effects’ 
which may have translational utility in CRC prognostication.             
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(iii) Desorption electrospray ionisation imaging MS (DESI-MSI) represents 
a more sophisticated method for histology-driven imaging mass 
spectrometry and permits ‘chemical mapping’ of the CRC tumour 
microenvironment in a way not possible until now. This technique can be 
used to derive an entirely new pool of biomolecular data with which to 
develop next-generation cancer biomarkers for prognostic and therapeutic 
personalisation.    
Currently, the complexity and volume of data generated by MSI experimentation 
represents a major rate-limiting step, hampering translational application of this 
approach. My work in CRC MSI profiling has concurrently led to the development of a 
novel bio-informatics pipeline designed to address current challenges, and this 
platform is also introduced in the following thesis.       
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1.1 Colorectal cancer  
 
1.1.1 Background 
Colorectal cancer (CRC) is the third most common cause of cancer-related death 
world-wide, with over 1 million new cases diagnosed annually.1 It is responsible for an 
estimated half-a-million deaths per annum and confers a disease-specific mortality of 
33% in the developed world.2 Approximately 30,000 patients in England and Wales 
are diagnosed with CRC every year,3 though cancer registry data suggest that the 
incidence may be plateauing, perhaps as a result of heightened public awareness and 
nationwide screening initiatives.3  
The majority of cases of CRC arise sporadically; proposed risk factors include 
advancing age,4 male gender,5 colonic polyps,6 pre-existing inflammatory bowel 
disease7, 8 and various environmental factors such as smoking,9 excess alcohol 
consumption,10, 11 excess dietary fat and red meat, inadequate dietary fibre12 and 
obesity.12, 13 A familial predisposition is found in up to 20% of patients, with Lynch 
syndrome (also known as hereditary non-polyposis colorectal cancer, HNPCC) and 
familial adenomatous polyposis (FAP) being the most frequently observed hereditary 
syndromes.1  
Colorectal cancers arise most frequently in the rectum (38%), followed by the sigmoid 
colon (21%) and caecum (12%), though can involve any segment of the colorectal 
tract (Figure 1.1). Differences in natural history, treatment approach and long-term 
outcome demand that clear distinction be made between primary cancers of the colon 
and those of the rectum.14, 15 While it is generally accepted that the term ‘colon’ refers 
to all of the large intestine proximal to the rectum, the precise definition of ‘rectum’ 
itself remains debated. From the anatomist’s perspective the rectum begins at the 
level of the third sacral vertebra.16 However, there remains some disagreement from a 
surgical oncology viewpoint; recent guidelines published by the Association of 
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achieve adequate proximal and distal tumour clearance, radial spread can make 
complete surgical resection (R0 resection) more technically demanding.       
Lymphatic spread 
Typically lymphatic spread of CC begins with involvement of lymph nodes (LNs) in the 
immediate vicinity of the bowel wall. This is followed by infiltration of the LNs arranged 
along the ileo-colic, right colic, mid-colic, left colic and sigmoidal arteries, before 
eventual spread to the para-aortic LNs located at the origins of the superior and 
inferior mesenteric arteries.19, 20 This ordered progression of nodal involvement occurs 
in the majority of cases, though is found to occur non-sequentially in a small 
proportion of patients, where lymphatic spread ‘skips’ nodal tiers.21 Unlike rectal 
cancer (RC), it is uncommon for CC that has not breached the bowel wall to exhibit 
lymphatic dissemination.21  
Haematogenous spread 
Blood-borne spread to the liver via the portal circulation represents the principal path 
of haematogenous spread from CC. Approximately 15-25% of patients will have 
detectable hepatic metastatic deposits at the time of diagnosis (synchronous 
metastasis),22, 23 and a further 20% will go on to experience hepatic disease relapse at 
a later stage (metachronous metastasis).24, 25 The lung is the next most common 
organ to be involved as a remote metastatic site in CC, with around 10% of patients 
developing pulmonary metastases.26 Other less frequently observed sites of CC 
metastases include the ovaries, adrenal glands, brain, bone and kidneys.26 
Transcoelomic spread 
Colon cancer can spread via sub-peritoneal lymphatic networks to involve the 
peritoneum, and the identification of peritoneal carcinomatosis represents a significant 
negative prognostic indicator.27 Additionally peritoneal spread may occur by virtue of 
viable cancer cells being shed from the bowel surface, giving rise to malignant ascites, 
a notion supported by the finding of free, viable tumour cells on the fresh surface of 
CRC specimens during surgical resection.28 
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involve the sacrum and the sacral plexus. Local tumour advancement requires more 
radical surgical resection, often necessitating multi-visceral resection.30  
Lymphatic spread 
Lymphatic spread occurs predominantly in an ascending pattern via the higher 
haemorrhoidal inferior mesenteric arterial peduncle to the para-aortic LNs.29   In 
around 20-40% of tumours lying below the peritoneal reflection spread can occur in a 
lateral manner along the course of the middle haemorrhoidal artery.31 Spread in a 
downward direction to the inguinal LNs is infrequently observed.    
Haematogenous spread 
The principal organ for blood-borne dissemination is the liver (33%) with lung (22%) 
and adrenal glands (11%) constituting the most frequent extra-hepatic sites for 
metastases from RC.29  
Peritoneal spread 
This can occur in the setting of a locally aggressive tumour located above the 
peritoneal reflection, after invasion through the peritoneal coat.   
 
1.1.3 Molecular basis of colorectal cancer 
Colorectal carcinogenesis is understood to involve a series of genetic and epigenetic 
alterations that drive the transformation from normal colonic epithelial cells to 
cancer.32  This stepwise process results in sequential morphological change, from 
small adenomatous polyp, to larger dysplastic polyp, through to invasive cancer, and 
is termed the adenoma-carcinoma sequence.33 This pathway is commonly responsible 
for sporadic cases of CRC, though is also characteristically found in familial 
adenomatous polyposis (FAP). Complete transformation from benign polyp to 
definitive cancer in this manner is believed to take on average between 8 and 12 
years.32, 34 Mutation in the adenomatous polyposis coli (APC) gene, a component of 
the Wnt signal transduction pathway, is thought to be the initiating molecular event in 
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the adenoma-carcinoma sequence, and is followed by successive mutations in KRAS 
and P53 which herald progressive adenomatous, and eventually carcinomatous 
transformation.33 This oncogenic pathway is also commonly referred to as the 
chromosomal instability (CIN) pathway, because fundamental chromosomal 
abnormalities such as deletions and insertions are typically identified in cancers that 
develop via this route. The CIN pathway is now regarded as one of at least four 
distinct molecular pathways involved in colorectal carcinogenesis, the other three 
being the microsatellite instability (MSI) pathway, the CpG island methylator 
phenotype (CIMP) pathway and the serrated pathway.1 Chromosomal instability (CIN) 
is observed in 65-70% of sporadic CRCs and refers to an accelerated rate of gain or 
loss of all or part of a chromosome(s), leading to between-cell chromosomal 
heterogeneity.35 This variation leads to an imbalance in chromosome count 
(‘aneuploidy’), a feature long considered integral to the development of colorectal and 
other neoplasms.36, 37 Several theories have been proposed for CIN initiation; the 
fidelity of chromosomal segregation at mitosis is governed by several cell-cycle control 
systems, including the spindle-assembly checkpoint.38 Dysfunctional activity at this 
key mitotic checkpoint has been implicated as a cause of imbalanced chromosomal 
segregation, resulting in chromosomally unstable daughter cells.39 Other proposed 
molecular drivers for CIN include telomerase dysfunction40 and malfunctions in DNA 
damage-response apparatus.41  
Microsatellite instability (MSI) is frequently identified in CRCs arising from hereditary 
non-polyposis colon cancer (HNPCC, also known as Lynch syndrome) though is also 
found in 10-15% of sporadic CRC cases;42-44 microsatellites are defined as short 
repeating DNA sequences, usually located in non-encoding regions, which by virtue of 
their repetitive nature are prone to error.45 Mismatch repair (MMR) genes play a 
critical role in identifying and correcting these errors, and a failure of this mechanism 
leads to persistence of errors and alterations in microsatellite sequence length – 
termed microsatellite instability (MSI). It is thought that MSI can occur as a 
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consequence of mutational inactivation of MMR genes, or alternatively through 
hypermethylation-induced transcriptional silencing of MLH1, a key member of the 
MMR gene family.46  
The third type of genomic instability observed in CRC involves the CIMP pathway; 
promotor methylation leads to gene silencing and is generally accepted to represent a 
normal process that accompanies ageing.47 However, abnormally increased 
methylation (hyper-methylation) is identifiable in around 20% of CRCs, and this is now 
understood to lead to silencing of several key tumour-suppressor genes. Promoter 
hypermethylation is not restricted to CRC, and has been demonstrated in various 
other tumour types including gastric, lung, liver and ovarian cancer.48  
The serrated pathway is responsible for an estimated 7.5% of CRCs, and tumours that 
develop via this route usually arise on the background of serrated precursor lesions 
such as hyperplastic polyps, sessile serrated polyps and serrated adenomas.49 
Serrated adenocarcinomas represent a heterogeneous group of tumours which are 
initiated by a distinct series of molecular events different from those involved in the 
classical adenoma-carcinoma sequence.50, 51 
The molecular mechanisms involved in the pathways outlined above are not mutually 
exclusive, and it is now understood that there can be significant mechanistic overlap, 
leading to a proposed biological classification system into which CRCs are assigned 
based on (i) type of genetic instability (CIN/MSI) (ii) CIMP status (negative/low/high) 
and (iii) morphological origin (adenoma/serrated polyp). In this way five subtypes of 
colorectal cancer have been described1, 52 (Table 1.1).   
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Table 1.1 Molecular classification of CRC 
  
 
1.1.4 The colorectal cancer clinical pathway 
1.1.4.1 Pre-treatment diagnosis and staging 
A definitive pre-treatment diagnosis of CRC is based on histopathological confirmation 
of malignancy following lower gastrointestinal endoscopy (colonoscopy or flexible 
sigmoidoscopy) and lesion biopsy. Standard pre-treatment work-up for CC and RC 
involves clinical examination, endoscopy, confirmation of histology, staging computed 
tomography (CT) imaging of the chest, abdomen and pelvis to assess extent of local 
and distant disease, and multi-disciplinary team (MDT) discussion regarding optimal 
treatment strategy. Though CT is capable of visualising the mesorectal fascia,53 MRI 
is presently regarded as the most detailed local staging modality for RC54 as it 
provides precise information on the topographical relationship between the tumour 
and the surrounding mesorectal fascial envelope.55  
 
Chromosomal 
instability (CIN) 
pathway 
Mismatch 
repair 
pathway 
(MMR) 
Serrated pathway 
Hybrid 
pathway 
 Group I Group II Group III Group IV Group V 
 (Hereditary and sporadic) (Hereditary) Hereditary Sporadic Sporadic 
CIMP status Negative Negative High High Low 
MSI status Stable High instability 
Stable/low 
instability 
High 
instability 
Stable/low 
instability 
Chromosomal 
stability 
status 
Unstable Stable Stable Stable Unstable 
KRAS status Mutated 
May or may 
not be 
mutated 
Normal Normal Mutated 
BRAF status Normal Normal Mutated Mutated Normal 
MLH1 status Normal Mutated 
Partially 
methylated 
Methylated Normal 
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TNM (TNM 5).61 Table 1.2 summarises the key pathological criteria required for TNM 
stage determination in CRC, and outlines the principal differences between the 5th and 
7th editions of the CRC TNM manual guidelines. Corresponding UICC cancer stage 
(Stage I-IV) is determined based on TNM classification (Table 1.3). The Dukes’ 
classification (Table 1.4) 62 predates the TNM system and is less frequently used in 
modern oncological practice. 
    
Table 1.2 TNM classification of CRC 
 TNM 5 TNM 7 
pT1 Tumour invades submucosa As in TNM 5 
pT2 Tumour invades muscularis 
propria 
As in TNM 5 
pT3 Tumour invades subserosa or 
non-peritonealised 
pericolic/perirectal tissues 
As in TNM 5 
pT4 Tumour directly invades other 
organs or structures (pT4a) 
and/or perforates visceral 
peritoneum (pT4b) 
As in TNM 5 but criteria for pT4a and b are 
reversed 
pN1 
Metastasis in 1-3 regional LNs; 
tumour nodules in perirectal or 
pericolic 
adipose tissue without 
histological evidence of residual 
LNs are classified 
according to size 
As TNM 5 but subdivision into pN1a (metastasis 
in a single 
regional LN) and pN1b (metastasis in 2-3 
regional LNs); plus pN1c - tumour deposits 
(satellites) in the 
subserosa, or in non-peritonealised pericolic or 
perirectal soft tissue without regional LN 
metastasis 
pN2 
Metastasis in 4 or more regional 
LNs 
As TNM 5 but subdivision into pN2a (metastasis 
in 
4-6 regional LNs) and pN2b (metastasis in  7 
regional LNs 
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Table 1.3 UICC staging classification criteria for CRC 
UICC stage TNM stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage I T2 N0 M0 
Stage II-A T3 N0 M0 
Stage II-B T4 N0 M0 
Stage III-A T1-2 N1 M0 
Stage III-B T3-4 N1 M0 
Stage III-C Any T N2 M0 
Stage IV Any T any N M1 
Tis tumour confined to the mucosa; cancer in situ 
M1 distant metastases 
 
Table 1.4 Dukes’ classification system for CRC 
Dukes’ stage Pathological criteria 
A Tumour confined to intestinal wall 
B Tumour invading through intestinal wall 
C Tumour with lymph node involvement 
 
 
Current approaches to pre-treatment determination of T-stage 
Precise pre-operative characterisation of local tumour extent is essential for treatment 
planning in CRC. For CC accurate pre-operative staging determines intended extent 
of resection and facilitates appropriate patient selection for NA therapy. The currently 
active FOxTROT (Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative 
Therapy for patients with high-risk, operable colon cancer) clinical trial has been 
designed primarily to evaluate the role of NA chemotherapy in the setting of locally 
advanced CC (T4 tumours or T3 tumours with depth of invasion 5mm into muscularis 
propria).63 However, a secondary aim of this study has been to assess the accuracy of 
pre-treatment staging CT as a means of identifying ‘high risk’ CC suitable for NA 
therapy.63 Thus far the trial has found that pre-operative CT is able to identify ‘high 
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risk’ (T3/T4) tumours (as subsequently confirmed by a pathologist) with a sensitivity of 
87% and specificity of 49%.63 While these findings underline the essential role of CT in 
preoperative CC staging, there remains scope for improving on these figures; for 
example the low reported specificity of 49% implies that a significant number of study 
participants will have been over-staged by CT. Novel additional methods for 
ascertaining pre-operative T-stage would be valuable in this setting as a supplement 
to conventional radiological methods.  
For rectal cancers, MRI has emerged as the most accurate modality with which to 
assess loco-regional tumour burden.64 The strength of MRI lies in the ability to provide 
accurate information regarding the circumferential resection margin (CRM).65 A 
positive CRM (defined as tumour within 1mm of the resection margin65) has been 
shown to lead to increased local recurrence66 and reduced survival,67 and the 
mesorectal fascial plane depicted on MRI has been shown to correlate with the fascia 
propria of the mesorectum resected with TME, which defines the CRM.68 However, 
MRI can be inaccurate in distinguishing T2 from T3 tumours; data from the 
MERCURY Study Group found that on MRI 42% of T2 tumours and 33% of T3 
tumours were over- and under-staged respectively for T-class.69 Endorectal 
ultrasound (EUS) is also used in local staging of RC, though with this approach an 
estimated 18% of T2 rectal lesions are overstaged and 13% of T3 cancers are 
understaged.70 These difficulties in radiological determination of T-stage would have 
significant impact on therapeutic decision-making if all radiologically staged T3 rectal 
cancers were to receive NA therapy. With current radiological imaging modalities 
incorrect T-stage assignment based on MRI/EUS findings can potentially lead to pre-
operative over-treatment of T2 tumours and under-treatment of T3 tumours and this 
underscores the critical need for improved pre-therapy determination of T-class in RC.        
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Current approaches to pre-treatment determination of N-stage  
Determination of LN status prior to surgery is an important factor in deciding whether 
patients with CRC are offered NA therapy. Although NA therapy does not currently 
form a routine part of the treatment pathway in CC, this is likely to change in the future 
and the role of NA therapy in the management of locally advanced, operable CC is 
currently under investigation in the multicentre FOxTROT study,71 which has 
demonstrated encouraging early results. The difficulty with appropriate patient 
selection for such therapy rests in part with the fact that CT-based assessment of LN 
status for CC is challenging. A recent study by Leufkens et al found that CT was able 
to correctly identify LN positive CC with a sensitivity and specificity of 76% and 55%, 
respectively.72 These figures provide a compelling rationale for developing additional 
radiology-independent methods for determining LN status at the pre-treatment phase 
of the CRC clinical pathway. In RC management the role of NA therapy (either long 
course chemoradiotherapy (LCCR) or short course radiotherapy (SCR)) is far better 
established, and at present it is advised that patients with LN positive RC be 
considered for NA therapy.73 However, similar to the difficulties reported in CT staging 
of nodal status in CC, so there are comparable challenges encountered in radiological 
assessment of LN involvement in RC, regardless of choice of imaging modality. To 
illustrate this point, a recent pooled analysis of data from 90 studies reported 
sensitivities and specificities of EUS (67% and 78% respectively) versus MRI (66% 
and 76% respectively) for determining LN status in patients with biopsy confirmed 
RC.74 Difficulties with imaging-centred LN classification are further compounded by 
the recent acknowledgement that increased nodal volume may not necessarily denote 
malignancy.75, 76 These data serve to further highlight the unmet need for enhanced 
nodal classification at the pre-treatment stage. 
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1.1.4.2 Surgical management 
Complete surgical resection represents the only curative strategy in the management 
of CRC and standardized oncological approaches are well established for CC78, 79 and 
RC.80  
For CC, complete oncological resection requires removal of vascular and lymphatic 
vessels at the root of the primary feeding arterial tributary.78 Where the cancerous 
lesion is equidistant from two feeding vessels, it is recommended that both are ligated 
at their origin.81 The identification of portal circulation neoplastic cells in cancer 
patients, and their increase during surgery82 has validated the principle of ‘no-touch’ 
tumour isolation pioneered by Turnbull,83 which advocates early division of major 
vascular pedicles supplying the involved colonic segment. It is believed that removing 
between 5 and 10cm of healthy colon on either side of the tumour will allow adequate 
clearance of epicolic and paracolic lymph nodes, in order to minimise the risk of local 
recurrence.84, 85 Furthermore, it is now suggested that at least 12 lymph nodes are 
taken en-bloc with the cancer specimen in order to accurately determine nodal 
status.86, 87 The finding of adjoining visceral involvement at the time of surgery (T4 
disease) may necessitate en-bloc resection in order to achieve a microscopically 
cancer-free resection margin (R0 resection).  
For tumours located in the right colon a right hemicolectomy with ileo-transverse 
anastomosis is recommended. For transverse colon lesions, a right or left 
hemicolectomy extended to the transverse, a transverse colectomy or a subtotal 
colectomy can be performed, depending on the portion of transverse colon that is 
affected. More recently transverse colectomy has fallen out of favour owing to high 
reported rates of anastomotic dehiscence.88 For tumours arising in the left colon, a left 
hemicolectomy or segmental resection can be carried out. In patients with 
synchronous tumours of the colon, HNPCC or multiple polyps, a total colectomy is 
advocated.89 
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For cancers of the rectum, the contemporary technique of total mesorectal excision 
(TME), popularised by Heald, has been shown to improve local tumour control and 
overall survival,90 whilst also permitting sphincter function preservation and restored 
bowel continuity for improved quality of life.91 The mesorectum is the layer of fatty, 
lymphovascular and neural tissue, measuring 2-3cm in thickness, encasing the rectum 
from the level of the sacral promontory to the pelvic floor,92 itself enveloped by a layer 
of fascia. Mesorectal excision90 refers to the precise removal of this intact soft tissue 
envelope using sharp/diathermic dissection along the avascular areolar plane 
between the mesorectal fascia and the fascia of the pelvic side wall.90 Mesorectal 
excision can be classified as partial (partial mesorectal excision, PME) or total (total 
mesorectal excision, TME); the latter involves complete excision of the mesorectum 
down to the pelvic floor and is performed for tumours involving the middle/lower third 
of the rectum.93 The less disruptive PME can be considered for carcinomas involving 
the upper third of the rectum.94 The more radical abdomino-perineal excision of 
rectum (APER) is performed far less frequently in modern practice, being reserved 
typically for extensive tumours of lower third of the rectum.   
Surgical resection for CC can be achieved by conventional open or laparoscopic 
means, and large-scale trials have confirmed the oncological equivalence of 
laparoscopy compared with open surgery in this setting.95-97 Comparatively, for RC 
level-1 evidence is lacking, though it is anticipated that the upcoming results from 
currently open RCTs will strengthen the evidence for improved short-term and 
equivalent long-term outcomes with laparoscopic RC surgery.98  
Since the widespread adoption of conventional laparoscopy a variety of minimal-
access surgical (MIS) techniques have been introduced in colorectal surgical practice, 
and the role of these approaches, such as transanal endoscopic microsurgery 
(TEMS)99 and endoscopic mucosal resection (EMR)100 in the management of benign 
and malignant colorectal tumours is currently the subject of multi-national RCT-based 
evaluation. The anticipated increasing application of these ‘organ-sparing’ approaches 
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1.1.4.3 Prognostic histopathological parameters in colorectal cancer 
Clinical and pathological risk prediction/stratification after colorectal cancer resection 
is based on histopathological tumour staging and characterisation, which in broad 
terms aims to: (1) determine completeness of resection (2) accurately stage the 
resected tumour and (3) identify patients likely to benefit from adjuvant therapy. 
Pathological tumour stage (pTNM) is determined according to the criteria outlined in 
Table 1.2.  
The finding of cancer deposits in resected LNs confers a significant negative 
prognostic impact and represents one of the most important clinico-pathological 
predictors for recurrence and survival in CRC.102 The finding of regional LN 
metastases is associated with an increased risk of local and/or distant disease 
relapse, and current guidelines recommend that these patients (UICC stage III) be 
considered for adjuvant chemotherapy.103 Unfortunately, around 10-25% of patients in 
whom no evidence of LN involvement can be found (UICC stage I or II) go on to 
experience local recurrence or distant metastatic disease within 5 years.104, 105 This 
has called for the development of more robust means of determining LN status at the 
time of initial treatment to avoid under-staging. Several strategies have been 
suggested to address this requirement, including multi-level LN sectioning (MLS) to 
evaluate a larger proportion of nodal tissue,106 immunohistochemical staining for 
cytokeratins and other tumour markers,106  and application of polymerase-chain 
reaction (PCR) based methods to identify LNs harbouring mutant KRAS or p53.107 
These methods are aimed at identifying micro-metastatic LN involvement, and 
although all have shown early promise, each technique is fundamentally reliant on the 
acquisition of sufficient nodal material at time of surgery. Nodes harbouring metastatic 
or micro-metastatic disease can be missed if an insufficient number of LNs are 
obtained at the time of resection, or if recommended histopathological assessment 
guidelines are not strictly adhered to.  
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For CC current data suggest that a minimum of 12 LNs should be examined per 
cancer resection specimen to allow adequate staging.108 However, a recent analysis 
of 1585 patients undergoing right or left hemicolectomy for stage II or III colon cancer, 
where the average number of LNs obtained was 18.5, concluded that achieving an 
85% probability of true LN negative disease would require examining approximately 
40 LNs.109   
Similarly for RC current TNM guidelines advocate retrieval and histopathological 
evaluation of at least 12 LNs with the resection specimen.93 This recommendation is 
validated by the findings of Caplin et al who demonstrated that node negative patients 
with TME specimens providing fewer than 7 LNs for evaluation had a prognosis 
similar to that of patients with confirmed LN positive disease.110 Likewise Tepper et al 
found improved disease-free survival in patients having more than 14 LNs evaluated 
compared with those with fewer than 8.111 Though these studies confirm the 
importance of adequate LN yield, experts also acknowledge that in practice, even 
acquiring the minimum recommended number of 12 LNs can be challenging. This is 
evidenced by the findings of the landmark Dutch TME trial, where over 80% of 
patients deemed to have LN negative disease had fewer than 12 LNs assessed by the 
pathologist.112 
Besides LN status, other factors that are routinely assessed include primary tumour 
characteristics (including depth of tumour penetration in the bowel wall, histological 
subtype, histological grade and differentiation, tumour budding and its invasive front, 
venous/lymphatic/perineural/lymphatic invasion) and the status of the surgical 
resection margins (proximal, distal and circumferential; free (R0), microscopic residual 
disease (R1), macroscopic residual disease (R2)). In addition, emerging data on novel 
prognostic strategies such as immunological cancer scoring and tumour micro-
environmental profiling have shown significant early promise.113, 114 Biochemical 
profiling does not currently form a routine part of the CRC pathological evaluation 
strategy; however, recent advances in analytical biochemistry101 have led the 
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development of a variety of profiling platforms that are well suited for this purpose, and 
can offer additional insights into CRC biology. Table 1.5 provides a summary of the 
major histopathological features assessed in CRC and outlines the potential 
contribution that novel tissue-biochemistry profiling approaches can deliver in this 
context.  
 
Table 1.5 Established histopathological prognostic markers in colorectal cancer. Text 
emphasised in blue highlights potential areas of application for emerging molecular profiling 
and molecular imaging platforms 
Pathological 
parameter 
Summary Prognostic effect Future perspectives 
Lymph node 
status 
 12 LNs should be 
assessed93, 108 
 Some studies advocate 
a greater number109, 111 
 Risk of LN metastases 
increases with depth of 
tumour invasion115, 116 
 LN involvement impacts 
negatively on LR and 
DFS117 
 LN positive patients 
(UICC Stage III) should 
routinely be considered 
for adjuvant therapy87 
 Molecular markers may be used to 
identity LN metastasis in 
morphologically bland LN tissue107, 
118 
 Techniques such as sentinel LN 
sampling may improve detection of 
LN positive disease119 
 Emerging profiling methods may 
improve pre-operative and post-
operative determination of LN status 
Tumour depth of 
invasion 
 Submucosal invasion 
permits vascular and 
lymphatic 
dissemination 
 Absolute thickness of 
submucosal invasion 
predicts LR after 
endoscopic resection120 
 Important independent 
prognostic variable for 
larger surgically 
resected tumours121 
 Improved biomolecular 
characterisation of changes arising 
during local tumour advancement 
may offer a means of developing 
next-generation, targeted cancer 
down-staging approaches 
Tumour size 
 Prognostic impact of 
lesion size remains 
debated122 
 A number of studies 
have shown no effect 
on prognosis122 
 Others suggest 
increased size confers 
independent negative 
prognostic impact123 
 Increasing polyp size 
also associated with 
- 
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increased malignant 
potential124 
Histological 
sub-type 
 Majority of CRCs are 
adenocarcinomas 
 Mucinous and signet 
ring adenocarcinoma 
constitute ~ 8% and 1-
2% of these 
respectively125 
 Impact of mucinous 
histology on prognosis 
is unclear with 
conflicting evidence126 
 Signet ring morphology 
is an independent 
negative prognostic 
factor127 
 Emerging molecular profiling 
approaches can offer fresh 
biochemical perspectives on the 
metabolic diversity of these 
histological variants  
Differentiation 
 Inconsistently used as 
a prognostic factor 
due to subjective 
nature of assessment 
 
 Multivariate analysis 
has demonstrated 
inferior survival 
outcomes for poorly 
differentiated and 
undifferentiated 
cancers128 
 Emerging molecular profiling 
approaches can offer fresh 
biochemical perspectives on the 
biology of these histological 
variants 
Lymphovascular 
invasion 
 EMVI in CRC is 
reported with an 
incidence ranging 
from 10-90% 
depending on staining 
approach used129 
 Use of elastic stain on 
all tumour blocks 
results in highest pick-
up rate129 
 LVI is an significant, 
stage-independent 
negative prognostic 
factor in CRC123 
 EMVI appears to be 
prognostically more 
significant than IMVI130 
 LVI in UICC Stage II 
CRC requires 
consideration for 
adjuvant therapy 
 Significant inter-observer variability 
has been reported with regards to 
LVI detection 
 Novel molecular imaging 
methodologies may be capable of 
detecting chemical signatures in 
vascular channel walls to 
supplement conventional staining 
methods 
Perineural 
invasion 
 Reported in up to 33% 
of CRCs131 
 Some studies have 
indicated significant 
under-reporting of this 
feature123 
 Associated with 
reduced DFS and 
increased LR132 
 Should prompt 
consideration for 
adjuvant therapy in 
Stage II disease  
 Novel molecular imaging 
methodologies may be capable of 
improving detection of perineural 
invasion using biochemical means 
Tumour budding 
 Indicator of tumour 
invasiveness133 
 Thought to be a 
feature specific to 
tumours exhibiting an 
infiltrating growth 
pattern134 
 Has been shown to be 
an independent 
prognostic factor for LR 
and DFS133 
 Some evidence to 
suggest inversely 
correlative relationship 
between presence of 
tumour budding and 
- 
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1.2 Introduction to metabolic profiling: ‘Metabonomics’ 
Systems biology involves integrating and analysing complex data from multiple 
research domains to create a biologically comprehensive view of system activity.138 
This approach represents an expanding translational research initiative, driven by the 
need to understand the biological processes involved in health and disease more 
precisely.139 Well established fields on the systems biology landscape include 
genomics (the study of the entire genome of an organism), transcriptomics (the study 
of the gene expression of an organism) and proteomics (the study of the protein 
expression of an organism). The majority of research undertaken to investigate CRC 
biology over the last two decades has focused largely on macro-molecules (DNA, 
RNA, protein); while these avenues of research continue to make important strides, it 
is now widely acknowledged that a macro-molecular view is incapable of providing all 
the biological answers.  In this regard, ‘Metabonomics’ (also known as metabolomics 
or metabolic profiling) has emerged more recently as a means of interrogating micro-
molecular fluxes that accompany complex disease processes such as cancer. 
Metabonomics is defined as the systematic study of dynamic metabolic shifts that 
occur in a living system in response to drugs, environmental stimuli or disease.140 This 
approach permits the simultaneous identification and quantification of thousands of 
‘small molecules’, at the lower end of the molecular-weight spectrum, creating a 
unique metabolic ‘fingerprint’.  
Although intended to complement upstream genomic and proteomic information 
metabonomics offers several advantages over these other ‘-omics’ approaches. For 
example, though numerous gene and protein expression alterations have been 
identified in human disease, determining the relevance of these expression changes 
and the biochemical networks they influence has been limited by the vast size of the 
human proteome and its myriad of functions. The ‘metabolome’ (defined as the 
complete set of low-molecular weight metabolites contained within a biological 
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system) adopts a post-transcriptional view and can be considered as the downstream 
summation of preceding gene expression and protein activity, illustrating the true 
functional state of a given bio-system.101 In addition, from an interpretational 
perspective metabolic profiling is aided by the fact that the human metabolome is 
comprised of an estimated 2500 metabolites, in comparison to the estimated 25000 
genes and 1 million proteins that make up the human genome and proteome 
respectively.141 This can significantly streamline data handling, mining and biomarker 
retrieval. Furthermore, metabolic profiling approaches provide biomolecular 
information that reflects gut microbial activity and other environment-driven system 
signatures, information that cannot be captured at genomic, transcriptomic or 
proteomic levels.101 These technologies are therefore particularly well-suited to the 
evaluation of aetiologically diverse diseases such as cancer.    
Metabolic profiling approaches have been successfully applied to the analysis of 
numerous information-rich biofluids142-146 and tissue samples.147-152 This versatility 
lends itself well to surgery, where highly diverse biological material can be sampled 
from patients based on the type and location of pathology encountered. Importantly, 
with respect to the aims of this body of work, a limited number of studies have 
demonstrated potential for metabolic profiling approaches in the identification of 
chemical biomarkers for ovarian,146 gastric,148 lung,149 colorectal,150 breast,151 and 
prostate152 cancers. It is anticipated that in the near future metabolic profiling 
technologies will become a highly valuable tool in surgical oncology, where the 
metabolic adaptations initiated by complex pathological processes such as cancer are 
still only partially understood. Between-host variation in these metabolic fluxes may 
account for the vast heterogeneity encountered in cancer-related outcomes, and 
characterising these will be critical to realising the ultimate objective of precision 
cancer care.153   
In broad terms, the two most well established analytical techniques in metabolic 
profiling are nuclear magnetic resonance (NMR) spectroscopy154 and mass 
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spectrometry (MS).155 Nuclear magnetic resonance (NMR) is a phenomenon which 
occurs when atomic nuclei are immersed in a static magnetic field and then exposed 
to a second oscillating magnetic field.101 Under these conditions, the nuclei of certain 
atoms (those with an odd number of protons, neutrons or both) exhibit a property 
termed ‘spin’ (I), and this generates an electrical signal. The spin properties of 
different atomic nuclei comprising a given analyte resonate at characteristic 
frequencies and these resonances can be measured and spectrally displayed. From 
the positions and intensities of the peaks in spectra generated by this means, both the 
nature of the biochemical species and the relative concentrations in which they are 
present in a sample can be determined154 (Figure 1.6A). 
In mass spectrometry (MS) the biochemical composition of a sample is derived 
according to the mass-to-charge (m/z) ratio of the particles within it.101 In principal, MS 
-based studies involve first ionising the sample being evaluated by one of a variety of 
ionisation techniques (for example using an electron beam) to generate charged 
particles (ions)155 (Figure 1.6B). The ions are fed through an analyser and separated 
based on m/z ratio using an externally applied electromagnetic field.155 The resulting 
focused beam of ions is then detected, and the resulting ion signature is depicted as a 
spectral MS profile (Figure 1.6B). As with NMR spectroscopy, the biochemical species 
and their relative concentrations can be determined from the positions and intensities 
of the spectral peaks, respectively. Metabolite separation in conventional MS studies 
employs either gas chromatography (GC-MS) or liquid chromatography (LC-MS) and 
the choice of technique here is based largely on the chemical compound being 
investigated.156 Gas chromatography is sensitive and reliable as a separation method, 
though it is not well-suited to the analysis of large and thermo-labile compounds such 
as sugar nucleotides or large oligosaccharides (due to the limited volatility of these 
molecular compounds).157 Liquid chromatography is the preferred separation method 
under these circumstances. Mass spectrometry experiments can be carried out using 
targeted157 or untargeted158 approaches depending on whether the aim is to search 
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for, and quantitate, pre-defined chemical sub-classes, or to generate a more holistic 
biochemical phenotype.   
Concurrent advances in other areas of medical spectroscopy should be acknowledged 
here with respect to their growing application in tissue profiling. The application of 
emerging optical techniques such as fluorescence, reflectance and Raman 
spectroscopy has shown considerable promise in cancer diagnostics over the last 
decade.159, 160  Although these methods are not directly linked with the approaches 
employed in this thesis, it is likely that they will offer an additional layer of information 
to complement metabolic phenotyping strategies.   
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Until recently the inability to non-destructively profile tissue specimens has presented 
a challenge as sample preparation steps with conventional NMR and MS analysis 
lead to significant tissue architectural disruption. Recent advances in NMR and MS 
technology have sought to address this limitation and have led to an explosion of 
next-generation intact-tissue analytical platforms including, but not limited to, high-
resolution magic-angle spinning NMR (HR MAS-NMR) spectroscopy 161 and imaging 
mass spectrometry methodologies such as matrix-assisted laser desorption 
ionisation imaging MS (MALDI-MSI),162 secondary ion mass spectrometry (SIMS) 163-
165 and desorption electrospray ionisation imaging MS (DESI-MSI).166, 167 The full 
translational potential of these techniques in systems oncology has yet to be realized; 
however, by virtue of their non-destructive nature these approaches all have one 
advantageous property in common: namely the ability to correlate tissue architecture 
with biochemical characteristics and thus to bridge the gap between cancer 
morphology and metabolism. A comprehensive description of these techniques and 
the theoretical principles of NMR spectroscopy and MS are provided in Chapter 3.  
 
1.3 Metabolic deregulation in cancer: Warburg and beyond 
The concept of altered metabolism in cancer was first described in the 1920s by Otto 
Warburg who demonstrated that cancer cells consume high levels of glucose, 
converting it to lactate (‘aerobic glycolysis’) even in the presence of sufficient oxygen 
supply.168 This phenomenon is termed the Warburg effect and represents the 
fundamental basis for much of the research conducted on tumour cell metabolism 
since. Increased tumour cell glycolysis generates abundant energy in the form of 
adenosine triphosphate (ATP) albeit at the expense of glucose stores, and the lactate 
that accumulates as a consequence creates an acidic microenvironment.168 This 
seemingly inhospitable environment is now thought to actually encourage tumour 
survival and metastasis by selecting for more aggressive tumour sub-clones.169   
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The theme of reduced tissue glucose and increased glycolysis has been revisited by 
numerous studies and it is now widely accepted that relative to healthy cells, cancer 
cells exhibit an enhanced glycolytic mechanism with reduced oxidative 
phosphorylation.101 In keeping with this concept a recent colorectal cancer based 
study by Ong et al identified increased glucose uptake in cancer cells as a hallmark 
metabolic trait in cancerous tissue.170 Interestingly however, the group found that the 
Warburg effect was also a feature in pre-malignant polyp cells, before the initiation of 
hypoxia, suggesting that the ‘glycolytic switch’ may be triggered before the ‘hypoxic’ 
and ‘angiogenic’ switches that are thought to precede definitive cancerous 
alteration.170 This notion is further supported by a recent study by Yakoub et al 
demonstrating abnormal metabolic signatures in histologically bland oesophageal 
tissue. The authors postulated that cancers arise in areas of altered metabolic 
phenotype and that this biochemical transformation occurs before any morphological 
features of malignancy are apparent.171 These studies provide key information on the 
energy requirements necessary for cells with malignant potential to complete the 
process of cancerous transformation and indicate the potential role of metabolic 
interrogation in early cancer diagnosis. In addition the fact that so many tumour types 
demonstrate such critical dependence of glycolysis presents an attractive avenue for 
therapeutic intervention, and a number of groups have evaluated the use of glycolytic 
pathway enzyme-inhibitors as novel anti-cancer agents with encouraging results.172-
177 
Glycolysis alone is incapable of matching the high energetic requirements of 
developing cancer cells, and a number of other metabolites have been implicated in 
carcinogenesis, including glutamine (which has been identified as a key bio-energetic 
substrate in various cancer cell subtypes) 178, 179 and phosphorylated lipid metabolites 
(which play a central role in cell replication).180 Fluxes in these and other  metabolites 
appear to confer a survival advantage to cancer cells through modulation of cellular 
energetics, cancer-cell signalling and metabolic optimisation of the tumour cell 
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milieu.181 The interrogation of these metabolic profiles presents exciting possibilities 
for the future discovery of tumour-specific cancer biomarkers and for the design of 
novel biological targets based on cancer-specific metabolic properties. Table 1.6 
provides a summary of some recent studies employing metabolic profiling 
approaches in the study of cancer.101  
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Author, 
Year, 
Location 
Analyte Platform Sample size Study design & findings Implicated metabolic pathways 
Significant metabolic 
discriminators 
Colorectal       
Denkert et al 
182, 2008, 
Germany 
Tissue GC-MS CRC (27) HMt 
(18) 
Study design: Comparison of TMP for 
CRC vs. HMt from colectomy 
specimens. 
Findings: Distinct TMP for CRC vs. 
HMt 
TCA cycle 
Nucleotide biosynthesis 
Protein metabolism 
Lipid metabolism 
 in CRC : oleic acid, N-
acetylglycine, inositol stereoisomer 
 in CRC: alamine, phenylalanine, 
methionine, proline 
 
Chan et al 
147, 2009, 
Singapore 
Tissue HR MAS-
NMR 
GC-MS 
CRC (31) HMt 
(31) 
Study design: Comparison of TMP for 
CRC vs. HMt 
Findings: Discriminatory TMP with 
both NMR and MS for CRC vs. HMt. 
NMR also found distinct TMP for 
colon  vs. rectal cancers 
Glycolysis 
Nucleotide biosynthesis 
Lipid metabolism 
Steroid metabolism 
NMR 
 in CRC : lipids, PEG and glucose 
 in CRC: choline-containing 
compounds, taurine, lactate 
 
MS 
 in CRC: fumarate, malate, 
glucose 
 in CRC: lactate, phosphate, L-
glycine 
 
Ritchie et al 
142, 2010, 
Canada 
Serum FTICR-MS 
LC-MS 
NMR 
CRC (222) HC 
(220) 
Study design: Comparison of SMP 
for PR CRC vs. HC in 3 independent 
populations from USA and Japan 
Findings: Discriminatory fatty acid 
profile in all 3 populations for CRC 
vs. HC. 
Fatty acid metabolism  in CRC: hydroxylated ultra-long 
chain fatty acids. 
Wang et al 
143, 2010, 
China 
Urine UPLC-MS CRC (50) BP 
(34) HC (34) 
Study design: Comparison of UMP 
for CRC vs. BP vs. HC 
Findings: Discriminatory UMP for 
CRC vs. BP vs. HC. Metabolic 
patterns identified to correspond with 
adenoma-carcinoma sequence. 
Glutamine metabolism 
Fatty acid oxidation 
Nucleotide biosynthesis 
Protein metabolism 
 in HCBPCRC: acylcarnitine 
(C1 3:0) 
 in HCBPCRC: 
phenylacetylglutamine, 
prolylleucine, aspartylysine, uridine, 
pseudouridine 
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Qiu et al 183,  
2010, China 
Urine GC-MS CRC (60) HC 
(63) 
Study design: Comparison of UMP 
for PR CRC vs. PO CRC vs. HC 
Findings: Distinct UMP for pre-
operative vs. post-operative vs. HC. 
Tryptophan metabolism 
TCA cycle 
 in CRC: succinate, isocitrate, 3-
methylhistidine, citrate 
 in CRC: hydroxytryptophan, 
glutamate, 5-hydroxyindoleacetate 
 
PO CRC samples showed a return 
towards levels of these compounds 
seen in HC. 
 
Breast       
Bathen et al 
184 , 2007, 
Norway 
Tissue HR MAS-
MRS 
BCa (77) Study design: TMP comparison of 
cancer vs. adjacent normal tissue 
from 77 patients with BCa. 
Comparison of TMP for different 
clinicopathological features (LN 
status/hormone receptor status). 
Findings: Distinct TMP for LN +ve 
and hormone +ve BCa. 
N/A Hormone +ve status 
 taurine 
 glycine, phosphocholine 
 
LN +ve status 
 lactate, glycine, phosphocholine 
 taurine, glycerophosphocholine 
 
Sitter et al 
151, 2009, 
Norway 
Tissue HR MAS-
NMR 
BCa (29) Study design: TMP comparison of 
clinically defined good (13) and poor 
(16) prognosis breast cancer 
specimens. 
Findings: Distinct TMP identified for 
good and poor prognosis breast 
cancers. 
N/A Good prognosis:  glycine 
Poor prognosis:  glucose,   
Sugimoto et 
al 144, 2010, 
Japan 
Saliva CE-TOF-MS BCa (30) HC 
(87) 
Study design: Comparison of SaMP 
for BCa vs. HC.  
Findings: Distinct SaMP for BCa vs. 
HC  
Amino acid metabolism 
Phospholipid metabolism 
 in BCa: teurine, 
glycerophosphocholine 
 in BCa: leucine, isoleucine, 
tyrosine, lysine, proline 
Asiago et al 
185 , 2010, 
USA 
Serum H-NMR 
GC-MS 
BCa (56) Study design: Serial SMP (5 per 
patient) over a 6-year follow up 
period for patients with previously 
surgically treated BCa to identify 
Amino acid metabolism 
Glycolysis 
Phospholipid metabolism 
Fatty acid metabolism 
 in RBCa: formate, histidine, 
proline, choline 
 in RBCa: tyrosine, lactate 
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recurrence associated metabolic 
profiles.  
Findings: SMP able to predict 
likelihood of recurrence with 86% 
sensitivity and 84% specificity.  
Oakman et 
al 186, 2011, 
Italy 
Serum NMR EBCa (41) 
MBCa (51) 
Study design: Comparison of SMP 
for EBCa vs. MBCa. 
Findings: Distinct SMP for EBCa vs. 
MBCa 
Lipid metabolism 
Nucleotide biosynthesis 
Glycolysis 
 in MBCa: lipids 
 in MBCa: phenylalanine, glucose, 
proline, lysine 
Prostate       
Sreekumar 
et al 187, 
2009, USA 
Tissue 
Plasma 
Urine 
GC-MS 
LC-MS 
BPPCa (59) 
BNC (51) 
Study design: Triple-axis profiling of 
tissue, serum and urine to compare 
BPPCa vs. BNC 
Findings: Distinct profiles for benign 
vs. clinically localised cancer vs. 
metastatic disease. Sarcosine 
implicated as particularly significant 
metabolite.  
Amino acid metabolism 
Nitrogen breakdown pathways 
 in benignPCaMetastatic 
disease: sarcosine, uracil, 
kynuremine, glycerol-3-phosphate, 
leucine, proline. 
  
Maxeiner et 
al 188,  2010, 
USA 
Tissue HR MAS-
NMR 
RPCa (16) 
NRPCa (32) 
Study design: Retrospective HR-MAS 
NMR evaluation of tissue from 48 
patients who had previously 
undergone radical prostatectomy to 
identify BCR-associated TMP. 
Findings: able to ‘predict’ BCR with 
accuracy of 78% based on four 
principal metabolic components.  
N/A N/A 
Thysell et al 
152, 2010, 
Sweden 
Bone 
Tissue 
Plasma 
GC-MS 
 
BMPCa (20) 
BNC (30) 
Study design: Triple-axis profiling of 
bone, prostatic tissue and plasma to 
identify metabolic disturbances 
associated with PCa progression and 
metastasis. 
Findings:  Distinct profiles for benign 
vs. clinically localised cancer vs. 
Amino acid metabolism 
Cholesterol handling and metabolism 
 in benignPCaMetastatic 
disease: cholesterol, fumarate, citric 
acid, myo-inositol, glycerol-3-
phosphate. 
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Table 1.6 Application of metabolic profiling strategies in colorectal, breast, prostate and lung cancers demonstrating recurring themes of altered metabolism 
across cancer subtypes 
UPLC/MS ultra-performance liquid chromatography mass spectrometry; CRC colorectal cancer; HC healthy control; UMP urinary metabolite profile; PR pre-
operative; PO post-operative; N/A data not provided; LMWC low molecular weight compound; GC-MS gas chromatography mass spectrometry; TMP tissue 
metabolite profile; HMt healthy matched tissue; TCA tricarboxylic acid; HR MAS- NMR high resolution magic-angle spinning nuclear magnetic resonance; 
PEG polyethylene glycol; FTICR-MS Fourier transform ion cyclotron resonance mass spectrometry; SMP serum metabolite profile; BP benign polyps; HR 
MAS-MRS high resolution magic-angle spinning magnetic resonance spectroscopy; BCa breast cancer; LN lymph node; CE-TOF-MS capillary 
electrophoreses time-of-flight mass spectrometry; SaMP salivary metabolite profile; RBCa recurrent breast cancer;  EBCa early breast cancer; MBCa 
metastatic breast cancer; BPPCa biopsy-positive prostate cancer; BNC biopsy negative control; RPCa recurrent prostate cancer; NRPCa non-recurrent 
prostate cancer; BCR biochemical recurrence; BMPCa bone metastasised prostate cancer; LCa lung cancer. 
metastatic disease. Cholesterol 
identified as important marker of 
bony metastases.  
Lung       
Rocha et al 
149, 2010, 
Portugal 
Tissue HR MAS-
NMR 
LCa (12) HMt 
(12) 
Study design: Comparison of TMP for 
LCa vs. HMt (taken from healthy 
tissue adjacent to tumour).  
Findings: Inherently different 
metabolic signatures found between 
LCa and HMt.  
Glycolysis 
Energy metabolism 
Phospholipid metabolism 
 in LCa: glucose, myo-inositol, 
inosine/adenosine, acetate 
 in LCa: lactate, phosphocholine, 
GPC. 
Carrola et al 
145, 2011, 
Portugal 
Urine NMR LCa (71) HC 
(54)  
Study design: Comparison of UMP 
for LCa vs. HC.  
Findings: Very good discrimination 
between LCa and HC with 93% 
sensitivity and 94% specificity.  
TCA cycle 
Nicotinate metabolism 
Nicotinamide metabolism 
 in LCa: hippurate, trigonelline 
 in LCa: β hydroxyisovalerate,  
hydroxyisobutyrate, N-
acetylglutamine, creatinine. 
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1.4 Potential translational application of metabolic profiling 
approaches at key phases of the colorectal cancer patient 
journey 
The emerging metabolic profiling methods outlined in section 1.2 constitute a broad 
class of bio-analytical approaches that can offer novel insights into CRC biology. The 
rich molecular information these methods generate, the potential for correlation of 
tissue morphology with biochemistry, and the rapid time-scale on which certain 
platforms evaluated here can provide disease-relevant data, offer the potential for 
translational deployment of NMR spectroscopy and MS technologies at different, key 
phases of the CRC clinical pathway.101  
High resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) 
spectroscopy has been shown to be capable of non-destructive and highly reproducible 
profiling of intact tissue samples and has the potential to inform the clinician regarding 
tissue characteristics (for example cancerous versus healthy tissue) within a rapid time-
frame, requiring only minimal tissue volume (typically 10mg per sample). The speed 
of this approach, minimal tissue requirements and minimal sample preparation 
procedure mean that this technique can potentially be used to evaluate endoscopically 
derived tissue biopsies, for ultra-fast tissue diagnostics, based purely on biochemistry. 
In addition, this technique may provide a novel approach for intra-operative tissue 
diagnosis as an alternative to tissue frozen-section.   
Imaging mass spectrometry (MSI) is a rapidly advancing branch of MS that provides an 
additional layer of spatio-chemical information to supplement conventional histological 
and immunohistochemical tissue classification methods. This technology is currently 
most likely to have translational impact at the prognostic end of the CRC clinical 
pathway, as currently more tissue is required for this analysis than is routinely obtained 
at time of endoscopic biopsy.        
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with potential to impact at different phases of the CRC clinical journey as 
summarised in Figure 1.8. The specific aims and objectives of the different 
components of this work are outlined more precisely in Chapter 2.   
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Chapter 2 – Aims and objectives 
 
High resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) 
spectroscopy 
 
In this section of my research the following hypotheses were formulated and tested: 
1. HR-MAS NMR spectroscopic profiling can deliver novel metabolite-based 
data for ultra-fast and robust distinction of cancerous from healthy colorectal 
tissue samples 
2. HR-MAS NMR spectroscopic profiling of colorectal tissue can identify 
metabolic differences at tissue level between primary cancers of the colon 
and rectum 
3. HR-MAS NMR spectroscopic signatures derived from colorectal cancer tissue 
samples can identify molecular predictors of cancer stage (T-stage and/or N-
stage) 
 
Specific objectives designed to test the above hypotheses: 
1. To develop HR-MAS NMR derived metabolic bio-panels to distinguish 
cancerous from healthy matched colorectal mucosal samples obtained from a 
prospectively recruited cohort of patients with biopsy confirmed CRC 
2. To develop HR-MAS NMR based models to identify biochemical differences 
between cancerous tissue samples obtained from colonic tumours and rectal 
tumours 
3. To identify and characterise variation in HR-MAS NMR profiles of CRC tissue 
according to local tumour extent (T-stage) and nodal dissemination (N-stage) 
 
 
1 
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Matrix-assisted laser desorption ionisation imaging mass spectrometry (MALDI-MSI)  
 
 
In this section of my research the following hypotheses were formulated and tested: 
1. MALDI-MSI analysis of CRC tissue can provide region-specific chemical 
information for tumour microenvironmental profiling 
2. MALDI-MSI profiling of CRC and healthy adjacent tissue will reveal section 
specific differences according to presence/absence of cancer to develop 
methods for ‘chemical histological’ tissue assignment 
3. MALDI-MSI profiling of ‘tumour-adjacent’ and ‘tumour-remote’ non-cancer 
bearing mucosa can reveal differences in biochemistry within the tumour field 
which can build on current theories of field cancerisation and may have 
prognostic significance.  
 
 Specific objectives designed to test the above hypotheses: 
1. To identify MALDI-MSI derived biochemical signatures within different tissue 
types comprising the CRC tumour microenvironment by direct co-registration 
with corresponding H&E stained tissue sections 
2. To develop a novel method with which to summarise the global metabolic 
profile obtained from MALDI-MSI analysis of cancer-bearing and non-cancer 
–bearing tissue sections with a view to test a proof-of-concept ‘machine-
learned’ approach to tissue classification 
3. To perform MALDI-MSI based comparison of tumour-adjacent and tumour-
remote healthy mucosa to develop novel chemical based means of identifying 
the tumour field   
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Desorption electrospray ionisation imaging mass spectrometry (DESI-MSI)  
 
 
In this section of my research the following hypotheses were formulated and tested: 
1. DESI-MSI profiling of colorectal cancer tissue can provide metabolic insights 
into tumour microenvironmental biology with enhanced ability to co-register 
metabolic signatures with morphological regions of interest (ROI) 
2. DESI-MSI profiling of CRC tissue can be used to create ROI-specific 
chemical databank for sample-to-sample comparative molecular analysis 
without the need for laser capture micro-dissection  
 
Specific objectives designed to test the above hypotheses: 
1. To identify DESI-MSI derived biochemical signatures within different tissue 
types comprising the CRC tumour microenvironment by direct co-registration 
with same section H&E stained images  
2. To compile a ‘histologically authentic’ chemical database comprised of ROI-
specific molecular ion patterns for novel sample-to-sample biological 
comparative analysis 
3. To concurrently develop a novel software interface for intuitive, ‘clinician-
friendly’ visualisation, mining and analysis of histology-driven MSI data 
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neutrons in a given atomic nucleus. Where the number of protons and neutrons are 
both even, then I=0 i.e. there is no overall spin.190 A characteristic of atomic nuclei is 
that a nucleus of odd mass number (here mass number is defined as the sum of the 
number of protons and neutrons) will have a half integer spin (i.e. I=1/2, 3/2, 5/2), while 
a nucleus of even mass number will possess an integer spin value (i.e. I=1, 2, 3).190, 192 
The spin properties for various atomic nuclei are provided in Table 3.1 according to this 
principle.    
 
Table 3.1 Spin properties for various atomic nuclei 
Number of protons Number of neutrons Spin quantum 
number (I) 
Examples 
Even Even 0 12C, 16O, 32S 
Odd Even ½ 1H, 19F, 31P 
Odd Even 3/2 11B,35Cl, 79Br 
Even Odd ½ 13C 
Even Odd 3/2 127I 
Even Odd 5/2 17O 
Odd Odd 1 2H, 14N 
 
 
In quantum mechanical terms, a nucleus of spin I will have 2I + 1 possible spin 
orientations.190 Spectral interpretation in NMR is simplified where the spectra are 
generated by isotopes capable of assuming only two possible spin orientations. This is 
the case for spin I=1/2 nuclei (where 2I +1=2, meaning there are 2 possible nuclear 
spin states). Accordingly, in organic chemistry elemental isotopes of particular interest 
are 1H, 13C, 19F and 31P, which all possess I=1/2. 
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The FID is a time domain signal which must then undergo Fourier transformation to 
convert the acquired signal into the frequency domain, producing a spectrum depicting 
the resonance frequencies of the different atomic nuclei comprising the sample being 
analysed.190 Molecular species in the resulting spectra are labelled according to 
chemical shift (δ), which is typically expressed in parts per million (ppm) and is 
calculated from equation 3.1 
 
  
       
    
        (3.1) 
 
Where δ is the chemical shift, γ is the resonance frequency of a given molecular 
species of interest and γref is the resonance frequency of a reference compound. The 
detected frequencies for 1H nuclei are conventionally referenced against tetra-
methylsilane (TMS) which is assigned a chemical shift of δ 0.00.   
 
3.1.4 1H NMR and basic 1D and 2D NMR experiments 
The 1H nucleus is the most commonly observed nucleus in NMR spectroscopy. 
Hydrogen is present in most organic molecules and the intrinsic sensitivity of the proton 
together with its abundance in living systems make it a highly favourable nucleus to 
observe in NMR-based chemical fingerprinting of biological samples.  With one-
dimensional (1D) NMR experiments chemical compounds are characterised based on 
spectral amplitude plotted against a single frequency axis.154 This approach can allow 
rapid determination of the chemical composition of a given sample and provide a direct 
measure of chemical concentration based on a single internal standard. However, 
biochemical assignment can be challenging in circumstances where there is significant 
spectral peak congestion and overlapping of features, and this represents a limitation 
with 1D methods.154 Where the aim is to profile chemical species at the lower end of 
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3.1.5 High-resolution magic angle spinning (HR-MAS) NMR 
spectroscopy for metabolic profiling of intact tissue 
samples 
Nuclear magnetic resonance (NMR) is a highly versatile analytical approach that has 
been successfully applied for the investigation of liquid-state systems, solid-state 
systems and intact organisms (as in the case of magnetic resonance imaging, MRI). 
Variation in sample properties, in particular with respect to differences in sample 
nuclear spin interactions mean that different NMR techniques and experiments need to 
be employed for each application. For example, with MRI the large spectral signal 
generated by water is principally used for imaging because of the low chemical 
sensitivity of this approach.195 In vivo localised magnetic resonance spectroscopy 
(MRS) methodologies have been developed for application in biomedical science to 
improve localised chemical signal detection, but these approaches are still largely 
limited to detection of signals arising from highly abundant compounds such as lactate 
and choline.190 In liquid-state and solid-state NMR the overwhelming spectral signal 
generated by water can be easily eliminated by applying a water suppression 
sequence, and liquid-state analysis offers the highest spectral resolution and 
sensitivity.196 This is largely due to the fact that liquids produce sharp, distinct NMR 
spectral signals, whereas the technical challenge with solid-state NMR lies in the fact 
that the more densely cellular environment results in broader resonances, which are 
more difficult to unambiguously interpret and annotate196 (Figure 3.5).  
The technique of high-resolution magic angle spinning (HR-MAS) solid-state NMR 
spectroscopy was first developed by Andrew197 and Lowe198 with the aim of reducing 
line-broadening effects seen with NMR analysis of intact solid samples. These 
broadening effects chiefly arise due to the phenomenon of anisotropic nuclear 
interaction (ANI).190 This term describes the principle whereby the spatial proximity 
between one atomic nucleus and another in a sample suspended within a magnetic 
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3.2 Mass spectrometry 
3.2.1 Basic principles of mass spectrometry (MS) 
Mass spectrometry (MS) encompasses a broad class of bio-analytical approaches that 
have been successfully applied in metabolic phenotyping studies.199, 200 Although the 
majority of published applications to date in metabonomics have relied on NMR-based 
profiling, MS provides an additional, alternative means of determining the molecular 
composition of both liquid-state and solid-state samples, with high sensitivity.200 In MS 
experiments molecular information (chemical composition, relative biomolecular 
abundance and individual chemical structure)  is expressed in terms of mass-to-charge 
(m/z) ratio which is ascertained based on: (1) the principle that compounds with 
different molecular composition exhibit measurable differences in molecular mass (m) 
and (2) the fact that a charged particle immersed in an electromagnetic field will 
experience a force due to the electric field and a force due to the magnetic field; this is 
referred to as the Lorentz Force phenomenon and is summarised by equation 3.2190 
 
                                            (3.2) 
 
Where   is the Lorentz force for a given charged particle (in newtons),   is the electric 
charge of the particle (in coulombs),   is the electric field (in volts per meter),    is the 
magnetic field (in tesla) and   is the velocity of the particle (in milliseconds). According 
to Newton’s second law (equation 3.3),190 force is equal to the product of mass ( ) and 
acceleration ( ) and this in turn can be used to generate a differential equation from 
which the mass-to-charge ratio can be derived (equation 3.4). 
 
                         (3.3) 
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                                      (3.4) 
 
The charge value ( ) derived by this means is conventionally expressed as a charge 
number (z) by dividing by the elementary charge constant ( , 1.602 x 10-19).190 For the 
remainder of this thesis mass-to-charge ratio is referred to as m/z in keeping with this 
practice.190, 199   
Based on the theory outlined above, the first step in any MS experiment is the 
generation of molecular ions (creating the charge, z) from the sample being analysed. 
This requires an ion source, of which a variety are available for experimental use 
depending on study objectives.190 Two of the most common methods for generating 
sample ions are matrix-assisted laser desorption ionisation (MALDI), developed by 
Karas and Hillencamp201 and electrospray ionisation (ESI) introduced by Fenn.202 Both 
of these techniques are referred to as “soft” ionisation methods, as they permit the 
acquisition of intact ionic species from organic molecules of biological interest 
(peptides, proteins, lipids) that are fragile and have the tendency to fragment into 
daughter ions when subjected to alternative ionisation methods. The MALDI technique 
consists of two primary steps for ion generation; firstly a matrix-solution is applied to 
the sample, which results in co-crystallisation of matrix-associated molecules and 
analyte molecules.203 The three most commonly used matrix solutions for this purpose 
are 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), α-cyano-4-hydroxycinnamic 
acid (alpha-cyano or alpha-matrix) and 2,5-dihydroxybenzoic acid (DHB).204 The 
second step involves irradiation of matrix and analyte crystals with a UV laser system 
(such as nitrogen laser or neodymium-doped yttrium aluminium garnet, (Nd:YAG)). 
This leads to desorption and ionisation of matrix-associated molecules which in turn 
brings about generation of ion-state analyte particles through proton transfer (Figure 
3.6).190  
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crystallised biomolecules is then irradiated with a pulsed beam of UV/infra-red light to 
initiate desorption and ionisation 208. With SIMS-MSI, high energy primary ions (e.g. 
Ar+, In+, Ga+, etc.) are used to strike the tissue sample surface inducing a collision 
cascade that leads to the emission of secondary neutral molecules and ions, which are 
then directed into the mass spectrometer for analysis 219. This approach is particularly 
well suited to the spatial mapping of ‘ultra-low’ molecular weight molecules (< ~300 
amu) and elements, as the large amount of energy produced by primary ion barrage 
results in significant biomolecular decomposition.208 In DESI-MSI the tissue sample 
surface is bombarded, at atmospheric pressure, with a fine spray of charged droplets, 
resulting in ionisation of small organic molecules and large biomolecules, which are 
then delivered by vacuum into the mass spectrometer in the form of de-solvated 
ions.166 With each of these described approaches, operating characteristics and 
experimental parameters can be modulated to suit specific analytical objectives and 
can be customised for the identification of particular biomolecular species 
(peptides/proteins/lipids etc.).  
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Standard MSI experimental workflow involves sample preparation (depending on the 
chosen analytical technique), sample analysis using a mass spectrometer, and data 
acquisition according to spectral profiles obtained from a defined array of positions 
from the tissue section.220 Acquired data are comprised of a sequential list of spatially-
resolved mass spectra, each corresponding to a particular pixel on the MSI image file. 
Thus, in common with other ‘–omics’ based techniques MSI approaches generate vast, 
multi-dimensional data sets, however they present the additional, inherent, challenge of 
exploring and interpreting spatial and spectral information in tandem. In addition, 
unique considerations with MSI data interpretation concern optimisation of m/z 
accuracy, spatial resolution and mass resolution, and a variety of data pre-processing 
steps can be employed to address these issues.221, 222 Consequently, a critical step in 
the successful translation of MSI approaches to the clinical setting is the development 
of novel data treatment methodologies that can meet these demands, in as-streamlined 
a fashion as possible, to identify intra-sample and inter-sample spatio-chemical 
features of clinical relevance. In recent years a number of analytical strategies have 
been proposed to meet these requirements though consensus has yet to be reached 
regarding the ideal data treatment pathway. Several novel approaches have been 
developed for MSI data handling and interpretation as part of this work and these 
methods are presented in the subsequent chapters of this thesis.  
 
3.3 Bioinformatics strategies for metabolic phenotyping  
3.3.1 Data treatment requirements for “-omics” approaches 
The overwhelming volume of data generated by high-throughput “-omics” approaches 
in biomedical research demands effective bio-statistical tools capable of summarising 
and scaling down data burden (i.e. filtering out “redundant” data, often referred to as 
“dimensionality reduction” in this context in the literature), whilst maximising biologically 
relevant information capture. The drive towards a more holistic molecular 
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understanding of human disease means that molecular profiling studies 
(genomics/proteomics/metabonomics) have witnessed a steady shift towards 
increasing numbers of biomolecular properties (gene panels/protein 
signatures/metabolites) for characterisation of a given sample/experiment. Such data 
are typically arranged in the form of data matrices with x rows, each constituting a 
given observation and y columns containing data on a given measured variable/factor 
(in the case of metabolic profiling studies, particular chemical shifts or m/z values, for 
example).  Efficient and robust analysis of these data continues to present a logistical 
challenge but in recent years “-omics” methodologies have benefitted significantly from 
the introduction of an array of data pre-processing, processing and interrogation 
strategies that are able to handle and statistically evaluate such data. The terms 
“chemometrics” and/or “bioinformatics” are conventionally used to describe these 
methodologies. The fundamental bioinformatics steps for data treatment in 
metabonomics experimentation can be categorised broadly as: (1) pre-processing 
steps (2) processing steps and (3) multivariate analytical steps. 
 
3.3.2 Data pre-processing and processing 
Regardless of profiling method (NMR or MS), metabolic profiling experiments generate 
a degree of unwanted spectral signal or “noise” which should ideally be 
removed/accounted for prior to data analysis. In addition instrument and experimental 
parameter inaccuracies can result in mal-alignment of peaks arising from the same 
biomolecule from one sample to the next.223 Pre-processing of raw spectral data is 
performed in order to eliminate redundant noise-related signals and also to align 
spectra acquired from different samples, typically using a known standard chemical 
compound as the reference peak (Figure 3.12). 
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Data processing following application of the pre-processing steps outlined above varies 
according to the type of experiment being performed. In general terms the key steps in 
processing of data involve normalisation and scaling.224  
The primary aim of metabolic profiling studies is to determine biochemical differences 
between samples according to a particular variable of interest; here the relative 
relationship between different compounds in response to a given stimuli/environmental 
factor/disease state is more important than the exact quantities at which compounds 
are present per se, as the latter is frequently influenced by non-biological factors such 
as data acquisition settings, experimental variability, sample dilution effects and sample 
inhomogeneity.225 Normalisation is a key step in metabolic profiling studies designed to 
compensate for biologically redundant systematic variation in metabolite concentration 
patterns across a sample set, and thus permits data from all samples in a data set to 
be directly compared. Among the normalisation methods used in metabolic profiling the 
two most frequently employed are total intensity normalisation226 and probabilistic 
quotient normalisation.223 In the former method each sample spectrum is set a unit total 
intensity by expressing each data point as a fraction of the total spectral integral.226 
Probabilistic quotient normalisation scales spectra on the basis of the most probable 
dilution factor, which is estimated by comparing chemical spectral amplitudes with 
those seen in a reference spectrum.223 Each of these approaches is subject to 
particular strengths and limitations and choice of normalisation method often varies 
according to experimental design. For example, total intensity normalisation has been 
shown to be an ineffective method in circumstances where one particular chemical 
species is found at very high concentrations.223 In the chapters that follow in this thesis 
several different normalisation approaches have been employed based on study 
requirements. Figure 3.13 illustrates the effect of normalisation on spectral 
interpretation using original data from HR-MAS NMR profiled tissue samples.         
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features a scaling operation is performed after data normalisation. Several methods are 
available for this process including mean-centring, where dependence on magnitude as 
a determinant of significance is reduced and weighting reflects the covariance of 
variables.225 Other commonly employed scaling methods include unit variance 
scaling227 and Pareto scaling227 and functionality for application of these approaches is 
built-in to commonly used software platforms for metabolic data mining, such as 
SIMCA (Umetrics AB, Sweden) and MATLAB (MathWorks, USA).     
 
3.3.3  Multivariate analytical methods 
The two most commonly employed multivariate methods for interrogation of metabolic 
profiling data are principal component analysis (PCA)228 and partial least squares 
regression (PLS).229 The former is an unsupervised method that provides a 
mathematical means of scaling down the total number of variables in a sample being 
analysed. The objective here is to remove redundant data and reduce data-set 
multidimensionality, thereby facilitating the identification of the most influential variables 
or “principal components”, whilst at the same time retaining as much of the original 
sample features as possible. In PCA the original observations/data points are 
subjected to orthogonal linear transformation and projected onto a new co-ordinate 
system as a series of principal components. For metabolic profiling data, the principal 
components represent a new set of variables derived from the weighted sum of original 
spectroscopic features, and each component consists of “scores” which summarise 
similarities/differences between samples. The first principal component accounts for 
the largest possible variation within the dataset and each subsequent component is 
orthogonally placed with respect to the preceding one and explains the highest 
remaining variation.224, 228  This technique is useful for evaluating the global variation 
within a dataset and for identification of outlier data points.  
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Partial least squares (PLS) analysis is a supervised dimensionality reduction method 
that combines features from PCA with multivariate regression.229 It is a particularly 
advantageous method in circumstances where a quantitative association is sought 
between two data sets, where it is used in its discriminant analysis (DA) form (PLS-
DA).230 This discriminant analytical approach can be used to develop predictive models 
(for example to ascertain the capacity of a certain metabolite-signature to distinguish 
between cancerous and healthy tissue) and PLS-DA model predictive capacity is 
conventionally summarised using Q2 and R2 statistics, which are referred to in 
subsequent chapters of this thesis. The Q2 value essentially offers a guide as to the 
apparent predictive capacity of a given discriminant model, while R2 informs the user 
regarding the degree of variation between groups that is genuinely accounted for by 
the data. For example, if one is performing discriminant analysis of metabolite 
signatures between cancerous and healthy tissue, a R2 value of 1.0 would imply that 
differences between classes are accounted for entirely by differences in metabolite 
signature. On the other hand, a R2 value of 0.2 would suggest that the model has 
weaker predictive capacity as only 20% of the differences between groups are 
accounted for by metabolic variation.              
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4.1  Background 
The mortality associated with colorectal cancer (CRC) remains unacceptably high 
despite advances in operative technique and the widespread adoption of combined-
modality treatment approaches that include chemo- and/or radiotherapy231, 232 as well 
as novel targeted agents in select cases.233 Relative 5-year survival remains below 
60% in most developed nations,234 and this figure presents a compelling rationale for: 
(a) improving our understanding of the molecular processes that drive CRC 
development and progression and (b) developing more sophisticated methods for CRC 
diagnosis, staging and treatment.   
 
Figure 4.1 Age-adjusted 5-year relative survival for patients with colorectal cancer234 
 
 
 
 
 
 
 
 
 
Over the past two decades genomic, proteomic and transcriptomic studies have 
characterised a number of molecular pathways involved in colorectal carcinogenesis, 
from which at least five distinct molecular phenotypes have emerged.1 The 
‘metabolome’ lies furthest downstream along the ‘-omics’ cascade and can provide an 
additional layer of micro-molecular information with respect to CRC biology to 
complement upstream macro-molecular (DNA, RNA, protein) profiles. The metabolome 
can be defined as the complete set of low-molecular weight metabolites contained 
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within a living system101, 140 and this rich information pool represents a largely untapped 
biological resource in systems oncology.  
The recent advances in analytical biochemistry and computational science outlined in 
Chapters 1 and 3 have led to the development of an array of metabolic profiling 
technologies with which to interrogate the cancer metabolome.101 For this section of my 
research I chose to employ high-resolution magic angle spinning nuclear magnetic 
resonance (HR-MAS NMR) spectroscopy161 combined with in-house developed bio-
statistical approaches to investigate the metabolic phenotype of biopsy-sized samples 
of CRC and healthy adjacent mucosa; this technique permits ultra-fast, non-destructive 
tissue metabolic profiling, and generates a unique sample-specific metabolic 
‘fingerprint’. A key advantage with this technology over other platforms is that sample 
preparation and analysis result in only minimal tissue architectural disruption, allowing 
a sample to be retrieved, post HR-MAS NMR profiling, and subjected to conventional 
histopathological assessment.161, 235, 236 By this approach, HR-MAS NMR spectroscopy 
derived metabolic signatures can be directly correlated with corresponding 
histological/immunohistochemical parameters of interest. This is in contrast to other 
metabolic profiling methodologies such as gas chromatography mass spectrometry 
(GC/MS),147 where tissue samples are generally mixed with complex solvents, ultra-
sonicated, centrifuged and repeatedly vortex-mixed, rendering them unsuitable for 
subsequent histopathological evaluation. An additional advantage with HR-MAS NMR 
is that analysis can be performed using only ~10mg of tissue, meaning that this 
approach could be used to evaluate small tissue volumes typically acquired at time of 
endoscopic biopsy.   
To date a number of small-scale studies have utilized HR-MAS NMR based profiling for 
characterization of CRC tissue metabolic fingerprints.147, 237, 238 For example, Chan et al 
observed alterations in protein turnover, lipid synthesis and glycolysis in CRC tissue 
compared with matched control samples.147 The authors sought to develop metabolite-
based models according to tumour stage, but were unable to achieve this objective 
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owing to the small number of samples in each stage category. In another recent study, 
Righi et al reported HR-MAS NMR based data from samples of colorectal tissue 
acquired from 23 patients (14 patients with CRC and 9 healthy subjects) and identified 
similar metabolic tendencies associated with CRC.238 However, this study was limited 
somewhat by the small sample size and furthermore the authors did not histologically 
evaluate HR-MAS NMR profiled tissue samples, resulting in uncertainty regarding 
exact tissue composition.238 Jimenez et al, at Imperial College London, have more 
recently published data on a previously recruited cohort of CRC patients with long-term 
oncological follow-up data (no overlap with the current study population) where cancer 
tissue samples and adjacent healthy mucosa were profiled using an HR-MAS NMR 
spectroscopy approach; this study demonstrated the potential for prediction of disease-
free survival after CRC resection using metabolite-based spectroscopic models.237     
Building on the work described above, this study was undertaken to address three 
specific aims: (1) To comprehensively characterise the CRC metabolome with a view to 
developing a robust metabolic signature to classify colorectal tissue samples as 
cancerous or healthy; (2) To identify metabolic differences at tissue level between 
colonic and rectal cancer tissue and (3) To determine whether HR-MAS NMR 
spectroscopic profiles can be used to predict local tumour burden (T-Stage) and/or 
lymph node status (N-Stage).  
 
4.2  Materials and methods 
4.2.1  Patient recruitment and sample acquisition 
This study was approved by the institutional review board at Imperial College 
Healthcare NHS Trust (REC reference numbers 07/H0712/112 and 11/LO/0686). From 
November 2010 to January 2012 tissue samples were obtained after written consent 
from 44 consecutive patients undergoing elective surgical resection for confirmed CRC 
at St Mary’s Hospital (London, UK). This information is summarized in the modified 
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REMARK participant flow diagram and checklist (Appendix D). Corresponding 
demographic and clinico-pathological data (Table 4.1) were extracted from case notes 
and stored in a prospectively maintained database. Following surgical extraction 
cancer specimens were taken on ice to the pathology department where they were 
immediately opened and sampled by a senior pathologist (Professor Robert Goldin, 
Centre for Pathology, Imperial College London). Fresh samples were retrieved from 
centre of tumour (n=44) and from macroscopically healthy-appearing mucosa 5cm from 
the tumor margin (n=44). These samples were transferred immediately to a freezer at -
80ºC for storage prior to processing. The mean time interval from specimen extraction 
to freezing of harvested samples was 25+/-5.3 minutes.  
 
4.2.2  Histopathological tissue evaluation 
All surgical resection specimens were evaluated by a senior pathologist (RDG). 
Tumours were graded as well, moderately or poorly differentiated and were assessed 
for evidence of extramural venous invasion, lymphovascular invasion and perineural 
invasion. Final pathological tumour stage (pTNM) was based on formal appraisal of the 
complete cancer resection specimen and was assigned according to the fifth edition of 
the UICC Tumour-Node-Metastasis (TNM) classification system.239  
All tissue samples retrieved from centre of tumour and profiled by HR-MAS NMR were 
subsequently H&E stained and assessed by histopathological means to confirm the 
presence of tumour.  
 
4.2.3  Sample preparation and HR-MAS NMR experimental protocol 
Tissue samples were kept on ice at all times during the experimental preparation 
process to minimize metabolite degradation. Where tissue volume permitted, two 
replicates were prepared for HR-MAS NMR analysis from each original tissue sample, 
to compensate for anticipated tissue heterogeneity. Sampling was performed using a 
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multivariate analysis. For univariate analysis the analysis of variance (ANOVA) method 
was used to identify the statistical significance (reported as p-values) of the 
discriminatory capacity of a given individual metabolic feature.224 For multivariate 
analysis I applied unsupervised principal component analysis (PCA) and supervised 
orthogonal partial least squares-discriminant analysis (OPLS-DA) using SIMCA-P+ 
(v.13.0.1, Umetrics AB, Sweden) and an in-house developed script operating in 
MATLAB. Orthogonal PLS-DA (OPLS-DA) is an extension of the PLS-DA method for 
discriminant analysis described in the previous chapter (Chapter 3, Sub-section 3.3.3) 
and was employed preferentially here as it allows improved visualization of class 
separability.245 A seven-fold cross validation approach was used to assess multivariate 
model strength;246 this involved partitioning sample data in each model into seven 
subsets after which six subsets were then used as training data with one retained as 
the validation set. This method is illustrated in Figure 4.4. This cross validation process 
was repeated seven times, with each of the seven sample subsets used exactly once 
as the validation set for each model. For each generated OPLS-DA model, cross-
validated Q2 values were obtained to evaluate model predictive capacity, before 
robustness was further assessed by calculating the area under the curve (AUC) from 
corresponding receiver operating characteristic (ROC) curves.247 With ROC curve 
analysis an AUC of 1 represents a ‘perfect’ test and an AUC of 0.5 represents a test 
without any discriminatory worth. Conventionally discriminatory accuracy with this 
metric is interpreted as follows: AUC 0.90-1 (excellent); AUC 0.80-0.90 (good); AUC 
0.70-0.80 (fair); AUC 0.60-0.70 (poor); AUC 0.50-0.60 (worthless).248  
Where OPLS-DA scatter plots revealed separation between classes, loadings plots 
were generated and assessed to identify the biochemical species most responsible for 
discrimination. Loadings plots allow identification of chemical signatures that are 
more/less abundant in one experimental class compared to another, with colour coding 
to signify the statistical significance of relative metabolite changes.    
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4.3  Results 
4.3.1  Patient demographics and tumour characteristics 
The 44 study participants included 26 males (59%) and 18 females (41%) with a 
median age of 72 years (range, 56-87). These patients were consecutively enrolled to 
the study where possible to minimise selection bias. Over the study timeframe a total of 
64 consecutive potentially eligible patients were identified for this study. Reasons for 
study omission for 20 of these patients were as follows: (1) Enrolment to FOxTROT 
study, precluding in-house assessment of surgical specimen (n=7); (2) Patient decision 
not to take part in study (n=4); (3) No pathology personnel available outside of 
standard working hours to evaluate and sample resection specimen (n=4); (4) Inability 
to sample rectal cancer resection specimen due to potential for compromising 
circumferential resection margin (CRM) status assessment. This information is 
summarised in the REMARK flow diagram and checklist provided as supplementary 
material in Appendix D.    
All surgical resection specimens were confirmed as adenocarcinoma on pathological 
assessment by a single pathologist (RDG). Tumours were located in the transverse 
colon (n=3; 7%), descending colon/proximal sigmoid colon (n=5; 11%), ascending 
colon (n=6; 14%), recto-sigmoid (n=8; 18%), caecum (n=10; 23%) and rectum (n=12; 
27%) in order of increasing prevalence. A summary of demographic and clinico-
pathological characteristics is provided in Table 4.1.     
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Table 4.1 Demographic and clinico-pathological characteristics 
 N % 
Age, median (range) 72 (56-87)  
Gender   
                Male 26 59 
                Female 18 41 
Location of primary tumour   
                Transverse colon 3 7 
                Descending/proximal sigmoid colon 5 11 
                Ascending colon 6 14 
                Recto-sigmoid 8 18 
                Caecum  10 23 
                Rectum 12 27 
Tumour Differentiation   
                Well differentiated 1 2 
                Moderately differentiated 32 73 
                Poorly differentiated 11 25 
pT Stage   
                T1 3 7 
                T2 9 20 
                T3 20 46 
                T4 12 27 
UICC Stage   
                 I 9 20 
                 II 18 41 
                 III 15 34 
                 IV 2 5 
Lymph node status   
                 N0 27 61 
                 N1/N2 17 39 
Extramural vascular invasion (EMVI)   
                 Yes 18 41 
                 No 26 59 
Lymphovascular invasion (LVI)   
                 Yes 14 32 
                 No 30 68 
Perineural invasion (PNI)   
                 Yes 7 16 
                 No 37 84 
Pre-operative chemotherapy/radiotherapy   
                 LCCR 3 7 
                 SCR 4 9 
                 None 37 84 
 
LCCR long-course chemoradiotherapy; SCR short-course radiotherapy 
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4.3.2  Determining metabolic differences between cancerous and 
adjacent healthy colorectal mucosa using HR-MAS NMR 
spectroscopy  
A total of 171 CPMG spectral profiles were generated from tissue samples obtained 
from centre of tumour (n=88) and healthy-appearing mucosa 5cm from the tumour 
margin (n=83). Representative annotated HR-MAS NMR spectra for centre of tumour 
and healthy mucosal samples (5cm from tumour margin) are shown in Figure 4.5. 
Spectral profiles were imported into SIMCA and MATLAB software packages for 
analysis using unsupervised PCA and supervised OPLS-DA multivariate approaches. 
The cross-validated OPLS-DA model generated revealed clear separation between 
cancerous and healthy tissue samples based on metabolic profiles (R2Y=0.94; 
Q2Y=0.72; Figure 4.6A). Corresponding ROC curve analysis constructed using 7-fold 
cross validated predicted scores further confirmed the robustness of the OPLS-DA 
model in distinguishing between cancerous and non-cancerous tissue samples, with an 
area under the curve (AUC) of 0.98 (Figure 4.6B). The loadings plot (Figure 4.7) shows 
that the key metabolic discriminators between groups are lactate, taurine, iso-
glutamine, glycine and scyllo-inositol (found in relatively higher concentrations in 
cancer) and lipid/triglyceride species (found in relatively higher concentrations in 
healthy tissue). Table 4.2 provides a summary of observed metabolic differences 
between cancerous and healthy colorectal tissue samples with biochemical species 
numerically annotated in the table for ease of cross-referencing with the representative 
spectra shown in Figure 4.5.   
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Figure 4.5 Annotated representative HR-MAS NMR spectral signatures from A CRC tissue 
and B macroscopically healthy appearing mucosa 5cm from tumour margin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Lipids/triglycerides (-CH3); 2 Lipids/triglycerides (-CH2-); 3 Lipids/triglycerides (C=C-CH2); 4 
Lipids/triglycerides (=CH-); 5 Lactate (-CH3); 6 Lactate (-CH-); 7 Valine (-CH3); 8 Alanine (-
CH3); 9 Leucine (β-CH2 γ-CH); 10 Acetate (-CH3); 11 Iso-glutamine (β-CH2); 12 Creatine (-
CH3); 13 Creatine (-CH2-); 14 Glycerophosphoryl-choline (N(CH3)3); 15 Taurine (-CH2-NH); 16 
Taurine (CH2SO3); 17 Scyllo-inositol (-O-H); 18 Glycine (-CH2); 19 β-glucose (1-CH); 20 α-
glucose (1-CH); § residual water signal 
 
99 
 
Table 4.2 Summary of NMR spectral metabolite assignments with corresponding chemical 
structures, chemical shifts (ppm) and observed pattern variations between cancerous and 
healthy colorectal mucosa  
† refer to Figure 4.5 
Peak 
No. † 
Metabolite 
Chemical 
group 
Ppm 
Relative 
pattern 
intensity  
Function 
1 Lipids/triglycerides -CH3 0.90  in healthy Cell membrane biosynthesis 
2 Lipids/triglycerides -(CH2)n- 1.29  in healthy Cell membrane biosynthesis 
3 Lipids/triglycerides C=C-CH2 2.02  in healthy Cell membrane biosynthesis 
4 Lipids/triglycerides =CH- 5.33  in healthy Cell membrane biosynthesis 
5 Lactate -CH3 1.33  in cancer 
Bi-product of  cancer cell 
glycolysis 
6 Lactate -CH- 4.15  in cancer 
Bi-product of  cancer cell 
glycolysis 
7 Valine -CH3 1.02 ↔ Ketogenic amino acid 
8 Alanine -CH3 1.47 ↔ Gluconeogenic amino acid 
9 Leucine β-CH2 γ-CH 1.72 ↔ Ketogenic amino acid 
10 Acetate -CH3 1.92 ↔ 
Bi-product of gut microbial 
fibre fermentation 
11 Iso-glutamine β-CH2 2.34  in cancer 
Bi-product of gut microbial cell 
wall degradation 
12 Creatine -CH3 3.02 ↔ 
Enhancement of ATP 
regeneration 
13 Creatine -CH2- 3.93 ↔ 
Enhancement of ATP 
regeneration 
14 
Glycerophosphoryl-
choline (GPC) 
N(CH3)3 3.22  in cancer Cell volume regulation 
15 Taurine -CH2-NH 3.26  in cancer 
Protein building block; cell 
membrane stabilisation 
16 Taurine CH2SO3 3.42  in cancer 
Protein building block; cell 
membrane stabilisation 
17 Scyllo-inositol -O-H 3.34  in cancer Osmotic regulation 
18 Glycine CH2 3.56  in cancer Protein building block 
19 β-glucose 1-CH 4.67  in healthy Energy generation 
20 α-glucose 1-CH 5.24  in healthy Energy generation 
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Figure 4.7 Loadings diagram for data summarised in OPLS-DA scatter plot allowing identification of principle metabolites responsible for discrimination 
between colorectal cancer tissue and healthy mucosa. This approach has been combined with ANOVA analysis to ascertain statistical significance of the 
contribution of individual peaks to class separation.     
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4.3.3 Determining metabolic differences between colon and rectal 
cancer tissue using HR-MAS NMR spectroscopy 
A total of 88 CPMG spectral profiles were generated from centre of colon tumour 
(n=49) and centre of rectal tumour (n=39) tissue samples. The ‘colon’ class comprised 
samples obtained from caecum, ascending colon, transverse colon, descending colon 
and proximal sigmoid/sigmoid colon. Tumour tissue was classified as ‘rectal’ if retrieved 
from rectosigmoid or rectal cancers. Figure 4.8A shows the OPLS-DA model scores 
generated using this classification approach (R2Y=0.94; Q2Y=0.33) with corresponding 
7-fold cross validated ROC curve analysis shown in Figure 4.8B (AUC=0.86). The 
model allows metabolite-based distinction to be made between tumour samples 
according to location, with colon cancer tissue seen to harbour significantly greater 
concentrations of acetate and arginine relative to rectal cancers (Figure 4.9A). Rectal 
tumours by comparison were found to have increased concentrations of lactate (Figure 
4.9A). The lactate peak at 1.33 is difficult to visualise in Figure 4.9A as the strong lipid 
presence overwhelms this signal. A STOCSY analysis driven by the apex of the –CH3 
signal for lactate at 4.1 was performed to clarify this further, and permitted clear 
identification of the main lactate peak (Figure 4.9B). To strengthen the validity of the 
identified metabolic differences between colon and rectal cancer tissue I performed 
additional OPLS-DA and ROC curve analysis after exclusion of cases having received 
neo-adjuvant chemo- and/or radiotherapy. Figure 4.10A shows the OPLS-DA model 
scores generated after exclusion of these samples (R2Y=0.80; Q2Y=0.21) and reveals 
clear distinction between colon and rectal cancer tissue samples with corresponding 7-
fold cross validated ROC curve analysis shown in Figure 4.10B (AUC=0.83). 
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Figure 4.10 A OPLS-DA scatter plot demonstrating separation between colon cancer (blue) 
and rectal cancer tissue samples (red) after exclusion of samples obtained from patients 
having received neo-adjuvant therapy B Corresponding ROC curve analysis confirming that 
the OPLS-DA discriminatory model is “good” at distinguishing between cancer tissue samples 
according to tumour location (AUC = 0.83) and that the previously observed difference retains 
significance, independently of administration of pre-operative chemotherapy/radiotherapy.   
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4.34  Determining metabolic differences between colorectal cancer 
tissue samples according to cancer stage  
For this phase of analysis I first performed comparison of CPMG spectral profiles from 
centre of tumour tissue samples obtained from T1/2 tumours (12 patients; 23 spectra), 
T3 tumours (20 patients; 41 spectra) and T4 tumours (12 patients; 24 spectra) to 
determine whether metabolic characteristics could be identified with which to ascertain 
local tumour extent (T-stage). Figure 4.11A shows the OPLS-DA model scores plot 
generated from this classification approach, with visible clustering of samples 
according to T-stage (T1/2 in blue, T3 in green, T4 in red). In Figure 4.11B the 
misclassification table shows that this metabolite-driven means of determining local 
tumour stage was able to correctly assign samples as T1/2, T3 or T4 in 91%, 90% and 
75% of cases respectively. Corresponding 7-fold cross validated ROC curve analysis 
(Figure 4.11C) further confirmed the robustness of this model for classification of 
tumour tissue samples according to T-stage based on metabolic profiles. 
Biochemical differences between the different T-stage tumours were then explored 
by performing OPLS-DA analysis between groups (T1/2 versus T3, T3 versus T4). 
This approach revealed specific metabolic phenotypes associated with each stage of 
local tumour development (Figure 4.12). I found T3 tumour tissue to have 
significantly greater concentrations of lipids/triglycerides (p<0.05) and acetate 
(p<0.05) compared with T1/2 tumours. In contrast, T1/2 tumours contained greater 
concentrations of glycerophosphoryl-choline (GPC) (p<0.05) relative to T3 tumours. 
By comparison, T4 tumours had a unique ‘metabotype’ of their own, marked by a 
general depleted biochemical state, with significantly reduced levels of 
lipids/triglycerides, acetate and succinate relative to T3 cancers. These metabolic 
fluxes are summarised in Figure 4.12.    
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analytical platforms101 with the potential to study these adaptations in unprecedented 
detail. High-resolution magic angle spinning nuclear magnetic resonance (HR-MAS 
NMR) spectroscopy is one of the most powerful metabolic profiling techniques to 
emerge in recent years.101, 161 This approach allows comprehensive, ultra-fast and non-
destructive metabolic profiling of intact tissue samples, and has shown early promise in 
previous biomarker-discovery studies in breast 151, lung 250,  prostate 251 and colorectal 
cancer 147, 237. In this study, I employed this analytical approach to study the metabolic 
profiles of cancerous and adjacent healthy mucosa obtained from patients undergoing 
surgical resection for confirmed CRC. To date, this study represents the largest of its 
kind in CRC research and differs from earlier work in that clinically-driven objectives 
were predefined from the study outset with clear rationale.  To enhance the 
translational impact of this work the study objectives, methodology, results and key 
conclusions that I have employed here were devised in accordance with guidelines 
proposed by the Reporting Recommendations for Tumour Marker Prognostic Studies 
(REMARK) framework.252 The REMARK checklist and flow diagram that accompany 
this work are provided as supplementary material in Appendix D.  
My first analytical aim in this study was to compare HR-MAS NMR spectroscopic 
profiles between centre of tumour samples and healthy adjacent mucosa. The objective 
here was to metabolically phenotype CRC as comprehensively as possible using state-
of-the-art technology to progress beyond the Warburg effect. This has the potential to 
unlock an entirely new pool of CRC-specific metabolic data with which to develop next-
generation diagnostic approaches.  
To enhance the validity of my findings, all CRC tissue samples were evaluated after 
HR-MAS NMR spectroscopy by a pathologist (RDG) to confirm the presence of cancer 
cells. As expected, this revealed significant morphological variation with tissue samples 
containing differing amounts of tumour, stroma, healthy mucosa, and inflammatory 
debris. Tumour-bearing regions themselves showed considerable intra- and inter-
sample disparity with respect to density and consistency, with significant variation in 
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the presence and extent of viable tumour and histological tumour necrosis. This 
heterogeneity meant that robust analysis of biochemical signatures according to the 
presence/absence of features such as necrosis was not feasible. Despite this observed 
heterogeneity, distinct spectral signatures were observed for cancerous and healthy 
tissue samples. Specifically, CRC tissue was discriminated from healthy mucosa by 
significantly increased levels of lactate (p<0.005), taurine (p<0.005), iso-glutamine 
(p<0.005), glycine and scyllo-inositol (p<0.005) and significantly decreased levels of 
lipid and triglyceride species (p<0.005).   
Increased concentrations of lactate in CRC tissue have been previously reported by 
Nicholson et al 147, 237; cancer cells have glycolytic rates up to 200 times greater than 
that of healthy counterpart cells253 and this results in the generation of vast quantities of 
lactate from pyruvate (instead of predominant mitochondrial oxidation of pyruvate as 
normally occurs). Taurine (2-aminoethane sulphonic acid) is a ubiquitous beta-amino 
acid derived from methionine and cysteine metabolism and is known to play a role in 
several critical physiological functions including cellular osmoregulation and cell-
membrane stabilization.237 In addition it acts as an important protein building-block, and 
these collective functions may explain why increased levels of taurine were found in 
cancer tissue, as rapid tumour-cell growth is likely to place greater demands on protein 
turnover, membrane stabilization and osmo-regulatory mechanisms 237. Increased 
levels of glycine found in CRC tissue also reflect rapid cellular proliferation as this 
essential amino acid is a key precursor for protein synthesis. Scyllo-inositol is a 
naturally occurring stereoisomer of inositol (cyclohexane-1,2,3,4,5,6-hexol) and serves 
a variety of biological functions including intracellular calcium homeostatic control, cell 
membrane potential maintenance and cell signal transduction. Increased physiological 
requirements during tumour growth are likely to explain the increased levels of scyllo-
inositol that were observed in tumour tissue. Concentrations of iso-glutamine were 
found to be significantly greater in cancerous tissue relative to healthy, and this finding 
was recently reported for the first time in a study undertaken by Jimenez et al at 
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Imperial College London.237 Iso-glutamine is a degradation product of muramyl 
dipeptide (N-acetyl-muramyl-L-alanyl-D-isoglutamine, MDP), which itself is a 
breakdown product of gut microbial cell walls. Increased levels of iso-glutamine in CRC 
tissue may be a reflection of increased gut microbial degradation within the cancerous 
microenvironment.237, 254 In addition to these findings, my results demonstrated a 
significant reduction in lipid and triglyceride levels (p<0.005) in CRC tissue relative to 
healthy adjacent mucosal samples. These biomolecules are key cell-membrane 
constituents, and the finding of reduced levels in CRC tissue is likely to be secondary 
to higher lipid utilisation for this purpose by rapidly proliferating tumour cells.  
My second aim for this work was to determine biochemical differences at the tissue 
level between colon and rectal cancers. Discrete tumour genetic and epigenetic 
features have been reported in colorectal cancer according to anatomical site255 though 
relatively little is known regarding the metabolic differences between these tumours. In 
the current study I performed a metabolite-based comparison of colon and rectal 
tumour tissue as previous studies have revealed some differences in disseminative 
tendency,256 response to radiotherapy257 and natural history.258 For example, rectal 
cancers are predisposed to local recurrence, while colonic tumour progression is 
characterised by metastatic spread to the liver. While these observations may in part 
be due to differences in lymphatic and venous drainage, there may be additional, as 
yet unidentified, biochemical differences to account for this variation.  
My results demonstrate that colonic cancer tissue can be reliably discriminated from 
rectal cancer tissue by significantly elevated levels of acetate (p<0.005) and arginine 
(p<0.005) and relatively reduced concentrations of lactate (p<0.005). Acetate is one of 
the main short-chain fatty acids produced by gut microbial fermentation of resistant 
starches, dietary fibres and other low-digestible polysacharrides.259 The explanation(s) 
for increased acetate found in colonic tumour tissue samples in this study remain 
uncertain, though this finding may imply that gut microbial fermentative processes are 
better preserved, or even up-regulated, in the setting of colon cancer relative to rectal. 
113 
 
A proportion of rectal cancer cases in the present study were treated with pre-operative 
chemo and/or radiotherapy, and there is experimental evidence to suggest that this 
causes disruption to intestinal microbiota.260 In addition, it is understood that the 
metabolic fate of acetate is fundamentally different in cancerous compared with healthy 
cells.261 In cancer cells, an anabolic mechanism is thought to dominate, where acetate 
is used for lipid/fatty acid synthesis. It is conceivable that this process is more 
prominent in colonic relative to rectal cancers though this requires further investigation. 
A greater proportion of rectal cancer cases (6/20; 30%) received neo-adjuvant (NA) 
therapy compared with colon cancer cases (1/44; 2%), and this discrepancy may have 
contributed to the differences I identified in the present study. The a priori decision to 
apply a 7-fold cross-validation analytical approach will have compensated for this 
confounding effect though may not have abolished its impact altogether. On the other 
hand it is important to note that previous animal studies have shown that tissue lactate 
levels undergo marked reduction following chemo- and/or radiotherapy262-264 and this 
observation is therefore at odds with the suggestion that NA treatment has accounted 
for the differences reported here, since I found rectal tumours to contain significantly 
higher levels of lactate relative to colonic tumours. I sought to validate these findings 
further by performing discriminant analysis between colonic and rectal tumour tissue 
after exclusion of samples from patients who had received NA therapy (Figure 4.10). 
This sub-analysis revealed good separation between groups and suggests that there 
are genuine biochemical differences between colonic and rectal cancers which may be 
of clinical relevance in future ‘personalised’ approaches to CRC management. In 
addition I performed discriminant analysis of centre of tumour and healthy mucosa 
samples obtained from patients with rectal cancer receiving/not receiving NA therapy 
though these models did not reveal any unifying biochemical differences between 
these groups. This is likely explained by: (1) the relatively small number of samples 
involved (7 out of 12 rectal cancer patients receiving versus 5 out of 12 not receiving 
NA therapy) (2) the variability in treatment type amongst those receiving NA therapy (4 
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out of 7 received long course chemotherapy, 3 out of 7 received short course 
radiotherapy) and (3) significant differences in response to NA therapy (3 out of 7 
showing ‘good’, 1 showing ‘moderate’ and 2 showing ‘poor’ response to NA therapy). 
This represents an area that warrants further investigation, and in the future I plan to 
undertake prospective analysis of pre-treatment and post-treatment samples of CRC 
tissue and adjacent healthy mucosa from patients receiving and not receiving NA 
therapy, with the aims of (i) developing predictive models of likely response to therapy 
and (ii) enhancing our understanding of the local metabolic consequences of NA 
therapy.               
My third aim in this study was to develop metabolite-based models for determination of 
local tumour extent (T-stage). Precise pre-operative T-stage confirmation is essential 
for appropriate treatment planning.58 Currently local staging remains largely dependent 
on radiological assessment, with computed tomography (CT) in the case of colon 
cancer77 and endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) 
preferred in rectal cancer.69 Each approach is subject to limitations, and as a result a 
proportion of patients are either under- or over-staged, with subsequent effects on 
therapeutic decision-making. The FOxTROT Study reported that CT could only 
correctly identify ‘high risk’ T3/T4 colonic cancers with a sensitivity and specificity of 
87% and 49% respectively.77 Garcia-Aguilar et al reported that up to 18% of T2 and 
13% of T3 rectal lesions were over- and under-staged respectively based on EUS 
findings.70 Similarly data from the multicentre MERCURY Study Group found that 42% 
of T2 rectal tumours and 33% of T3 rectal tumours were over- or under-staged 
respectively using MRI.265 These figures make a compelling case for the development 
of novel radiology-independent means of confirming tumour T-stage. My findings 
suggest that tumour tissue metabolic profiling approaches may offer an opportunity to 
address this objective. I was able to correctly assign tumour samples according to T-
stage as T1/2, T3 or T4 in 91, 90 and 75% of cases respectively in the current data set 
using metabolite-driven models. Moreover, I identified unique metabolic signatures for 
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tumour tissue at different local stages of development. The transition from T1/2 stage 
to T3 was marked by increases in lipid/triglycerides and acetate and a reduction in 
glycerophosphoryl-choline (GPC). In contrast T4 tumours were found to exhibit a 
general reduction in lipids, acetate and succinate relative to T3 lesions. The T3 growth 
phase may represent the most metabolically demanding phase of local development, 
marking the transition point between what are conventionally considered ‘early’ and 
‘locally advanced’ tumours. The T4 stage by comparison seems to be characterised by 
a metabolically more depleted phenotype. These preliminary findings highlight the 
novel potential of ex-vivo HR-MAS NMR tissue profiling as a means of improving pre-
treatment staging accuracy in CRC. In addition they appear to suggest that different T-
stage tumours are associated with unique metabolic microenvironments, which may in 
turn facilitate the future development of stage-specific downstaging approaches, 
designed to precisely disrupt tumour metabolism at different phases of growth. No clear 
differences were observed with respect to lymph node status in this study; it may be 
that disease dissemination beyond the bowel represents a more systemic biochemical 
step in cancer invasiveness, and perhaps the best method for evaluating this would be 
through analysis of a more ‘systemically representative’ biological sample, such as 
plasma/serum. This will be an interesting future area of research to pursue.  
In the future it is foreseeable that the T-stage-specific chemical fingerprints I have 
described here could be used to demonstrate CRC biochemical characteristics in-vivo 
using magnetic resonance spectroscopy (MRS). This approach has been studied for 
over 40 years, but currently has limited clinical utility due to its inherent biochemical 
insensitivity and the relatively small number of metabolites (typically choline-based 
chemical species and lipids) that are detectable in comparison to HR-MAS NMR 
spectroscopy.266, 267 This is largely explained by the fact that most clinically deployed 
MR-based devices operate at between 1.5 to 3.0T (Tesla), compared to the 400MHz 
NMR spectrometer employed in the present study, which operates above the 9T range 
and thus permits far more detailed biochemical assessment. Though this situation is 
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unlikely to change in the immediate future, in the long-term it is anticipated that the 
routine combination of MRS analytical packages with MRI systems operating within 
higher magnetic field strength, will allow biochemical characterisation of ‘difficult to 
access’ anatomical regions in unparalleled detail.  
The work presented in this chapter is subject to a number of inherent limitations which 
must be outlined; firstly, I acknowledge that this research represents preliminary 
findings, which while promising, require further validation with a much larger cohort of 
patients in the future before concrete conclusions can be drawn. Secondly, though I 
have identified biochemical profiles that are capable of predicting local tumour extent 
(T-stage) with good accuracy in this pilot study, I have not been able to reliably perform 
direct comparison of HR-MAS NMR staging accuracy with current gold-standards 
(namely CT and MRI for colonic and rectal cancer staging respectively) in a like-for-like 
manner. This would have required comparison of HR-MAS NMR profiles of pre-
operative tissue samples (obtained at time of endoscopic biopsy) with expert reviewed 
pre-operative CT and MRI imaging data. This line of investigation will be the focus of a 
future study that I plan to undertake. It is important to stress that I do not regard this 
technology as a replacement for radiological cancer staging. The latter is likely to 
remain the gold-standard means of evaluating tumour extent in the foreseeable future, 
and detailed imaging is critical for precise tumour localisation and operative planning. 
However, novel molecular methods for stage prediction such as HR-MAS NMR can be 
used to validate radiological conclusions or indicate a need for re-assessment in cases 
of disagreement. In addition, they offer fresh molecular insights into local tumour 
progression which is beyond the scope of currently available imaging platforms, and 
this information can have implications for future anti-cancer drug development.  
In the current study it took between 20-25 minutes in total from sample acquisition to 
identification of a tissue specific biochemical profile. Although this is not an 
unreasonable length of time for such detailed interrogation, it currently lags behind the 
average time taken for tissue frozen section, which is typically between 10-20 
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minutes.268-270 One can expect this time to reduce in the near future as swifter, more 
automated experimental methods are introduced.  
A final consideration with clinical translation of any new technology is cost; initial outlay 
costs for the spectrometer and the robotic autosampler used in this study were 
approximately £350,000. Though expensive, once installed I have found the technology 
to be highly reliable, requiring very limited maintenance.  The main expenditure is 
incurred through purchasing of the required cryo-liquids (helium and nitrogen) and my 
laboratory costs per day equated to approximately £300. I have calculated that the cost 
of the materials per sample (taking into account rotors, rotor caps, wastage etc.) was 
approximately £12. In view of the novel and clinically relevant molecular information 
that is provided by this analytical approach the required costs do not seem inordinate, 
though may represent a hurdle for smaller institutions.   
 
4.5  Summary 
High resolution magic angle spinning NMR spectroscopy of intact tissue samples has 
emerged as a highly promising technique in cancer research offering an entirely novel 
molecular viewpoint downstream of the genome and proteome. Currently this 
technology is not routinely employed in the clinical setting for evaluation of cancer 
tissue samples, and this relates at least in part to the associated financial costs as well 
as the requirement for dedicated personnel and facilities for NMR spectroscopy, which 
are not commonplace outside of large healthcare research institutions. However, it is 
anticipated that in the future HR-MAS NMR-based platforms will become more 
affordable, and more streamlined, automated analytical workflows will be developed 
which should facilitate smoother translation of the technology to clinical cancer 
profiling. The findings presented here are promising and require validation on a larger 
cohort of patients. I have demonstrated the ability of HR-MAS NMR to identify CRC-
specific metabolic signatures that provide new insights into molecular pathogenesis, 
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and in the future these may pave the way for the discovery of next generation anti-
cancer drug targets. The HR-MAS technique allows accurate and fast confirmation of 
the presence of CRC in a tissue sample and this has potential for rapid cancer 
diagnosis as well as intra-operative tissue characterisation. In addition my results 
highlight the potential for development of novel means of addressing current limitations 
in cancer staging. The preliminary findings presented here suggest that tumour 
microenvironmental metabolism may undergo modification during local advancement, 
with characteristic molecular fingerprints observed for tumours of differing T-stage. 
Moreover, the differences found at the metabolic level between tumours of the colon 
and rectum challenge our understanding of the biochemical differences that exist 
between different anatomical regions in the large bowel.      
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5.1  Background 
The tumour microenvironment (TME) is thought to play a critical role in solid organ 
cancer development and progression271 and TME profiling approaches are gaining 
increasing attention in cancer systems biology.272-274 Imaging mass spectrometry (MSI) 
methods utilising techniques such as matrix-assisted laser-desorption ionisation 
(MALDI), 275-277 desorption electrospray ionisation (DESI) 167, 278, 279 and secondary ion 
mass spectrometry (SIMS) 164, 280 have demonstrated some early promise in this area, 
offering a means of ‘chemically mapping’ tissue sections, without the requirement for 
specific staining/labelling agents. One of the key advantages of MSI as an analytical 
tool lies in the ability to measure biochemical activity with direct correlation to 
morphological features of interest, bypassing the need for time-consuming steps such 
as laser-capture micro-dissection. The latter by its very nature results in significant 
disruption to tumour and its surrounding tissues, preventing visualisation of 
biomolecules within their native backdrop.  
To date a number of small studies have successfully employed MSI approaches for 
characterisation of region-specific protein/peptide distribution within the cancer TME.277, 
281-283 More recently, the ability of MSI to assess the localisation and concentration 
distribution of chemotherapeutic compounds in cancer tissue has also been 
demonstrated, and this has potential to offer fresh perspectives on anti-cancer drug 
mechanisms and efficacy.216, 284   
Of the available MSI techniques MALDI has been the most widely used in the recent 
literature.275-277 This technique is a ‘matrix-assisted’ approach that involves the 
application of a chemical solution (referred to as a ‘matrix solution’ in this context) to 
the tissue surface to crystallise biomolecules prior to ionisation (Figure 5.1).275 
Commonly employed solutions for this purpose include α-cyano-4-hydroxycinnamic 
acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB). Where employed in this study the 
term ‘matrix’, refers to this experimental solution and should not be confused with the 
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m/z value molecular species.286 I have chosen to apply this method for this part of my 
thesis.  
  
5.2  Exploring the cancer ‘lipidome’ via imaging mass spectrometry 
Lipid profiling in particular represents an attractive avenue for novel CRC biomarker 
discovery as there is growing evidence to suggest that membrane lipids play a vital role 
in carcinogenesis.287, 288 Lipids are key cell membrane constituents289 and serve several 
critical physiological roles including regulation of energy metabolism,289 cellular 
signalling290 and trafficking of immune cells.291 Disordered lipid metabolism at the 
cellular level is now recognised as a common feature across a variety of cancer 
subtypes.292 Imaging mass spectrometry-based techniques offer a means of mapping 
lipid biochemistry in unparalleled detail within different tissue subtypes comprising the 
TME. Current methods for lipid detection and localisation such as staining with Nile 
Red, Oil Red O or osmium tetroxide can be applied to frozen sections 293, and while 
these can reveal the distribution of a handful of specific lipid fractions, they lack the 
ability to provide a more holistic lipid profile, as can be achieved with MSI.  
To date a limited number of studies have applied MSI-based approaches to identify 
specific lipid signatures with respect to CRC; Shimma et al identified region-specific 
lipid profiles in CRC liver metastasis samples obtained from a single patient 294, and 
more recently Thomas et al found a panel of lipid-based biomarkers to be up- and 
down-regulated in CRC liver metastasis tissue sections obtained from three patients 
295. These preliminary studies have highlighted the potential of lipid profiling in 
identification of disease-relevant lipid signatures for next-generation biomarker 
discovery.         
For this section of my work I applied a MALDI-MSI profiling approach to determine 
morphologically localized lipid signatures in colorectal tissue samples (CRC, n=12; 
healthy ‘tumour-remote’ colorectal mucosa, n=12; healthy ‘tumour-adjacent’ colorectal 
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mucosa, n=12) obtained from a small, prospectively recruited cohort of patients with 
biopsy confirmed CRC. This study methodology is novel as until very recently most 
studies that have employed MALDI-MSI to evaluate primary CRC tissue have focused 
principally on protein expression,296, 297  with little or no consideration to downstream 
lipid biochemistry.  
Specifically I sought to address three primary objectives in this thesis segment:  
(1) To confirm the feasibility of MALDI-MSI for identification and characterisation of 
topographically discrete lipid signatures in different biological compartments 
within the CRC TME. 
(2) To use MALDI-MSI profiling for comparison of lipid biochemistry in ‘tumour-
adjacent’ and ‘tumour-remote’ healthy colorectal mucosa, in order to identify 
novel tumour-associated ‘field effects’ based on disordered lipid metabolism. 
(3) To develop a novel chemometric data-processing strategy for biochemistry-
driven tissue classification (cancerous colorectal versus healthy colorectal); to 
achieve this objective, MALDI-MSI lipid signatures from tissue sections 
obtained from centre of tumour and 10cm from tumour margin have been 
subjected to multivariate analysis to determine lipid species most responsible 
for discrimination between cancer-bearing and non-cancer bearing samples. 
The aim here was to use a small subset of MALDI-MSI images as training data 
to identify cancer-specific lipid signatures, and to then evaluate the predictive 
capacity of the generated model to distinguish cancerous from healthy tissue in 
the remaining samples.  
It is conceivable that study objective (3) could facilitate the future development of 
biochemistry-based methods for classifying tissue as ‘cancerous’ or ‘healthy’ (based on 
regional lipid distribution) to supplement current gold-standard approaches in tissue 
diagnostics.   
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5.3  Development of a novel method for efficient sample-to-sample 
comparison of MSI chemical data 
At present data pre-processing, processing and statistical evaluation strategies 
represent significant challenges to realising the full translational potential of MSI. 298 In 
MSI experiments ionisation is applied directly to the tissue surface across a pre-defined 
array of co-ordinates, each of which generates its own unique, spatially localised mass 
spectrum (Figure 3.9). This results in vast, multidimensional datasets which are 
challenging to analyse and interpret with conventional multivariate methodologies. The 
data treatment method proposed here was devised with the assistance of Dr Olivier 
Cloarec (Korrigan Sciences, UK) and allows spectra from all co-ordinates to be 
aggregated to create a single ‘super’ mass spectrum from each tissue section, which 
can then be used to perform efficient sample-to-sample and group-wise comparison. 
This method was implemented to allow me to precisely ascertain molecular differences 
between cancer-bearing and non-cancer bearing sections profiled by MSI; the 
distribution of discriminating molecular species can then be visualised using this 
approach on individual MALDI images by selectively searching for identified m/z values 
found to be responsible for class discrimination. 
 
5.4  Materials and methods 
5.4.1  Patient recruitment and sample acquisition 
This study was approved by the institutional review board at Imperial College 
Healthcare NHS Trust (REC reference number 07/H0712/112). Tissue specimens and 
related clinical data were collected with informed and written consent from 12 
prospectively recruited patients undergoing elective surgical resection for confirmed 
CRC at St Mary’s Hospital (London, UK). The demographic and clinico-pathological 
characteristics of these patients are summarized in Table 5.1).  
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Table 5.1 Demographic, clinical and histological data for study cohort 
 Number % 
Total number 12  
Age, median (range) 70 (26-87)  
Gender   
         M 7 58 
         F 5 42 
Location of primary tumor   
         Colon 10 83 
         Rectum 2 17 
Pathology   
Adenocarcinoma 12 100 
Differentiation   
          Well differentiated 0 0 
          Moderately differentiated 11 92 
          Poorly differentiated 1 8 
T-Stage   
          T1 0 0 
          T2 5 42 
          T3 5 42 
          T4 2 16 
UICC Stage   
           I  4 33 
           II 2 17 
           III 6 50 
           IV 0 0 
Lymph node status   
           N0 6 50 
           N1/N2 6 50 
 
Resected cancer specimens were taken on ice to the pathology department 
immediately after surgical extraction and were evaluated by a single pathologist (RDG) 
prior to sampling. Fresh tissue was retrieved from tumour centre (n=12) and 
macroscopically cancer-free ‘tumour-adjacent’ (directly adjacent to tumour; n=12) and 
‘tumour-remote’ (10cm from cancer margin; n=12) colorectal mucosa. These samples 
were immediately transferred to a freezer at -80ºC prior to processing. 
 
5.4.2  Sample preparation 
Tissue samples were cryo-sectioned using an SME Cryostat (ThermoShandon, USA) 
and LC-MS grade water (Sigma-Aldrich, Gillingham, U.K.) was used for embedding 
purposes. Conventional embedding/fixation media cannot be used for MSI analysis as 
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these interfere with spectral signal acquisition. Consecutive sections were generated 
for MALDI-MSI (12 μm) and histopathological (6 μm) analysis to allow co-registration of 
biochemical and architectural features. Sections were thaw mounted onto plain glass 
microscopy slides before those obtained for histopathology were subjected to 
haematoxylin and eosin (H&E) staining.  For MALDI-MSI tissue analysis, a uniform 
coating of α-cyano-4-hydroxycinnamic acid (CHCA) matrix solution was applied to 
designated tissue sections using an automated spray system (TM Sprayer, HTX 
Technologies, NC, USA) and a solution of 5mg/mL CHCA in 50:50 acetonitrile (ACN): 
0.1% TFA (aq.)  
 
5.4.3  MALDI-MSI data acquisition and pre-processing  
Mass spectrometric tissue analysis was carried out using a Waters® MALDI SYNAPT® 
G2 High Definition Mass Spectrometer (HDMSTM) System (Waters Corporation, 
Manchester, UK) (Figure 5.2).  
 
Figure 5.2 SYNAPT G2 with built in MALDI ion source 
 
 
 
 
 
 
 
 
 
Spectra were collected in the mass range m/z 50 to 1000. The neodymium-doped 
yttrium aluminium garnet (Nd:YAG) laser (355nm) was operated at a firing rate of 
200Hz with a spatial resolution of 70μm. Raw MALDI data were calibrated using a post-
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5.4.4  Pattern recognition for MALDI-MSI data analysis  
Statistical analysis in MSI-based experiments is challenging as this type of analytical 
approach calls for evaluation of high-throughput chemical data and spatial data in 
tandem, adding an additional layer of bio-statistical complexity to conventional ‘-omics’ 
data analysis. The two most commonly employed pattern recognition methods in 
metabolic profiling studies are principal component analysis (PCA) and partial least 
squares (PLS) regression analysis, as outlined in Chapter 3. The volume of raw data 
generated by a typical MALDI-MSI experiment is immense, as every co-ordinate of 
tissue over which ionisation is delivered will generate a detailed mass spectrum. The 
primary aims of PCA and PLS ‘dimensionality reduction’ techniques are to scale-down 
data burden in order to simplify data handling and interpretation (this is referred to as 
‘dimensionality reduction’ in bioinformatics). Principal component analysis (PCA) is an 
unsupervised method that illustrates the overall spread within a dataset by condensing 
sample-to-sample variation into a series of ‘principal components’, which can be used 
to model data. Partial least squares (PLS) methods are an extension of PCA and are 
linear regression techniques that use class information (for example whether a sample 
has been obtained from cancerous or healthy tissue) to maximise the discrimination 
between groups of observations, hence in this context the term PLS-DA is used (DA 
standing for discriminant analysis).  
In this study my overarching objective was to develop MALDI-MSI based discriminatory 
models to distinguish sample profiles according to tissue morphology. Hence I have 
applied the PLS-DA regression method, rather than PCA. This statistical technique 
takes original data points/observations and projects them onto a new set of axes where 
similarities/differences between classes of interest can be determined more intuitively, 
according to weighted sums/combinations of chemical features (referred to as latent 
variables, LV). Model predictive capacity using PLS-based methods is conventionally 
summarised using the Q2 statistic which normally ranges from 0 to 1; a Q2 of 0 implies 
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that the model has no predictive capacity above random chance/no-model estimates, 
while a Q2 of 1 implies that the generated model is ‘perfect’. In the case of very poor 
model predictive capacity the Q2 can even assume a negative value. Thus the higher 
the Q2 value the greater the predictive capacity of a given model to correctly 
discriminate between classes (for example distinguishing between cancerous and 
healthy tissue). 
 
5.5  Results 
5.5.1 Data Processing Strategy 
Two novel strategies for the evaluation of MALDI-MSI data have been developed and 
implemented for this part of my research to address the outlined study objectives. For 
identification of discrete lipid signatures within different TME component regions I 
identified morphological features of interest on H&E stained tissue sections and 
selected specific MALDI-MSI pixels corresponding to these different tissue types 
(tumour-adjacent mucosa, cancer, smooth muscle, tumour-adjacent stroma, fibrous 
tissue, tumour-remote mucosa). The aim of this approach was to develop lipid-based 
models for tissue-specific classification and to potentially highlight basic inter-
relationships between different TME zones of interest with respect to lipid biochemistry.  
The second analytical approach presented here was designed to allow information 
from multiple MALDI-MSI images to be combined to improve interpretation and 
enhance the validity of observed region-specific lipid activity across a set of samples. 
With this analytical model no histological information has been taken into account other 
than whether the tissue sample has been retrieved from an area judged 
macroscopically to be ‘cancer-bearing’ or ‘non-cancer bearing’. 
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5.5.2  Identification of topographically discrete lipid signatures in 
different regions within the colorectal cancer microenvironment 
In order to determine MALDI-MSI derived lipid signatures for specific morphological 
tissue types, I first selected regions of histologically confirmed cancer, smooth muscle, 
tumour-adjacent stroma and fibrous tissue from H&E stained centre of tumour tissue 
sections. In addition I included in this model cancer-free tumour-adjacent mucosa and 
tumour-remote mucosa (sampled from adjacent to tumour margin and 10cm from 
tumour margin respectively), to identify any potential cancer-associated field effects in 
morphologically bland, tumour-adjacent tissue.  Next, mass spectra were collected 
from pixels corresponding to these tissue regions on corresponding MALDI-MSI 
images (it is important to note that the same section could not be used for both MALDI-
MSI and H&E staining due to tissue disruption caused by MALDI analysis). A PLS-DA 
model was then fitted to differentiate MALDI-MSI profiles according to tissue type, 
using a 2 classifier system, as ‘cancer-bearing’ or ‘non-cancer bearing’. A Q2 value of 
0.79 was obtained for this model indicating robust separation of biochemical profiles 
according to tissue morphology. A P-value for this model was also calculated as an 
additional means of confirming multivariate model predictive capacity (cancerous 
versus all non-cancerous tissue types, p<0.001). The scores plot for the ‘cancerous 
versus non-cancerous tissue’ PLS-DA model is shown in Figure 5.4 and reveals clear 
differences in MALDI-MSI derived chemical signatures according to tissue type. Here 
the x-axis denotes whether the MALDI-MSI profile was acquired from cancerous or 
healthy tissue. Healthy tissue has been further colour-coded according to different 
morphological classes and these appear to cluster closely together according to tissue 
morphology.    
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Figure 5.4 PLS model scores plot revealing distribution of colour-coded MALDI-MSI profiles 
obtained from cancerous tissue regions and non-cancerous tissue regions (stroma, smooth 
muscle, submucosa, fibrous tissue, tumour-adjacent healthy mucosa and tumour-remote 
healthy mucosa). The x-axis denotes grouping of samples according to tissue class (non-
cancerous and cancerous) and the y-axis indicates a PLS-derived ‘score’ based on a weighted 
sum of molecular features for each data point; the closer the score is to ‘1’ the more likely it is 
to represent a cancerous region and likewise the closer the score is to ‘-1’ the more likely it is 
to be healthy based on identified chemical signatures. The plot reveals visible clustering of 
data points according to presence or absence of cancer, and also reveals grouping of samples 
of non-cancerous tissue according to tissue morphology. Data points from tumour-adjacent 
healthy mucosa are seen to lie in closer proximity to cancer compared to tumour-remote 
healthy mucosa.     
 
 
 
 
 
 
 
 
 
 
 
 
To demonstrate the feasibility of correctly localising cancerous tissue using this 
approach, PLS derived chemical signatures found to be associated with cancer 
(‘tumour scores’) were projected back onto ‘blank canvas’ MALDI-MSI images. The 
accuracy of cancer localisation was evaluated by co-registering these reconstructed 
MALDI-MSI images with corresponding H&E stained sections. Examples of 
132 
 
reconstructed images are shown in Figure 5.5 (A-F). Back-projection of tumour scores 
onto MALDI-MSI images from sections known to harbour tumour, revealed close 
correlation between the localisation of these scores and location of tumour on 
corresponding H&E stains (Figure 5.5 A-C). By contrast projection of tumour-
associated PLS scores onto non-tumour-bearing tissue sections showed no 
classification and a marked reduction in signal intensity, as anticipated (Figure 5.5 D-
F). 
 
Figure 5.5 MALDI-MSI images from sections of tumour-bearing (A-C) and non-tumour-bearing 
tissue (D-F). Selective projection of cancer-associated m/z values onto MALDI-MSI images 
reveals clear localisation of these molecular signatures within cancer-bearing areas when 
comparison is made with corresponding annotated H&E stained adjacent tissue sections 
(tumour-bearing regions on H&E sections have been outlined in blue for ease of co-
registration).  
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5.5.3 Identifying MALDI-MSI derived tumour-associated ‘field effects’ 
via comparison of tumour-adjacent and tumour-remote 
morphologically bland colorectal mucosa 
I further investigated the observed differences between tumour-adjacent and tumour-
remote colorectal mucosa with PLS-DA based multivariate models. The aim here was 
to determine the lipid fingerprint of tumour-adjacent healthy mucosa in comparison to 
tumour-remote tissue, and tumour itself.  
Figure 5.6 shows the PLS-DA scores plot for differentiating between tumour-adjacent 
and tumour-remote colorectal mucosa (Q2=0.76). This model indicates the presence of 
significant differences in mass spectral profiles obtained from morphologically healthy 
colorectal tissue according to proximity to tumour.  Figure 5.7A shows a three-class 
PLS-based scores plot with data points from tumour, tumour-remote (healthy) and 
tumour-adjacent (healthy) colorectal tissue plotted according to biochemical 
similarities/differences. This plot reveals visible overlap between data points acquired 
from tumour (blue) and tumour-adjacent (pink) sites – suggesting that the tumour field, 
even when morphologically free of cancerous invasion, exhibits metabolic properties, 
which closely mimic those of neighbouring cancerous zones. This stepwise molecular 
shift is also illustrated in the vertical scatter plot (Figure 5.7B). The statistical capacity 
of this model to correctly distinguish samples as belonging to tumour, tumour-adjacent 
or tumour-remote classes is summarised in the form of Q2 statistics as Q2=0.64, 
Q2=0.67 and Q2=0.69, respectively.   
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spectral characteristics. A ‘leave-one-patient-out’ approach was used for cross-
validation which means that each pair of slides corresponding to the same patient was 
removed before fitting the model.   
Figure 5.8A demonstrates the cross-validated PLS-DA scores plot generated for this 
discriminant analysis, as well as a selection of MALDI-MSI images for centre of tumour 
and 10cm from tumour margin tissue sections. These images demonstrate a visible 
trend towards increased molecular signal intensity in cancer-bearing relative to healthy 
tissue sections. This information can be used to construct a ‘loadings plot’ (Figure 
5.8B) where the molecular species that are more/less abundant for one class relative to 
another can be determined 245. This method of data visualisation is particularly useful 
as it maintains native MS spectral characteristics whilst also allowing identification of 
key biochemical class discriminators.  
With respect to chemical assignment, the loadings plot (Figure 5.8B) reveals that 
molecular species m/z 478.3 (M1), m/z 504.3 (M2) and m/z 760.6 (M3) are found in 
significantly higher concentrations in cancer-bearing samples relative to healthy tissue. 
These three m/z ions exhibited a similar regional distribution within tissue sections as 
shown in Figure 5.9C, appearing to be highly abundant in cancer-cell bearing areas 
(Figure 5.9B and C).  
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5.6  Discussion 
In this small feasibility study I have sought to develop and implement novel bio-
analytical and data processing strategies for MALDI-MSI based analysis of CRC tissue 
sections. My findings confirm the presence of lipid-based differences between 
cancerous and healthy colorectal tissue and demonstrate tumour-adjacent field effects 
with respect to lipid metabolism that may have translational significance. Chemical 
mapping of cancer tissue using this approach may have potential to provide novel 
molecular data with respect to TME biology.    
Accurate molecular characterisation of the TME represents a major research priority in 
systems oncology.299, 300 The TME is comprised of a variety of cell types as well as pro-
tumorigenic factors and a myriad of signalling molecules, all of which are thought to be 
involved in tumour development, survival and progression.300 Phenotyping the TME 
from a lipidomic/metabolic perspective has the potential to provide important biological 
information downstream of the cancer genome and proteome, and recent in vitro work 
has confirmed that the tumour niche exhibits compartmentalised metabolic activity.301 
For example, tumour cells are thought to impose conditions of oxidative stress on 
neighbouring cells creating adjacent zones of cellular catabolism, mitochondrial 
dysfunction and aerobic glycolysis.301 Imaging mass spectrometry approaches such as 
MALDI-MSI offer the opportunity to non-destructively characterise this activity, 
particularly with respect to the cancer lipidome. However, several refinements are 
necessary in order to facilitate the widespread application of MSI approaches in the 
clinical setting. Firstly, data treatment methodologies must be developed that can 
reduce the high-dimensionality of MSI data and display results in a streamlined and 
readily interpretable way. Furthermore, the profiling of very fine histological details (for 
example a thin strip of cancer-adjacent stroma) will call for more sophisticated 
experimental methods that allow the same tissue section to be effectively analysed by 
MSI and histology. Here I have used directly adjacent sections of tissue for MALDI-MSI 
141 
 
and H&E evaluation, and acknowledge that this would almost certainly allow features to 
occupy slightly different co-ordinates from one image modality to the next, making 
feature correlation more uncertain, especially in the case of fine structures. In addition 
MSI datasets present unique challenges where the aim is to build a model for 
comparison across multiple tissue samples. In the present study I have introduced a 
novel technique for integration of data from a given MALDI-MSI image to create a 
‘super’ mass spectrum summarizing all captured information efficiently. I have shown 
that using this approach, super-spectra generated from different tissue sections can be 
subjected to multivariate analysis to identify discriminant molecular features between 
groups (in this case CRC versus healthy tissue). Application of this technique to the 
small sample set tested here allowed distinction to be made between cancer-bearing 
and non-cancer bearing tissue samples, based on biochemistry. With shorter data 
acquisition-time and reduced costs foreseeable in the near future, this approach could 
facilitate the development of novel cancer evaluation strategies to supplement current 
gold standard histological techniques. While MSI techniques are intended to 
complement histology, it has previously been suggested that these methods could lead 
to the development of ‘automated’ tissue evaluation strategies.302 However, several 
critical questions remain regarding the ability of biochemistry-driven approaches to 
robustly identify cancer without morphological confirmation. For example, it is unclear 
from the current data-set (as well as other studies in this field) whether MALDI-MSI 
derived metabolic signatures are dependent on a particular threshold of cancer cell 
load being exceeded, or whether these signatures would still be detectable in the 
presence of a single or few tumour cells. From my own experience with the technology 
I firmly believe that MSI approaches will play an important role in cancer tissue 
evaluation in the future, and will supplement, but not replace, histopathology.    
The primary aim of this section of my work was to develop lipid-based profiles 
according to tissue typology (Figure 5.4). I was able to acquire distinct profiles for 
different tissue regions (tumour, stroma, fibrous tissue, smooth muscle, submucosa) 
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after identification of features of interest on corresponding H&E sections and co-
registration of these with MALDI-MSI images. More interestingly, the PLS-DA scores 
plot for this model highlighted some differences between tumour-remote and tumour-
adjacent healthy mucosa (Figures 1, 3 and 4). Pixels from MALDI-MSI images obtained 
from tumour-adjacent healthy mucosal samples occupied dimensional spaces on the 
scores plot that were very close to, and in many cases overlapped by, cancer tissue 
data points (Figure 5.7). This is not a new observation per se and the findings of this 
portion of my thesis support previous work related to the concept of ‘field 
cancerisation’. This idea was introduced by Slaughter303 and Orr304 in the 1950s  who 
independently observed that tumour-adjacent tissues exhibit significant changes in 
morphology prior to being invaded by cancer. In the present study the changes 
observed in tumour-adjacent tissue relate principally to lipid metabolism which may 
indicate an important role for lipids in the priming of neighbouring tissue prior to cancer 
invasion. I have opted to employ the term ‘cancer-adjacent metaboplasia’ (CAM) to 
describe these tumour-adjacent metabolic field effects, though confirmation of the 
consistency of this phenomenon, specifically with respect to lipid metabolism, will 
require more detailed investigation. Developing a system for grading the extent of 
CAM/metabolic field cancerisation in CRC may offer a new avenue of prognostic 
molecular profiling. In addition, the ability to utilise mass spectrometric (MS) methods 
for identifying and delineating the tumour field, offers a potential means of developing 
novel technologies for in vivo application. I have recently been involved with developing 
and validating a MS-based method of tissue characterisation using a technique we 
have termed Rapid Evaporative Ionisation Mass Spectrometry (REIMS).305-307 This falls 
outside of the scope of the current thesis and so is not discussed in detail here. In 
summary though, with this technique, different tissues being dissected with electro-
cautery have been found to exhibit characteristic molecular ion patterns within the 
cautery-induced vapour plume, which can be fed into a mass spectrometer. This 
vapour plume can be analysed rapidly using mass analyser technology to guide the 
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operating surgeon.307 My finding of unique MS-based lipid signatures in the tumour field  
can potentially be applied to this technology to offer the cancer surgeon a means of 
confirming when tumour deposits are in close proximity, and ‘skirting around’ these 
within the CAM field, to avoid disrupting/cutting into tumour itself. This could be 
particularly useful in cases of locally advanced or recurrent CRC where extended 
margin resection is often necessary, and where cancer lesion perception is severely 
hampered by local fibrosis and or mucinous response to pre-operative chemo-
radiotherapy.    
From a biochemical perspective this work has identified elevated levels of 
phosphatidyl-choline PC(16:0-18:1), LysoPC(16:0) and LysoPC(18:1)  in CRC tissue. 
This is not an entirely new finding in biological terms, as altered PC metabolism in 
cancerous tissue is well established and has recently been used to develop in-vivo 
magnetic resonance spectroscopy (MRS) based approaches to tumour localisation, 
across a variety of cancer subtypes.308-310 My results are in agreement with previous 
ex-vivo tissue profiling studies in breast and thyroid cancer.311, 312 Phosphatidyl-choline 
(16:0/18:1) was found in significantly increased concentrations in cancerous compared 
to healthy thyroid tissue in a recent study evaluating the significance of lipid 
composition in papillary thyroid cancer.312 In an earlier study by Williams et al, breast 
cancer cells were found to contain relatively increased concentrations of PC (16:0/18:1) 
compared to healthy counterparts.311    
Lipids comprise a group of diverse molecules with different structures and 
functionalities that play important roles in cellular processes. They are associated with 
a number of critical cellular functions including membrane synthesis, metabolic 
regulation and immunity.313, 314 Increasing evidence points towards an important role for 
lipids in carcinogenesis, and altered cellular phospholipid composition has recently 
been reported across a variety of cancer sub-types.315, 316 In addition, target tissue lipid 
composition has been shown to be of potentially prognostic significance in determining 
likely response to chemotherapy.317 Taken together, these observations indicate that 
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comprehensive characterisation of lipidomic profiles in CRC may offer an important 
new avenue of discovery for markers of diagnosis, prognosis and therapeutic efficacy. 
Although in this study I was able to localise only a small number of lipid species, future 
refinements in experimental workflow/parameters and the development of increasingly 
sensitive mass spectrometric profiling platforms promises to lead to more 
comprehensive mapping of the cancer lipidome.    
 
5.7  Summary 
This study demonstrates the development of two novel methods for analysis of CRC 
tissue using a MALDI-MSI approach. Using the first method I have demonstrated that 
different tissue regions in the CRC TME appear to harbour distinct lipid characteristics, 
and this finding is in keeping with emerging evidence across a variety of other cancer 
sub-types. In addition I have demonstrated MALDI-MSI based differences between 
tumour-adjacent and tumour-remote healthy colorectal mucosa, and this is in keeping 
with the established principle of ‘field cancerisation’, whereby cancers influence the 
local environment prior to invasion. These field effects require further investigation and 
may prove to be of prognostic significance. I have referred to this finding as ‘cancer-
adjacent metaboplasia’ (CAM), as the changes I noted were primarily related to lipid 
metabolism in the tumour field. In the second method introduced here I have sought to 
demonstrate the feasibility of biochemistry-driven tissue classification using MALDI-MSI 
derived super spectra. In the small number of samples evaluated here the applied 
analytical strategy was capable of distinguishing cancerous from non-cancerous tissue 
sections based on biochemistry and such approaches may be used to supplement 
established histopathological tissue evaluation strategies in the future. A limitation with 
the MALDI technique was that the need for tissue desiccation as well matrix 
application, render the tissue unfeasible for subsequent H&E staining. Alternative MSI 
techniques that are more histology-compatible may be required for precise correlation 
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of morphology and biochemistry inter-relationships, and these are the focus of the 
subsequent chapters of this thesis.     
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6.1  Background 
As shown in Chapter 5, MSI profiling of intact tissue sections has potential to provide 
topographically localised biochemical information to supplement conventional 
histopathological classification systems.207-210 Together with emerging metabolomics-
based profiling approaches such as HR-MAS NMR spectroscopy, MSI represents a 
highly promising technique in molecular cancer profiling101, 189 and is increasingly being 
used for the discovery of next-generation cancer biomarker panels.167, 211-213 Among the 
MSI methods currently available, the three most commonly employed to date are 
matrix-assisted laser desorption ionisation (MALDI),208, 213, 216 secondary ion mass 
spectrometry (SIMS) 163-165 and desorption electrospray ionisation (DESI).166, 167 With 
each of these described approaches, operating characteristics and experimental 
parameters can be modulated to suit specific analytical objectives and can be 
customized for the identification of particular biomolecular species. The work presented 
in the previous chapter of this thesis is certainly encouraging and my findings illustrate 
how MALDI-MSI analysis can provide a region-specific chemical fingerprint from tissue 
sections. However, while MSI undoubtedly has potential, my investigation into the 
MALDI method also served to confirm that current approaches in MSI lack both the 
sophistication and intuitiveness necessary to allow precise histology-directed tissue 
phenotyping. This would ideally require: (1) advanced image-alignment steps to allow 
unambiguous co-registration of biochemical signatures with morphology, (2) the use of 
same rather than adjacent tissue sections for MSI and histology (i.e. ‘histology-
compatible’ MSI techniques that permit effective H&E staining post MSI) and (3) the 
development of an efficient, intuitive data analytical pipeline capable of performing all 
steps of MSI data handling and interpretation. For this section of my work an alternative 
MSI method is introduced together with a streamlined data analytical framework 
developed to address the three requirements outlined above.    
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6.2  MSI-based approaches in clinical cancer research: current 
challenges and likely solutions 
Currently MSI is likely to exert greatest influence at the prognostic and therapeutic 
stages of the disease continuum, with three fundamental areas of application in cancer 
phenotyping. Firstly, it offers a means of chemically mapping morphological regions-of-
interest in order to develop next generation prognostic and therapeutic biomarkers. 
Secondly, it permits compartmentalised assessment of the distribution and biochemical 
influence of chemotherapeutic agents and/or their downstream metabolites within 
different tissue regions, offering novel insights into anti-cancer drug efficacy.214-217 
Thirdly, MSI methods may offer a means of developing ‘automated’ approaches for 
basic tissue classification based entirely on molecular ion composition. Such ‘machine-
learned’ methods may lessen the logistical and financial burden being placed on 
pathology services in the modern cancer-screening era.   
Until now the routine clinical application of MSI approaches has been restricted by 
inherent time/cost demands and associated heavy analytical workload. However, 
recent advances in MS technology combined with the richness of generated molecular 
information should ensure the widespread adoption of MSI technologies in the near- to 
mid-term. The major impediment to this progress currently centers on the choice of 
chemo-informatics workflow and to a lesser extent the choice of technique.  
The standard approach applied to MSI datasets involves a series of steps designed to 
reduce bio-analytical complexities for improved information recovery (dimensionality 
reduction), followed by pattern recognition analysis and molecular pattern 
interpretation. Conventional workflows, integrated into independently developed 
software packages such as BioMap (Novartis, Basel, Switzerland), SpectViewer (CEA, 
Paris, France), DataCubeExplorer (AMOLF, Amsterdam, Netherlands) and Mirion 
(JLU, Giessen, Germany) or within commercial packages from instrument 
manufacturers such as Xcalibur (Thermo Fisher Scientific Inc., Bremen, Germany) and 
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FlexImaging (Bruker Daltonics, Bremen, Germany) have capabilities limited to basic 
pre-processing and browsing through selected ion images. For example, for the work 
presented in Chapter 5 I used the BioMap platform, and while this allows visualization 
of individual m/z values on MSI images, it is not capable of displaying data in a more 
holistic way, which would be desirable. There is currently a need for more sophisticated 
chemo-informatics strategies and visualization systems that can streamline data 
processing and simultaneously maximise disease-relevant molecular information 
capture and display. These strategies will be critical to the successful clinical 
translation of MSI approaches.  
Typically, data pre-processing methods in MSI involve peak detection or ‘binning’ and 
filtering of solvent/matrix or ‘noise’ -related peaks,318, 319 followed by a data 
normalisation step (as described in Chapter 3). At present, the most widely applied 
approach involves integrating MSI spectra within a pre-defined ‘bin’ size (typically 
~0.01Da). This reduces mass detection accuracy and introduces biologically irrelevant 
spectral features, making unambiguous assignment of chemical species more difficult. 
In the case of normalisation, the total ion current (TIC)  scaling factor is frequently cited 
in the literature as an acceptable means of accounting for global intensity changes in 
an MSI dataset 320. However, it was recently demonstrated that the performance of this 
method can be compromised by single large molecular ion peak intensities.222, 321 An 
additional problem inherent to MS-based analysis of complex biological mixtures is the 
fact that molecules present in greater intensities within a given sample will tend to 
exhibit larger variations when subjected to repeated measurement.322 This disruption to 
variance constancy across the measurement range, known in statistical terms as 
heteroscedasticity, represents a significant barrier to the effective downstream 
application of multivariate analytical methods.322 To date a number of different 
strategies have been proposed in the literature to stabilise variance across the 
measurement range,318, 319 and Veselkov et al (Imperial College London) have recently 
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validated several variance stabilising normalisation techniques in the context of MS-
based profiling.322 
Beyond these pre-processing steps, MSI data needs to be effectively ‘fused’ with 
conventional histopathological information to allow the construction of large-scale 
molecular databases comprised of region-specific molecular biomarkers. Precise 
methods for co-registration of histological and MSI data is an essential prerequisite for 
this purpose and represents a further challenge at present. Of the software packages 
currently available only the proprietary Bruker package offers image co-registration and 
region-of-interest molecular ion pattern extraction, with the option to further process 
extracted spectra in the associated statistical toolbox ClinProTools.323 However, this 
approach (limited to data collected on Bruker instrumentation) requires the user to 
manually select features on the pre- and post-staining images to conduct co-
registration and can be subject to considerable error. Other less refined platforms have 
sought to achieve this objective by visual selection of particular regions-of-interest on 
H&E stained optical images, followed by selection of pixels occupying similar (but not 
precisely aligned) geographical co-ordinates on corresponding MSI heat-maps.222 I 
employed such a method in Chapter 5 and found that it permits only very crude co-
localisation of features from the two imaging modalities, and may be deemed sufficient 
perhaps only in instances where limited variation in cell typology is seen across the 
tissue section (e.g. cancerous cellular regions and healthy cellular regions only). A 
number of image-alignment algorithms have been developed and proposed in recent 
years, such as the use of fiducial markers to segment and align images,324 though 
currently there is no standardised image co-registration protocol in the context of 
histology-driven MSI, and marker-based/fiducial methods may lack the precision 
required for detailed definition of morphology-to-chemistry inter-relationships.  
Histology-driven, automated tissue identification further requires efficient and robust 
extraction of tissue-specific molecular ion patterns. The multidimensional nature of MSI 
datasets calls for effective dimensionality reduction techniques that are capable of 
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extracting tissue-specific multivariate molecular ion patterns (i.e. combinations of 
chemical patterns that distinguish one tissue type from others).325, 326 Currently, the 
most widely employed supervised dimensionality reduction technique in molecular 
phenotyping studies is partial least squares discriminant analysis (PLS-DA),327 which I 
have employed extensively in previous chapters of this thesis. With the PLS-based 
discriminant analysis method, model components are derived by maximising between-
class variance (i.e. the difference between class means as outlined in Table 6.1).326, 328 
A more mathematically elegant mode of discriminant analysis is to maximise the 
difference between class means while simultaneously minimising within-class 
variability. This is the objective of linear discriminant analysis (LDA) which maximises 
the ratio of between- versus within-class variance.326 Unfortunately, LDA cannot be 
directly applied in circumstances where the number of variables exceeds the number of 
samples, as is the case with the MSI data presented here. Principal component 
analysis (PCA) has been commonly applied as a pre-processing step before LDA 
(PCA-LDA) to mitigate this problem.167, 325 However, a problem arises here with respect 
to the selection of an optimal number of principal components. Introducing too many 
components into a model will increase the likelihood of model overfit (i.e. developing an 
artificially powerful statistical model), while retaining too few can result in the loss of 
discriminatory information.329 
For this section of my research I collaborated with Dr. Kirill Veselkov (Computational 
and Systems Medicine, Imperial College London), who has extensive experience in 
high-throughput data analysis, to develop a comprehensive data treatment framework 
with the aim of addressing the challenges outlined above in MSI data exploration. 
Through this collaboration a novel data processing strategy has been developed and I 
have applied this to the analysis of CRC tissue sections. Concurrently Dr. Veselkov 
and I have developed an in-house image co-registration platform designed to provide a 
user-friendly interface for simultaneous biochemical and histopathological evaluation of 
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cancer tissue sections. As a validation step in this chapter, the outlined workflow has 
been applied to the investigation of lipid signatures in CRC.  
 
6.3  Materials and methods 
6.3.1  Patient recruitment and sample acquisition 
This method development study was approved by the institutional review board at 
Imperial College Healthcare NHS Trust (REC reference number 07/H0712/112). 
Between November 2010 and January 2012 tissue specimens and related clinical data 
were collected with informed and written consent from patients undergoing elective 
surgical resection for confirmed CRC at St Mary’s Hospital (London, UK). Fresh CRC 
tissue samples were harvested from surgical resection specimens in the pathology 
department by a single gastrointestinal pathologist (RDG) and immediately transferred 
to a freezer at -80ºC prior to processing. Tissue samples were cryo-sectioned to 10m 
thickness with an SME cryotome (Sigma-Aldrich, Gillingham, U.K.) using 3% 
carboxymethyl cellulose as an embedding medium, before being thaw-mounted onto 
plain glass slides. This embedding media was tested prior to analysis and found to 
cause no difficulties with subsequent data interpretation, and additionally it made 
sectioning of tissues more practical.  
 
6.3.2  MSI data acquisition 
A limitation with the MALDI technique highlighted in Chapter 5 was the inability to H&E 
stain tissue sections post- MALDI analysis. This is owing to the fact that procedural 
steps of tissue desiccation and matrix-solution application rendered subsequent 
staining unfeasible. For method development in this study I chose to employ DESI-MSI 
as an alternative technique. The advantages with this approach are that: (1) it is a 
ambient ‘soft ionisation’ technique so minimal tissue architectural disruption is caused 
during analysis and (2) it requires no tissue dessication (as it operates at atmospheric 
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pressure) or matrix-solution application, meaning that (3) it allows the same tissue 
section to be first subjected to MSI and then H&E staining, allowing precise feature 
correlation.  
Tissue sections, prepared as outlined in section 6.3.1, were subjected to negative ion 
DESI-MSI analysis using an in-house Exactive mass spectrometer (Thermo Fisher 
Scientific Inc., Bremen, Germany) equipped with a custom-built, automated DESI ion 
source (Figure 6.1).  
 
Figure 6.1 Annotated technical set-up for DESI-MSI tissue profiling (1) Sample holder 
plate (2) Adjustable stage (3) DESI sprayer (4) DESI inlet capillary for transfer of 
molecular ions to mass spectrometer post-ionisation (5) Tissue section mounted onto 
plain glass slide (6) Electrospray solvent flow (7) Custom built DESI ion source  
 
 
 
 
 
 
 
 
 
 
 
The mass resolution used for all measurements was set to 100,000 with a mass 
accuracy of <4ppm. Spatial resolution for imaging experiments was set to 75μm. 
Methanol/water (95:5 v/v) was used as the electrospray solvent at a flow-rate of 
1.5L/min. Zero-grade nitrogen was used as nebulising gas at a pressure of 4bars. The 
height distance between the DESI sprayer and the sample surface was set to 2mm 
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with the distance between the sprayer and the inlet capillary set to 14mm. The distance 
between the sample surface and the inlet capillary of the mass spectrometer was 
<<1mm. The angle between the sprayer tip and the sample surface was set at 80. 
Mass spectra were collected in the mass range of m/z = 200-1,000. Following DESI-
MSI analysis, the tissue sections were stained with haematoxylin and eosin (H&E) and 
digitally scanned at high resolution using a NanoZoomer 2.0-HT digital slide scanner 
(Hamamatsu Corp., Japan) for precise visual comparison of biochemical topography 
and tissue architecture. 
 
6.3.3  Development of a comprehensive MSI data treatment pipeline 
6.3.3.1  Classification of tissue object pixels 
Accurate distinction between tissue object pixels and background is essential prior to 
the downstream filtering of biologically irrelevant peaks and image co-registration. 
Tissue object pixels in an MSI image usually exhibit higher intensity than background 
areas, which mainly contain signals due to solvent or noise. Based on this assumption, 
a system for tissue object pixel (TOP) identification was developed by setting an 
intensity threshold (t) to the total ion intensity (TI) image,330 as summarized in equation 
6.1.   
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Thus, where TI at a given (x, y) coordinate exceeds the designated intensity threshold 
(t), the pixel is designated as TOP, otherwise it is assigned to background. To further 
improve tissue object to background contrast, the TI image was calculated disregarding 
m/z features present in the pixel-wide outer border of a section, as these are likely to 
originate from solvent signals. 
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6.3.3.2  Elimination of ‘noise’- and solvent-related chemical signatures  
Due to inherent inaccuracies in mass detection, molecular ion peaks within a m/z range 
smaller than the native accuracy of the mass spectrometer (<4ppm in this case) were 
assigned to the same molecular ion species uniformly for all pixels on a tissue section. 
The resulting data volume contained hundreds-of-thousands of noise related m/z 
species, which are typically located at random in <1% of pixels.221, 298 Based on this 
principle, all molecular ion peaks present in <1% of tissue bearing pixels were removed 
from subsequent analysis. Additionally, m/z species were deemed to be of solvent-
related origin if their mean peak intensity within TOPs was less than their mean 
background intensity.  
 
6.3.3.3  Variance stabilising normalisation for enhanced retrieval of 
biologically relevant spectral data  
The downstream application of multivariate statistical techniques assumes that 
measurement noise structure is consistent across the whole intensity range. In the 
case of MSI datasets this condition is not fulfilled. Here error structure is characterised 
by increasing technical variance as a function of increased signal intensity, and peak 
intensities arise through a combination of genuine signals and noise-related signals 
from different sources, which can be additive or multiplicative in nature. 331 This 
principle is summarised in equation 6.2.  
 
k(ixj)η
k(ixj)(ixj)k(ixj)k(ixj) esnβx           (6.2)332 
 
where, xk(ixj) is the measured peak intensity (level) of the kth molecule in the (ixj)th MSI 
position, sk(ixj) is the expected peak intensity, βk(ixj)  is the random background noise, 
ηk(ixj)  is the random multiplicative noise, and n(ixj) is the normalisation scaling factor. 
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Additive noise is characterised by random fluctuations in the baseline, irrespective of 
the presence of molecular signals, and is derived from electronic noise in the 
equipment. Conversely, multiplicative noise grows with the signal intensity of a 
molecule and is often proportional to it.322 The objective of the logarithmic variance 
stabilizing normalisation approach devised and implemented here is to eliminate 
biologically redundant pixel-to-pixel variation in overall signal intensity for enhanced 
data capture. 
 
6.3.3.4  Advanced multivariate analysis for derivation of tissue-specific 
molecular ion patterns 
The hyper-spectral nature of MSI datasets calls for effective methods for 
‘dimensionality reduction’, or data streamlining, to derive meaningful biochemistry-
based models for tissue phenotyping. The principles of the four most common methods 
employed for this purpose in high-throughput data analysis are described in Table 6.1.  
 
Table 6.1 Principles of dimensionality reduction techniques and their solutions via eigen-
value decomposition 
Method 
Eigen-value 
decomposition 
Components derivation 
PCA  [St]w = w  
Maximises overall dataset variation, without specific 
regard to between-class differences 
PLS  [Sb]w = w  
Maximises between-class variation (difference in class 
means), disregarding within-class variability 
LDA  [Sw
-1Sb]w = w  
Maximises ratio of between- versus within- class 
variation, with the condition that within-class variance 
is non-singular (i.e. number of samples >> number of 
variables) 
RMMC  [Sb - Sw ]w = w  
Maximises between-class variance, whilst minimising 
within-class variation 
 
RMMC recursive maximum margin criterion. Sw within-class data scatter; Sb between-
class data scatter; w is the derived multivariate model 
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In the case of MSI data analysis, the ultimate aim (regardless of employed 
method) is to derive a series of components comprised of weighted sums of 
molecular ion patterns capable of accurately distinguishing tissue types or 
classes. This principle is summarised in equation 6.3.  
 
ETWX                     (6.3) 
 
Where X is a data matrix [samples x variables] after application of variance stabilising 
normalisation, T is a matrix of derived discriminating components [samples x 
components], W is a matrix of weights that summarises the contribution of original 
variables into discriminating components [components x variables] and E is a residual 
data matrix. It is assumed that the number of variables is far greater than the number of 
discriminating components. Here I have employed a method which maximises the 
difference (not the ratio) of between- versus within- class variance, referred to as the 
recursive maximum margin criterion (RMMC).333, 334  
 
6.3.3.5  Novel image co-registration method for precise correlation of 
MSI derived profiles with histology  
The novel image alignment and co-registration method developed for this work involves 
denoting the DESI-MSI image as the ‘reference’ and identifying a mathematical 
(Euclidean) similarity transformation325 such that the optical H&E stained (‘template’) 
image matches the reference DESI-MSI image as closely as possible with respect to 
shape, dimensions and orientation. With the DESI method this is possible very 
precisely as the same tissue section is used for both MSI and H&E staining. The image 
transformation algorithm used here involves three fundamental parameters which 
consist of image scaling, rotation and translation.  
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6.3.3.6  Integrated platform for intuitive MSI data processing and 
visualisation 
The prototype version of an in-house developed image co-registration platform has 
been implemented to allow histology-driven exploration of morphology-specific 
biochemical features in CRC tissue after image alignment, as described above. Using 
this interface, it is possible for the user to ‘zoom-in’ on and select multiple regions-of-
interest and perform multivariate pattern recognition analysis on corresponding spectral 
profiles. A built-in RMMC-based discriminatory analytical tool using a ‘one against all’ 
approach has been installed into this platform to allow robust separation between 
different tissue types according to biochemistry. Using this approach, I have attempted 
to derive tissue-specific discriminatory scores and multivariate molecular ion patterns 
by taking one tissue class at a time and comparing it to all others in a given tissue 
section (hence, ‘one against all’).  
 
6.4  Results  
6.4.1  Noise- and solvent-related data subtraction 
To ensure that spectral profiles obtained are of genuine biological relevance, it is 
essential to filter out spurious peaks related to measurement noise and/or applied 
experimental solvent(s). Typically, peaks due to noise are present in a small number of 
randomly selected pixels within a tissue object. Based on this principle, spectral 
features were considered to be of biological significance only when found in at least 1% 
of MSI pixels within the tissue object. A similar strategy has been previously described 
for MALDI-MSI data analysis,221 although here the authors applied this principle to all 
pixels in the MSI image, not just those within the confines of the tissue object. The 
approach I have employed in the present study refines this method further by applying 
the outlined strategy only to pixels within the tissue object, which should minimise the 
rate of false-positive genuine peak discovery. In addition, m/z species showing higher 
160 
 
intensity outside of the boundaries of the tissue area in the image were also discarded. 
The combination of these processing steps resulted in a significant reduction of 
spectral data volume from >250,000 to approximately 1,000-5,000 biologically relevant 
m/z values, thus enabling more efficient data handling/mining. 
 
6.4.2  Assessing the performance of VSN for improving information 
recovery 
To refine MSI data analysis I have opted to employ a log-based variance stabilising 
normalisation (VSN) method in favor of other commonly employed normalisation 
approaches. The application of multivariate statistical techniques assumes that the MSI 
measurement noise of molecular levels is consistent across the whole intensity 
range.322, 326 In the case of MSI datasets these requirements are not met as error 
structure is characterised by increasing technical variance as a function of increased 
signal intensity.322 Consequently, molecular species with higher peak intensities exhibit 
larger variability when repeatedly measured and thus weak signals can be 
overwhelmed by the noise of strong signals. Multiplicative noise in MSI measurements 
can arise due to a variety of instrumental, experimental and signal processing 
influences including fluctuations in solvent and nebulising gas flow rate in the case of 
DESI analysis. 322, 326 
To assess the performance of the log-based VSN strategy, I manually selected CRC 
DESI imaging data from three different tissue regions (Figure 6.3A), determined by a 
pathologist to be almost entirely morphologically uniform. Figure 6.3B illustrates the 
standard deviation as a function of the rank of the mean of peak intensity across the 
range of tissue regions. In the absence of heteroscedastic noise structure, the running 
median of the standard deviation should verge on horizontal, with minor oscillations 
only but no obvious trend, per se. In Figure 6.3B this condition is not met and the 
variation of peak intensity is seen to increase with the rank of mean intensity (i.e. as 
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The image alignment approach employed in the present study operates using an in-
house developed automated Euclidean image transformation (translation, rotation and 
scaling) algorithmic script based on a gradient descent optimisation approach. The 
majority of currently available image co-registration algorithms are not fit for purpose in 
this setting as they incorporate a manual, fiducial marker-based system which is 
hampered by user bias and thus lacks the required precision and reproducibility.327 
Using the method proposed here, once the ‘template’ (optical) and ‘reference’ (DESI-
MSI) images have been aligned, the user has the option for using a dual image 
magnification function for detailed correlation of features from both images in tandem, 
down to single pixel resolution. This function proves particularly useful when profiling 
discrete areas of histological interest (such as isolated clusters of lymphoid tissue, 
discrete vascular channels or invading tumour border zones, as exemplified on Figure 
6.3 and 6.4).  
  
6.4.4  Enhanced tissue-specific molecular ion pattern extraction using 
RMMC 
Following co-selection of multiple regions of interest on optical and corresponding 
DESI-MSI images (Figure 6.3A and Figure 6.4A), tissue type specific pixel regions 
(comprised of ~20 pixels) were subjected to supervised dimensionality reduction. The 
objective here is to use the least number of components to capture tissue type specific 
chemical signatures based on weighted combinations of molecular ion patterns. Here I 
have elected to simultaneously maximise the difference between inter-class and intra-
class variability using the proposed RMMC approach. This is a similar objective to that 
of PCA-LDA. 167 However, the RMMC approach avoids the necessity to select an 
optimal number of PC components prior to applying LDA, which can result in model 
under-fitting or over-fitting. To demonstrate the practical advantage of RMMC over 
PLS-based discriminating feature extraction, I have derived components (the number 
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of classes minus one) for classification of distinct tissue types from two different tissue 
sections (Table 6.2). ‘Leave-region-out’ cross-validation with k-nearest neighbor 
classification has been employed. This procedure involves iteratively leaving one 
randomly designated pixel region out and performing supervised dimensionality 
reduction on the retained tissue-specific pixels. The left-out pixel regions are then 
projected onto the trained discriminating space and subsequently subjected to k-
nearest neighbor classification. Superior classification accuracy was achieved using 
RMMC-based derived components, indicating better separability of different tissue 
types (Table 6.2).  
 
Table 6.2 ‘Leave-region-out’ cross-validation with k-nearest neighbor classification using 
PLS and RMMC feature extraction methods. 
 
  
 
Correctly classified (%)  
Tissue class  
Members 
(n)  
Partial Least Squares 
(PLS)  
Recursive Maximum 
Margin Criterion 
(RMMC)  
3-nn  5-nn  3-nn  5-nn  
 
Cancer 61  96.7  100  100  100  
Sample A 
Healthy 
mucosa 
73  93.8  95.4  98.5  98.5  
 
Muscle 76  93.3  93.3  93.3  93.3  
Overall classification accuracy 
(%) 
 94.6  96.2  97.3  97.3  
 
Cancer  48  87.5  89.6  91.7  100  
Sample B  
Blood 
vessel 
38  97.4  94.7  97.4  97.4  
 
Muscle  52  100  100  100  100  
Overall classification accuracy 
(%)  
94.2  94.9  96.4  99.3  
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6.4.5  Application of a ‘one against all’ method for extraction of tissue-
specific discriminating patterns  
The purpose of the final step here was to assess the feasibility of developing tissue 
chemistry based methods for tissue annotation. It can be envisioned that transition 
from one cell type to another may not necessarily be associated with abrupt 
biochemical changes, for example in the case of infiltrating tumour. This change can be 
captured by continuous discriminatory scores based on weighted combinations of 
multivariate ion species from pixels corresponding to a particular tissue type compared 
to all others. This strategy is known as ‘one against all’ in pattern recognition.328 I have 
employed the RMMC approach to extract tissue-specific molecular ion patterns 
capable of discriminating histologically-defined pixels belonging to one particular tissue 
type from all others. Subsequently these patterns are used to derive a continuous 
score for every pixel in the tissue section. These scores can be visualised in a color-
coded manner with the color intensity proportional to the score of a given pixel. This is 
exemplified in Figure 6.5, which shows highly accurate chemical reconstruction of 
different morphological regions (smooth muscle (blue), blood vessels (green) and 
colorectal cancer (red)) based on continuous scores derived from multivariate 
molecular ion patterns obtained from representative pixels as described. 
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Figure 6.5 Chemical reconstruction of tissue regions of interest using multivariate 
molecular ion patterns: A Optical H&E stained image B Aligned DESI-MSI RGB image C 
Reconstruction of three distinct histological regions (smooth muscle, blood vessels and 
colorectal adenocarcinoma) based on molecular ion patterns extracted by ‘one against all’ 
RMMC methodology. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
The discriminatory scores are then used to generate a ‘probability’ of a given pixel 
belonging to a given tissue type by means of logistic regression 335. Where the 
probability of a pixel belonging to a particular tissue class approaches one (>0.95), this 
pixel can unambiguously be assigned to the tissue class in question. Pixel-wise tissue-
class assignment as a function of the number of training pixels used is illustrated in 
Figure 6.6. 
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being classified as either tissue type. Spectra corresponding to these ‘border’ pixels 
can be used to investigate the unique biochemical changes that are associated with 
tumour invasion. The development and validation of this approach was critical to 
addressing the objectives of the next chapter in this thesis, where I was particularly 
interested in determining differences between cancer and adjacent cancer niche. In 
order to perform such comparison, it is first essential to confirm that these regions do 
indeed harbour distinct molecular profiles.  
 
Discussion 
Imaging mass spectrometry (MSI) offers a means of chemically mapping the 
tumor microenvironment intact, avoiding the need for time-consuming and 
disruptive procedural steps such as laser-capture microdissection. The inherently 
multidimensional nature of MSI datasets challenges conventional data treatment 
methodologies and has meant that until now the full potential of this emerging 
technique has remained unfulfilled. The principle aim of this part of my work was 
to create a comprehensive analytical framework (Figure 6.7) to enable more 
effective MSI data analysis for exploration of tumour microenvironmental 
biochemistry. The presented workflow has been specifically designed to address 
outlined barriers to effective translational MSI and includes optimised data pre-
processing steps, precise image co-registration and efficient tissue-specific 
molecular ion feature extraction.  The methodology described here permits the 
visualisation of molecular signatures with direct correlation to morphological 
regions of interest, which can offer new insights into how different tumour 
microenvironmental populations interact with one another and generate novel 
region-of-interest specific biomarkers and therapeutic targets. For the following 
chapter of this thesis I have used the methodological workflow outlined in this 
section for histologically-targeted profiling of the CRC microenvironment. 
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7.1  Background 
Although significant progress has been made in the molecular pathogenesis of 
colorectal cancer (CRC) in recent years,1 there remains a pressing need to enhance 
this understanding further in order to extend patient survival and develop more 
sophisticated methods for CRC prevention and treatment. The critical role of the 
tumour microenvironment (TME) in promotion of cancer-cell growth, survival and 
invasive potential is increasingly acknowledged across a variety of cancer subtypes,336-
339 and the last decade has seen a shift towards this avenue of cancer profiling.  
The TME, also referred to as the ‘cancer niche’, is comprised of a variety of cell types 
including myofibroblasts and α-smooth muscle actin expressing cells340 (amongst 
others), as well as molecular modulators of cancer that include growth factors, 
signalling molecules, and matrix-metalloproteinase enzymes.341 The dynamic interplay 
that has been observed in vitro between CRC cells and the adjacent niche,342 
challenges conventional tumour-centric theories and calls for the development of 
diagnostic, prognostic and therapeutic models that recognise assembly of the cancer 
niche as an early and fundamental step in carcinogenesis. As such the cancer niche 
represents not only a novel means of interrogating CRC biology, but also an emergent 
target for anti-cancer drug development.336  
Cancer cells are self-protective and possess mechanisms that allow evasion of 
immune system detection343 in addition to the ability to undergo de novo mutation, 
which allows them to acquire drug resistance.344 The cancer niche – though an integral 
part of a cancer’s anatomy and physiology – is still ultimately native tissue, ‘loyal’ to the 
host and thus conceivably less likely to have assumed these evasive properties.114 In 
this regard, developing targeted agents directed selectively towards the cancer niche 
may offer new opportunities for chemoprevention and cancer therapy.  
Achieving these objectives will demand analytical approaches that are capable of 
comprehensively profiling and summarising the synergistic relationship between cancer 
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Currently employed MSI methodologies such as MALDI-MSI,162, 275, 276 DESI-MSI167, 279, 
349 and SIMS164, 280 are beginning to demonstrate early promise in cancer biomarker 
discovery167 and have the ability to provide topography-specific molecular information, 
offering a logical approach for assessing cancer niche biochemistry.  
The pivotal role of lipids and fatty acids in carcinogenesis is increasingly recognised, 
and MSI methods are particularly well suited to profiling these low molecular weight 
molecules.279, 294, 350 Recent cell-based work has implicated lipids as critical regulators 
of cancer not only structurally, for cell membrane synthesis and stabilisation, but also in 
cell-signalling and cross-talk between cancer cells and adjacent niche.351 In the latter 
role they have been implicated as potential modulators of chemotherapeutic treatment 
response in a number of recent studies.352, 353  
For this study I applied a DESI-MSI based approach combined with the novel 
bioinformatics methods described in Chapter 6 for histologically-targeted profiling of 
lipid signatures in healthy and cancerous colorectal tissue sections. Specifically I have 
sought to address two primary objectives:  
(1) To characterise differences between cancerous epithelium, cancer niche and 
healthy matched colorectal epithelium with respect to lipid biochemistry.  
(2) To correlate cancer niche lipid profiles with established CRC histopathological 
prognostic indicators in order to determine the association between 
microenvironmental lipid signatures and cancer phenotype.   
To date no previous studies have specifically employed MSI techniques for the purpose 
of cancer niche directed profiling. I have elected to employ the DESI-MSI approach,279 
as from my earlier experience I have found this to offer several practical advantages 
over the other MSI methods; specifically: (a) DESI operates at atmospheric pressure,279 
avoiding the need for vacuum conditions; (b) The technique is ‘histology-friendly’, 
meaning that tissue sections can be subjected to haematoxylin and eosin (H&E) 
staining post MSI analysis for precise correlation of features; (c) Unlike techniques 
such as MALDI, no matrix solution need be applied to the tissue surface prior to 
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ionisation; this solution can interfere with acquired spectral signal and complicate 
unambiguous chemical interpretation.286  
 
7.2  Materials and methods 
7.2.1  Tissue sample acquisition and preparation 
This study was granted full ethical approval by the institutional review board at Imperial 
College Healthcare NHS Trust (REC reference number 07/H0712/112). Between 
November 2011 and September 2012 tissue specimens and related clinico-
pathological data were collected with informed and written consent from 33 patients 
undergoing planned surgical resection for confirmed CRC at a single cancer referral 
centre (St Mary’s Hospital (London, UK). Fresh tissue samples were harvested from 
centre of tumour (n=33) from surgical resection specimens. Matched healthy mucosa 
was also obtained from the latter 20 surgical resection specimens (10cm from tumour 
margin, n=20). Tissue harvesting was performed in the pathology department by a 
single senior gastrointestinal pathologist (RDG) and acquired samples were 
immediately transferred to a freezer at -80ºC prior to processing. Tissue samples were 
cryo-sectioned to 12m thickness with an SME cryotome (Sigma-Aldrich, Gillingham, 
U.K.) using 3% carboxy-methyl cellulose as an embedding medium, before being thaw-
mounted onto plain glass slides.  
 
7.2.2  Mass spectral data acquisition and processing 
Tissue sections were subjected to negative ion DESI-MSI analysis using an Exactive 
mass spectrometer (Thermo Fisher Scientific Inc., Bremen, Germany) equipped with 
an in-house developed automated DESI ion source (Supplementary Figure 1). The 
mass resolution used for all measurements was set to 100,000 with a mass accuracy 
of <4ppm. Spatial resolution for imaging experiments was set to 75μm. Methanol/water 
(95:5 v/v) was used as the electrospray solvent at a flow-rate of 1.5L/min. Zero-grade 
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nitrogen was used as nebulising gas at a pressure of 4bars. The height distance 
between the DESI sprayer and the sample surface was set to 2mm with the distance 
between the sprayer and the inlet capillary set to 14mm. The distance between the 
sample surface and the inlet capillary of the mass spectrometer was <<1mm. The 
angle between the sprayer tip and the sample surface was set at 80. Though these 
parameters are all modifiable, the settings I have used here afford optimal analytical 
accuracy for low molecular weight profiling.  
Mass spectra were collected in the mass range of m/z = 200-1,000. Following DESI-
MSI analysis, the tissue sections were H&E stained and digitally scanned at high 
resolution using a NanoZoomer 2.0-HT digital slide scanner (Hamamatsu Corp., 
Japan) to permit precise co-registration of biochemical signatures and tissue 
architecture. Raw spectral data were pre-processed using a novel bioinformatics 
workflow as described in Chapter 6. In summary this involved elimination of 
noise/solvent related spectral features followed by data normalisation using a log-
based variance stabilising transformation. A comprehensive description of these steps 
is provided in Chapter 6. 
         
7.2.3  Co-registration of MSI and H&E stained images for histology-
driven data mining 
I have implemented a comprehensive data processing algorithm for visualisation and 
interpretation of biochemical data for histology-directed chemical profiling, as outlined 
in Chapter 6. The fundamental requirement here is precise co-registration of features 
from MSI and optical (H&E stained) images. The methodology used here utilises an in-
house developed image alignment algorithm that subjects the optical image to a series 
of mathematically-determined adjustments, in order to create a precise pixel-to-pixel 
match for the two images (Chapter 6, Figure 6.2A).  
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In summary, this image alignment method comprises the following steps: (1) the optical 
image pixel resolution is reduced to match that of the corresponding MSI image; (2) 
tissue outline is delineated on both images using an object recognition algorithm we 
have previously described; (3) optimal transformation parameters (scaling, rotation and 
translation) for the optical image are determined by maximising the matching of object 
pixels between optical and MSI images (4) the derived transformation is applied in full 
resolution to generate a ‘warped’ optical image for precise feature co-registration. 
Once the images are co-aligned and matched with respect to shape, size and 
orientation the data visualisation toolbox I have developed with Dr Kirill Veselkov 
(Imperial College London) permits the user to select regions of interest (with zoom 
functionality) on the H&E stained image with automatic co-selection of corresponding 
chemical co-ordinates on the MSI image (Figure 6.2B). Chemical spectra unique to 
these regions can then be evaluated selectively (Figure 6.2C).      
 
7.2.4  Profiling cancer, cancer niche and healthy colorectal tissue using 
DESI-MSI 
Using the above methodology, regions of cancerous epithelium and cancer-adjacent 
‘niche’ were selected from co-aligned images obtained from 33 cancer tissue sections 
that were subjected to DESI-MSI profiling followed by H&E staining. Cancer niche was 
defined histologically as non-cancerous desmoplastic tissue directly adjacent to 
tumour-bearing regions. Morphology-specific region selection was performed under the 
supervision of a senior gastrointestinal pathologist (RDG). The spectral lipid 
composition of these regions was determined for each slide, and for each tissue 
section one chemical profile denoted ‘cancer niche’ and one denoted ‘cancer’ were 
exported into a histologically-verified chemical database to allow group-wise region-
specific chemical comparison. An overall chemical profile summarising lipid 
composition for each region profiled was generated using ~20 DESI-MSI pixels. I have 
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using a custom-developed bioinformatics toolbox. For univariate analysis a non-
parametric Kruskal-Wallis ANOVA-type analysis was employed in order to determine 
the relevance of a given molecular ion species with regards to observed class 
discrimination. All molecular ion species for which a P-value <0.05 was acquired were 
assumed to confer class-discriminatory power. These features were collectively 
entered into multivariate models in order to discover their cumulative capacity to drive 
class separation. For this purpose, I have chosen the recursive maximum margin 
criterion (RMMC) approach described in Chapter 6 in preference over other commonly 
employed discriminatory analysis methods such as partial least squares (PLS) and 
linear discriminant analysis (LDA). Multivariate model performance has been 
summarised according to the area under the curve (AUC) metric obtained from receiver 
operating characteristic (ROC) curve analysis.         
 
7.4  Results 
7.4.1  Patient demographics and tumour characteristics 
The 33 study participants included 23 males (69%) and 10 females (31%), with a 
median age of 71 years (range, 58–85). All participants had a definitive histological 
diagnosis of colorectal adenocarcinoma prior to surgery. Participants were 
consecutively enrolled to the study where possible to minimise selection bias. During 
the study time frame, a total of 45 potentially eligible consecutive patients were 
identified. Reasons for study omission for 12 of these patients were as follows: (1) 
enrolment to FOxTROT study, precluding opening of surgical specimen (n=3); (2) 
patient decision not to take part in study (n=4); (3) no pathologist available outside of 
standard working hours to evaluate and sample resection specimen (n=3); and (4) 
inability to sample rectal cancer resection specimen due to potential for compromising 
circumferential resection margin assessment (n=2). Tumours were located in the 
transverse colon (n = 3; 9%), left colon (splenic flexure, descending colon, sigmoid 
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colon; n=5; 15%), right colon (caecum, ascending colon, hepatic flexure; n = 11; 33%) 
and rectum (rectosigmoid, rectum; n = 14; 43%) in order of increasing prevalence. A 
summary of clinical and histopathological characteristics is provided in Table 7.1. 
 
Table 7.1 Clinical and histopathological characteristics of study cohort 
Demographic/tumour 
characteristics 
N % 
Gender 
Male 23 69 
Female 10 31 
Age   
<60 2 6 
>60 31 94 
BMI   
<30 27 81 
>30 6 19 
T-stage   
T1/2 7 21 
T3 14 42 
T4 12 37 
N-stage   
N0 17 51 
N1/2 16 49 
EMVI   
Positive 13 39 
Negative 20 61 
PNI   
Positive 5 15 
Negative 28 85 
LVI   
Positive 8 24 
Negative 25 76 
Differentiation   
Well 3 9 
Moderate 25 76 
Poor 5 15 
Mucinous   
Yes 8 24 
No 25 76 
NA therapy   
LCCR 2 6 
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7.4.2  Determining biochemical differences between cancerous 
epithelium, cancer niche and healthy colorectal epithelium using 
DESI-MSI 
In order to determine biochemical differences between cancerous epithelium, cancer 
niche and healthy epithelium I evaluated a total of 86 DESI-MSI spectral profiles 
acquired from areas of cancer (n=33), cancer niche (n=33) and morphologically healthy 
epithelium (n=20). Pre-processed spectra were imported into MATLAB for univariate 
and multivariate analysis and a recursive maximum margin criterion (RMMC) approach 
was used to demonstrate separation of data points according to tissue class-specific 
molecular ion composition. The scores plot for this discriminant analysis is shown in 
Figure 7.3A and demonstrates clustering of data points according to tissue morphology 
(cancerous epithelium in red, cancer niche in blue, healthy epithelium in green). 
Overlapped spectral profiles for these three groups are shown in Figure 7.3B with 
visible differences in spectral peak intensities according to tissue type. The key 
metabolic species responsible for discrimination between the three groups are 
summarised in Table 7.2 and Figure 7.4 where an analysis of variance (ANOVA) based 
approach has been used to determine the relative significance of each molecular 
species with respect to class separation (reported as P-values in the table). Proposed 
chemical assignments have been determined based on cross-referencing of identified 
m/z values with METLIN (http://metlin.scripps.edu/index.php) and LIPID MAPS 
(http://www.lipidmaps.org/) spectral databases as well as an in-house spectral lipid 
SCR 1 3 
None 30 91 
Tumour location   
Right colon 11 33 
Left colon 5 15 
Transverse colon 3 9 
Rectum 14 43 
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repository. The ability of the discriminant model to correctly distinguish between 
cancer, cancer niche and healthy epithelium is summarised by the following AUC 
values: cancer versus healthy (AUC=1.0); cancer versus cancer niche (AUC=0.92); 
cancer niche versus healthy (AUC=0.99). The corresponding ROC curves for this 
model are provided in Figure 7.5.       
  
Figure 7.3 A RMMC scores plot revealing clustering of region-specific spectral profiles 
derived by DESI-MSI according to morphology (cancerous epithelium, red; cancer niche, 
blue; healthy epithelium, green) B Annotated overlapped representative DESI-MSI 
spectra from these regions 
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Table 7.2 Chemical species responsible for discrimination between tissue classes 
(cancer, cancer niche, healthy) with observed trends in relative region-specific abundance 
and postulated chemical assignments.   
 
 
 
 
 
 
 
 
 
 
 
Identified 
m/z 
Exact 
theoretical 
m/z † 
Postulated chemical sub-class 
Observed 
abundance 
trend 
P-value 
283.25 283.2643 Stearic acid 
C18H35O2 
nCa > Ca >> H P < 0.001 
295.27 295.2643 Nonadecenoic acid 
C19H35O2 
nCa > Ca >> H P < 0.001 
307.27 307.2643 Eicosadienoic acid 
C20H35O2 
Ca > nCa > H P < 0.001 
309.28 309.2799 Eicosanoic acid 
C20H37O2 
Ca > nCa > H P < 0.001 
335.30 335.2956 Docosynoic acid 
C22H39O2 
nCa > Ca > H P < 0.001 
393.38 393.3738 Ximenic acid 
C26H49O2 
Ca > nCa > H P < 0.001 
716.53 716.5236 Phosphocholine 
C39H75NO8P 
Ca > H > nCa P < 0.001 
768.56 768.5549 Phosphocholine 
C43H79NO8P 
H > Ca > nCa P < 0.001 
807.51 807.5029 Phosphatidyl-inositol 
C41H76O13P 
Ca > H > nCa P < 0.001 
818.56 818.5705 Phosphatidyl-etholamine 
C47H81NO8P 
H > Ca/nCa P < 0.001 
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possible overall model predictive capacity has been summarised using ROC curve 
analysis. This information is summarised in Table 7.3.  
          
Table 7.3 Chemical differences in cancer niche DESI-MSI derived profiles according to 
histopathological parameters. The contribution of individual chemical species to class 
discrimination is summarised with P-values and overall model robustness is summarised with 
AUC values.   
 
Identified 
m/z 
Exact 
Theoretical 
m/z † 
Postulated chemical sub-
class 
Observed 
trend P-value Model AUC 
EMVI AUC=0.84 
305.25 305.2486 Linoleic acid 
C20H33O2 
 in EMVI +ve P = 0.024 
 
333.28 333.2799 Eicosatrienoic acid 
C22H37O2 
 in EMVI +ve P = 0.021 
 
701.52 701.5239 Phospho-ethanolamine 
C38H74NO7P 
 in EMVI +ve P = 0.031 
 
744.57 744.5549 Phosphocholine 
C41H79NO8P 
 in EMVI +ve P = 0.013 
 
LVI AUC=0.71 
700.54 700.5287 Phospho-etholamine 
C39H75NO7P 
 in LVI +ve P = 0.023 
 
728.57 728.5600 Phosphocholine 
C41H79NO7P 
 in LVI +ve P = 0.017 
 
861.56 861.5499 Phosphatidyl-inositol 
C45H82O13P 
 in LVI +ve P = 0.033 
 
PNI AUC=0.60 
365.35 365.3425 Nervonic acid 
C24H45O2 
 in PNI +ve P = 0.018 
 
393.38 393.3738 Ximenic acid 
C26H49O2 
 in PNI +ve P = 0.029 
 
599.32 599.3202 Phosphatidyl-inositol 
C27H52O12P 
 in PNI +ve P = 0.030 
 
862.57 862.5604 Phosphoserine 
C48H81NO10P 
 in PNI +ve P = 0.021 
 
LN status AUC=0.80 
439.4 439.4157 Octacosanoic acid 
C28H55O3 
 in LN +ve P = 0.0018 
 
816.53 816.5549 Phosphocholine 
C47H79NO8P  
 in LN +ve P = 0.023 
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856.52 856.5134 Phosphoserine 
C48H75NO10P 
 in LN +ve P = 0.0050 
 
T stage     AUC=0.72†, 0.79‡, 0.91δ 
236.11 - - T4 > T3 > T1/2 P = 0.037  
775.55 775.5495 Phosphoserine 
C42H80O10P 
T3 > T1/2 > T4 P = 0.015 
 
788.54 788.5447 Phosphoserine 
C42H79NO10P 
T1/2 > T3 > T4 P = 0.013 
 
AUC area under the curve; † T3 versus T4; ‡ T1/2 versus T3; δ T1/2 versus T4 
 
7.5  Discussion 
Colorectal cancer (CRC) is the 3rd most common cause of cancer-related mortality 
worldwide with an estimated 1 million new cases diagnosed annually.1 Despite 
refinements in operative technique and the widespread adoption of combined-modality 
therapy (CMT), age adjusted 5-year survival remains below 60% in most developed 
nations.234 Improving on this figure will require a more comprehensive understanding of 
CRC biology, and over the past few decades, significant breakthroughs have been 
made in this regard, revealing a catalogue of genetic and proteomic alterations that are 
now recognised as hallmark molecular signatures in CRC.1, 32, 33 Relatively more 
recently the pivotal role of the cancer microenvironment, or ‘niche’, in establishment, 
progression and metastasis of cancer has been established across a variety of tumour 
subtypes.354-356 Multiple different cell types populate this cancer-neighbouring tissue, 
including stromal fibroblasts, myofibroblasts, endothelial cells and immune cells, in 
addition to a host of signalling molecules, growth factors and proteases.357 Studies 
employing techniques such as immunohistochemistry  (IHC)114 and fluorescence in-situ 
hybridisation (FISH)358 have revealed synergistic genomic and proteomic interaction 
between cancer and neighbouring niche; for example a recent study of breast cancer 
identified differential expression of a series of genes in cancer-adjacent stroma relative 
to cancer and implicated these as important drivers of extra-cellular matrix remodelling 
that accompanies the transition from in-situ (DCIS) to invasive ductal carcinoma 
(IDC).359  Downstream of the genome and proteome the role of low-molecular weight 
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biomolecules (metabolites/fatty acids/lipids) in CRC is increasingly acknowledged.147, 
195, 244 Work using established CRC cell-lines has shown for example that cancer cells 
impose conditions of oxidative stress on neighbouring cells creating adjacent zones of 
cellular catabolism, mitochondrial dysfunction and aerobic glycolysis for the purposes 
of enhancing tumour cell survival.301 Mass spectrometry (MS) based analytical 
techniques offer a powerful means of measuring these metabolic fluxes but require 
tissue sample homogenisation rendering them unsuitable for region-specific profiling 
without being combined with laser capture micro-dissection of the region of interest. 
This fundamentally disrupts the cancer/cancer niche interface and makes accurate 
assessment of the interactivity between these compartments inherently more 
challenging.    
The recent emergence of imaging mass spectrometry (MSI) analytical platforms 
provides the opportunity to perform in-situ interrogation of the metabolic interplay that 
exists between cancer and cancer niche. These techniques represent an extension of 
conventional MS-based methods that combine high chemical sensitivity with spatial 
information – allowing simultaneous identification and topographical localisation of a 
variety of low molecular weight compounds from intact tissue sections (Figure 7.1). 
These approaches are particularly well suited to the profiling of lipid-based compounds, 
and this class of biomolecules have recently been implicated as key players in 
molecular carcinogenesis.360-363 Lipids comprise a group of diverse molecules with 
different structures and functionalities that serve essential roles in a variety of cellular 
processes including cell membrane synthesis, metabolic regulation and immunity.313, 314 
Altered cellular phospholipid composition has recently been observed in several cancer 
studies 315, 316 and in addition, target tissue lipid composition has been shown to be of 
potentially prognostic significance in determining likely response to chemotherapy.317 
Taken together, these observations suggest that comprehensive mapping of the CRC 
‘lipidome’ has the potential to deliver novel biomarkers for prognosis and treatment.   
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Like glucose metabolism, lipid activity in cancer cells is thought to regulate, and be 
regulated by, common oncogenic signalling pathways such as the Wnt/β-catenin 
pathway.364 To date the majority of research into lipid metabolism and cancer has 
focused on lipogenesis, with de novo enhancement of fatty acid synthesis, secondary 
to overexpression of fatty acid synthase (FASN), observed in a variety of cancers.365, 366 
Despite these developments the overall role of lipids in cancer remains only partially 
understood and the recent acknowledgement that lipolytic remodelling367 as well as 
lipogenesis is involved in tumour potentiation, has further clouded the issue. From this 
latter observation three further points arise: (1) simple linear descriptions (e.g. 
increased/decreased activity) cannot adequately sum up the complex lipidomic 
interactions that occur in cancer (2) simultaneous biosynthetic and mobilising activities 
observed in cancer with respect to lipids may point towards as yet unidentified 
reciprocal interactions between cancer and cancer niche (3) analytical strategies are 
required that can provide a detailed and quantitative overview of lipid biochemistry in 
cancer tissue.  
Building on the work outlined above and following my own MALDI-based evaluation of 
CRC summarised in Chapter 5, I sought in this study to profile lipid signatures in CRC 
and adjacent CRC niche using desorption electrospray ionisation (DESI) MSI. This 
technique is a highly practical MSI method as it requires no matrix deposition and 
operates at ambient atmospheric pressure, avoiding tissue desiccation (leaving a more 
‘histology-friendly’ post-analysis tissue section). Conventional methods for lipid 
detection and localisation such as staining with Nile Red, Oil Red O or osmium 
tetroxide can be applied to frozen sections,293 and while these can reveal the 
distribution of a limited number of lipid fractions, they lack the ability to generate a 
global lipid profile, as can be achieved with DESI-MSI.  
The first key finding of this study is that significant differences exist in lipid biochemistry 
within CRC bearing tissue regions compared to the CRC niche. These modifications do 
not necessarily conform to linear modelling as evidenced by the box plots in Figure 7.4. 
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For example, I observed significantly increased levels of stearic acid (m/z 283.25), a 
polyunsaturated fatty acid (PUFA), within the cancer niche relative to cancer. This 
PUFA has previously been shown to enhance cancer cell growth in vitro368 and my 
findings support the suggestion that the cancer microenvironment serves as a tumour-
friendly backdrop within which cancer cell growth is encouraged through de novo FA 
synthesis. However, an interesting observation in this study that challenges this notion 
was the finding of increased levels of nonadecenoic acid (m/z 295.27) in the cancer 
niche relative to cancer. Rather than assisting tumour development, this long-chain 
fatty acid has recently been shown to exert an inhibitory effect on the growth of various 
cancer cell lines.369 This raises questions regarding the true ‘fidelity’ of cancer-adjacent 
tissue. While on the one hand the CRC niche appears to be re-programmed to deliver 
cancer-friendly fatty acid species, it simultaneously seems to undergo re-modelling that 
produces biomolecules with the opposite effect. The balance between these ‘friendly’ 
and ‘hostile’ activities in the cancer niche may ultimately determine a cancer’s 
propensity for local survival and distant dissemination.      
With respect to cancerous cellular regions I noted significantly elevated levels of 
eicosanoic acid (m/z 309.28) and eicosadienoic acid (m/z 307.27), amongst other 
molecules, in cancer tissue relative to cancer niche and healthy epithelium, and these 
molecules have previously been implicated in malignancy.370 Eicosanoic acid, also 
known as arachid acid is formed by the hydrogenation of arachiodonic acid, and high 
levels of the latter in colonic epithelium have been shown to lead to epithelial cell injury 
followed by a compensatory increase in proliferative activity.370 My findings support 
these previous observations and again highlight the potential for disruption of these 
molecular events in designing novel approaches for CRC prevention and therapy.        
The other key finding in this study, which has not been reported before to my 
knowledge, was the identification of specific lipidomic features within the cancer niche 
that appear to correlate with cancer aggressiveness/pathological phenotype. These 
features principally comprised intact oxidised products of glycerophospholipids 
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including glycerophosphatidylcholines (GPCs), glycerophosphatidylethanolamines 
(GPEs), glycerophosphatidylserines (GPSs) and glycerophospatidylinositols (GPIs). 
GPIs have previously been shown to mediate cancer cell survival and play an 
important role in cell-migratory signalling;371, 372 GPEs, GPCs and GPSs have similarly 
been implicated in cancer biology, although their exact roles remain uncertain.373   
Global cancer microenvironmental signatures made up of the combinations of these 
molecular ion species were found to be capable of robustly distinguishing samples 
according to EMVI status (positive versus negative; AUC = 0.84), lymph node status 
(N0 versus N1/2; AUC = 0.80) and T-stage (T1/2 versus T3 versus T4; AUC = 0.72-
0.91). Robust determination of model discriminatory power for peri-neural invasion 
(PNI) was statistically unreliable owing to the significant disparity in group size (28 PNI 
–ve versus 5 PNI +ve), and this perhaps explains why despite the identification of 
several discriminating molecules on univariate analysis, the AUC derived for this model 
was only 0.60. Overall however, my findings indicate that modifications to the lipid 
content and makeup of the CRC niche may be necessary for cancers to assume a 
more hostile pathological phenotype. Further investigation of these observed 
phenomena is required, but the approach presented here offers new perspectives into 
CRC microenvironmental metabolism and may generate a new pool of biochemical 
data from which to design next-generation CRC therapies.     
 
7.6  Summary 
In conclusion this study represents the first report describing the use of imaging mass 
spectrometry (MSI) for CRC niche directed profiling. I opted to employ a DESI 
approach here for MSI profiling and this appears to be more practical compared with 
MALDI where the aim is to perform precise histologically-targeted analysis. My results 
reveal significant differences in fatty acid and phospholipid metabolism within 
cancerous regions relative to the cancer microenvironment indicating that distinct 
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metabolic re-modelling occurs in these zones. A combination of pro- and anti-cancer 
fatty acid modifications were observed in the CRC niche using DESI-MSI and this 
finding offers additional biologically relevant insights into the role of the cancer 
microenvironment.  Furthermore, alterations in cancer niche lipid composition were 
found to correlate with the presence or absence of established negative prognostic 
indicators in CRC including EMVI, LN status and advanced T-stage. I demonstrated in 
Chapter 4 of this thesis that cancer tissue samples reveal different metabolic 
signatures as they develop using HR-MAS NMR spectroscopy,195, 374 but here for the 
first time I have shown that subtle changes specifically within the CRC niche also 
accompany this tumour progression. Targeting these processes may offer the potential 
to develop new drugs designed to redirect the CRC niche towards an anti-cancer 
metabolic phenotype.  
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8.1  The rationale for this research 
The background to this work ultimately dates back to early observations made by 
Otto Warburg in the 1920’s that cancer cells harbour distinct metabolic tendencies 
relative to healthy counterparts, preferentially employing glycolytic pathways for ATP 
generation, even in the presence of abundant oxygen supply (aerobic glycolysis).168 
Over the past decade rapid advances in bio-analytical technologies have spawned a 
versatile array of metabolic phenotyping platforms that can be applied to the analysis 
of biological samples (tissue/urine/plasma etc.) to provide a more comprehensive 
overview of cancer metabolism.101 Concurrently, these technological strives have 
given rise to the field of ‘metabonomics’, a relatively new discipline in ‘personalised’ 
systems biology375 that seeks to quantitatively characterise metabolic adaptations 
occurring within a living system in response to drugs, environmental stimuli or 
disease.140 The term ‘metabonomics’ was first coined by Professor Jeremy Nicholson 
(Computational and Systems Medicine, Imperial College London) who has co-
supervised the work presented in this thesis.140, 189 More recently the term ‘metabolic 
phenotyping’ was introduced in this context, to better encapsulate the principle of 
metabolic classification in health and disease.189    
Over the course of my doctoral research programme I have had the opportunity to 
work in collaboration with a group of translational scientists and chemometricians 
headed by Professor Nicholson. This has allowed me to develop expertise in the 
experimental application of state-of-the-art NMR- and MS- based profiling 
technologies, with the overall objective of applying a variety of these approaches to 
the study of colorectal cancer (CRC) tissue in order to determine their translational 
utility. Considering the CRC clinical pathway as a series of steps (beginning with 
biopsy confirmation of cancer and culminating in surgical resection) (with or without 
postoperative adjuvant therapy)) my aim was to investigate the potential of NMR and 
MS approaches at different phases of this clinical continuum. The technologies under 
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investigation, naturally lend themselves well to particular points along this spectrum; 
HR-MAS NMR spectroscopy requires only a very small piece of tissue (~10mg 
typically) for spectroscopic profiling and so is very well suited to the analysis of 
endoscopic biopsy samples. By comparison, MSI techniques require a relatively 
larger volume of tissue, and so this method would likely be best suited to the 
prognostic end of the care pathway, with sampling and analysis of tissue acquired 
from CRC surgical resection specimens. 
 
8.2  Summary of findings and translational implications 
8.2.1  HR-MAS NMR spectroscopy 
The objectives of the first experimental section of this thesis (Chapter 4: Diagnosis 
and staging of colorectal cancer via HR-MAS NMR spectroscopy) were to (1) 
characterise the metabolic signatures associated with CRC and use these to develop 
a rapid method for tissue diagnosis, (2) to determine metabolic differences between 
colon cancer tissue and rectal cancer tissue and (3) to identify metabolic patterns in 
tissue that correlate with tumour stage. My analysis of tissue samples acquired from 
44 patients with confirmed CRC demonstrates that HR-MAS NMR spectroscopic 
profiling can rapidly and accurately distinguish cancerous from healthy tissue, and 
that this distinction, in chemical terms, is driven by differences in lipids/triglycerides 
and glucose concentration (found at lower levels in cancerous relative to healthy 
tissue) and taurine, lactate, iso-glutamine, glycine and scyllo-inositol (found at higher 
levels in cancerous relative to healthy tissue).  
In this study the average time taken from sample preparation to final analytical result 
was approximately 20 minutes. This is comparable to, though perhaps a little slower 
than, average times required for frozen-section tissue analysis (which typically range 
from 10-20 minutes).268-270 However, it is expected that HR-MAS analytical times will 
undergo marked reduction in the near future with the arrival of more powerful 
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spectrometers. The spectrometer I used for my experiments operates at a field-
strength of 400MHz. Our group are currently in the process of acquiring several 
higher field platforms for clinical-setting deployment (operating at 600MHz and 
800MHz). With these more powerful field-strengths analytical time will experience 
significant reduction; for example a 600MHz NMR platform will be at least twice as 
sensitive as the one used for the work presented here and an 800MHz magnet is 
twice as sensitive again (i.e. four times more sensitive than the 400MHz 
spectrometer used in this research). This increase in sensitivity translates to faster 
analytical time, such that an 800MHz machine will require only a quarter of the 
scanning time with a projected analysis time of just 5 minutes per sample compared 
to the current 20 minutes. This certainly offers potential for ultra-fast (‘near real-
time’), reliable tissue diagnostics and can supplement and even replace frozen-
section methods in the future, although this will require large-scale validatory 
assessment.  
In terms of the impact such approaches could have in the CRC pathway specifically, I 
foresee two main areas of application: (1) more rapid confirmation of lesion identity 
during endoscopic biopsy and (2) Intra-operative tissue profiling in challenging 
clinical circumstances. For application (2), while it is uncommon to require frozen-
section or intra-operative tissue identification in ‘routine’ CRC resective surgery, 
cases of locally advanced or recurrent CRC, especially following pre-operative 
chemoradiotherapy present unique challenges, as these cases are often associated 
with a significant fibrosis response and/or mucinous change resulting in poor 
delineation of tissue planes. Under these circumstances, an NMR spectrometer 
deployed in the operating theatre capable of delivering tissue specific molecular 
information in minutes would be valuable.                
My HR-MAS NMR experiments also revealed interesting biochemical differences 
between colonic and rectal cancers at the tissue level and these may help to improve 
our understanding of the molecular differences that exist between these tumour 
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subtypes, complementing a growing body of genomic and proteomic research in this 
area.255, 376, 377 Furthermore, perhaps the most intriguing finding from this section of 
my research was that of distinct metabolic signatures exhibited by CRCs as they 
locally advance. This has potential to supplement current radiology-centric local 
staging strategies at the pre-operative stage and may also lead to the identification of 
a novel pool of cancer down-staging targets.      
   
8.2.2  Chemical mapping of CRC tissue using MALDI-MSI  
In the second experimental section of my research (Chapter 5: Chemical mapping of 
colorectal cancer tissue sections via MALDI-MSI) I employed a MALDI-MSI approach 
to profile sections of cancerous tissue, cancer-neighbouring tissue and healthy 
cancer-remote epithelium. This strategy demonstrated the potential of MSI 
approaches for correctly identifying tissue sections as cancerous or non-cancerous 
using a supervised multivariate analytical approach in a small set of samples. It 
would be unwise and unsubstantiated to extrapolate from these findings, the 
suggestion that these approaches could replace histology, as has been postulated by 
other groups.302 The technique does however represent a promising method to 
supplement conventional tissue evaluation approaches. For example, comparative 
MALDI-MSI analysis of tumour-adjacent tissue and tumour-remote tissue revealed 
interesting cancer-associated molecular signatures within the cancer locale, which I 
have preliminary termed ‘cancer-adjacent metaboplasia’ (CAM). This latter 
observation requires further validation with a larger sample set but is broadly in 
keeping with the established concept of field cancerisation, popularised by 
Slaughter303 and Orr304 in the 1950s. A significant limitation with the MALDI technique 
in my experience is that while it is both powerful and chemically sensitive, it is not 
histology-friendly, meaning that the same tissue section cannot be chemically profiled 
and H&E stained, owing to disruption to the tissue surface caused by vacuum-
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The DESI approach is superior to MALDI in this regard as the ability to use the same 
tissue section (rather than a directly adjacent one) for both MSI and histology means 
that the two generated images can be precisely co-aligned for chemical fingerprinting 
of a given ROI. I then went on to apply this algorithm in Chapter 7 of the thesis, 
where I was particularly interested in profiling molecular activity within the cancer 
microenvironment/niche, relative to cancer.     
 
8.2.4  Profiling the CRC microenvironment using DESI-MSI 
For my final experimental section of this thesis (Chapter 7: DESI-MSI based analysis 
of the colorectal cancer microenvironment: profiling cancer ‘niche’ metabolism) I 
sought to combine the advanced bioinformatics pipeline described in the preceding 
Chapter with DESI-MSI profiling of CRC tissue sections. The important role of the 
cancer niche has been established across a variety of cancer subtypes, and 
complex, synergistic interaction is thought to occur between cancer and its 
immediate vicinity. Imaging mass spectrometry approaches represent a logical 
choice in terms of defining these relationships from a molecular perspective as they 
provide topographically localised information and thus allow the interplay between 
one tissue zone and another to be quantitatively characterised.  
I observed significant differences between cancer epithelium, cancer niche and 
healthy colorectal epithelium with respect lipid and fatty acid metabolism and 
moreover fatty acid signatures within the CRC niche were shown to correlate with 
pathological markers of cancer aggressiveness. This implies that in more 
pathologically aggressive cases of CRC the cancer niche undergoes modifications in 
metabolism that may be necessary for these traits to be assumed (for example 
lymphatic dissemination or extra-mural venous invasion). Though this requires more 
detailed investigation, my work in this area represents the first study where an MSI 
approach has been employed for cancer niche directed profiling. My results highlight 
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the novel potential of this strategy to develop next-generation targeted 
pharmacotherapies directed towards the cancer microenvironment.  
 
8.3 Promising areas for future work 
The work undertaken for this doctoral thesis has uncovered a series of NMR- and 
MS-derived metabolic signatures in CRC that have significant translational potential 
and can improve our understanding of the fundamental biological processes that 
drive CRC development and progression. This research only scratches the surface in 
terms of the potential of metabolic phenotyping techniques in systems oncology, and 
listed below are some additional areas of promising research in this field for the 
future:  
 Analysis of plasma/serum and urine samples at the pre-operative phase of 
the CRC clinical pathway to supplement tissue based information. In addition, 
the ease with which these samples can be collected and the rich molecular 
information that can be obtained through their analysis presents the 
opportunity for serial/longitudinal sample collection during patient surveillance 
to identify novel early systemic metabolic markers to predict likelihood of 
disease relapse/recurrence.  
 Fusion of metabolic data with imaging and histological information acquired 
via different profiling approaches may well generate more precise disease 
classification models (Figure 8.2). Currently these fusion approaches 
represent a major biomedical research priority and further work in this area 
will be critical to developing more sophisticated patient stratification 
approaches.  
 Tissue diagnostics would benefit from combined analytical approaches to 
provide topographically localised morphological, metabolic, genomic and 
proteomic information, ideally from the same tissue section. In this way a 
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REMARK checklist 
 
HR-MAS NMR high resolution magic angle spinning nuclear magnetic resonance † Pathological determination of T-stage according to the fifth edition of the 
UICC Tumour-Node-Metastasis (TNM) classification system CRC colorectal cancer CRM circumferential resection margin PCA principal component analysis 
PLS-DA partial least squares discriminant analysis GPC glycerophosphoryl-choline NA neo-adjuvant 
 
INTRODUCTION 
Marker(s) examined  HR-MAS NMR spectroscopy derived metabolic biopanels from intact tissue samples have been used to identify differences at metabolic level between (i) cancerous and healthy colorectal mucosa 
(ii) colon and rectal cancer mucosa and (iii) tumours of different T-stage†  
Hypotheses (i) HR-MAS NMR metabolic profiles can reliably distinguish between cancerous and healthy colorectal mucosa  
(ii) There are local tissue metabolic differences between colon and rectal tumour tissue  
(iii) Tumours of differing T-stage will exhibit different local metabolic phenotypes  
Study objectives To develop sensitive and specific HR-MAS NMR metabolic profiling strategies for discriminating: (i) cancerous from healthy colorectal mucosa (ii) colon and rectal tumour tissue and (iii) tumours of 
differing T-stage  
MATERIALS AND METHODS 
Patient recruitment After exclusion of 20 patients (reasons outlined below) 44 consecutively recruited adult patients (>18 years) undergoing elective resection for biopsy confirmed CRC at a single centre (St Mary’s 
Hospital, London, UK) were included in the study. Reasons for study exclusion: (i) Enrolled to FOxTROT study (n=7) (ii) Declined participation (n=4) (iii) Lack of pathology personnel for evaluation 
and sampling of specimen (n=4) (iv) Inability to sample rectal cancer specimen due to potential compromising of CRM assessment status (n=5)  
Specimen characteristics Fresh samples of colorectal mucosa retrieved from (i) centre of tumour and (ii) 5cm from tumour margin from all surgical resection specimens.   
Assay methods HR-MAS NMR experiments performed using a Bruker Avance III 400MHz spectrometer equipped with robotic auto-sampler. Spin rate set to 4500Hz. 
Study design Prospective observational study 
Employed statistical 
methods 
Unsupervised (PCA) and supervised (PLS-DA) multivariate analysis of data using SIMCA and MATLAB statistical software. For PCA 3x3 bi-cross validation was used. For PLS-DA we performed 7-fold 
cross-validation and diagnostic model accuracy was assessed using Q2 statistic (measure of model predictive capacity) and ROC curve analysis on cross-validated (predicted) discriminatory scores.  
Discriminatory metabolic 
biopanel determination 
The discriminatory scores for separating samples according to pre-defined hypotheses were derived as a weighted sum of all measured metabolic features. However, the majority of metabolic 
features have negligible contribution to the model (zero weight) and therefore we have reported only those exhibiting the highest influence (i.e. weight) on the model.  
RESULTS 
Model specific metabolic 
biopanel composition 
(i) Cancerous versus healthy colorectal mucosa (cancer relative to healthy):   lactate  isoglutamine  GPC  taurine  scyllo-inositol  glycine;   lipids/triglycerides   α-glucose  β-glucose  
(ii) Colon versus rectal cancer (colon relative to rectum):  acetate arginine;  lactate   
(iii) T1/2 versus T3 (T1/2 relative to T3):  GPC;  lipids/triglycerides  acetate          T3 versus T4 (T3 relative to T4)  succinate  acetate  lipids/triglycerides 
Biostatistical analysis (i) Cancerous versus healthy colorectal mucosa:  R2Y=0.94; Q2Y=0.72; 7-fold cross-validated ROC curve analysis on discriminatory scores AUC=0.98 
(ii) Colon versus rectal cancer:  R2Y=0.94; Q2Y=0.33; 7-fold cross-validated ROC curve analysis on discriminatory scores AUC=0.86 
(iii) T-stage: 7-fold cross-validated classification accuracy of metabolite-based model to correctly identify tumours as T1/2=91%, T3=90% and T4=75%  
DISCUSSION 
Interpretation of results (i) HR-MAS NMR profiling reveals distinct cancer-associated metabolic features with dysregulated glycolytic mechanisms, lipidomic activity and protein turnover 
(ii) Colon and rectal cancer tissue harbour different metabolic signatures 
(iii) CRC microenvironmental metabolism undergoes modification during local tumour advancement  
Clinical application (i) Building enhanced appreciation of colorectal cancer metabolism for identification of novel anti-cancer drug targets 
(ii) Improving current understanding of molecular heterogeneity between tumours of the colon and rectum which can help to explain observed phenotypic differences 
(iii) Stage specific metabolic profiles to supplement conventional local staging strategies and design novel therapies based on stage-specific disruption of tumour metabolism 
Future research (i) Large-scale validation of findings presented in the current study 
(ii) Identification of tissue metabolic characteristics associated with response to NA therapy 
(iii) Prospective comparison of predictive capacity of HR-MAS NMR profiling for local stage determination compared with established gold standards (CT and MRI) 
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